
<html lang="en"     class="pb-page"  data-request-id="390d4fa2-78c4-4c67-a389-d4fc89e53e2e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c02194;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-12;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells In Vitro" /></meta><meta name="dc.Creator" content="Magdalena  Slusarczyk" /></meta><meta name="dc.Creator" content="Michaela  Serpi" /></meta><meta name="dc.Creator" content="Essam  Ghazaly" /></meta><meta name="dc.Creator" content="Benson M.  Kariuki" /></meta><meta name="dc.Creator" content="Christopher  McGuigan" /></meta><meta name="dc.Creator" content="Chris  Pepper" /></meta><meta name="dc.Description" content="A 3′-protected route toward the synthesis of the diastereomers of clinically active ProTides, NUC-1031 and NUC-3373, is described. The in vitro cytotoxic activities of the individual diastereomers ..." /></meta><meta name="Description" content="A 3′-protected route toward the synthesis of the diastereomers of clinically active ProTides, NUC-1031 and NUC-3373, is described. The in vitro cytotoxic activities of the individual diastereomers ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 4, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02194" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02194" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02194" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02194" /></link>
        
    
    

<title>Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells In Vitro | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02194" /></meta><meta property="og:title" content="Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells In Vitro" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0010.jpeg" /></meta><meta property="og:description" content="A 3′-protected route toward the synthesis of the diastereomers of clinically active ProTides, NUC-1031 and NUC-3373, is described. The in vitro cytotoxic activities of the individual diastereomers were found to be similar to their diastereomeric mixtures. In the KG1a cell line, NUC-1031 and NUC-3373 have preferential cytotoxic effects on leukemic stem cells (LSCs). These effects were not diastereomer-specific and were not observed with the parental nucleoside analogues gemcitabine and FUDR, respectively. In addition, NUC-1031 preferentially targeted LSCs in primary AML samples and cancer stem cells in the prostate cancer cell line, LNCaP. Although the mechanism for this remains incompletely resolved, NUC-1031-treated cells showed increased levels of triphosphate in both LSC and bulk tumor fractions. As ProTides are not dependent on nucleoside transporters, it seems possible that the LSC targeting observed with ProTides may be caused, at least in part, by preferential accumulation of metabolized nucleos(t)ide analogues." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02194"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02194">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02194&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02194&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02194&amp;href=/doi/10.1021/acs.jmedchem.0c02194" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 8179-8193</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02169" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c02261" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells <i>In Vitro</i></span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Magdalena Slusarczyk</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Magdalena Slusarczyk</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Redwood Building, Cardiff CF10 3NB, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +44 (0)2920874551. Email: <a href="/cdn-cgi/l/email-protection#50033c25233122332a293b1d611033367e31337e253b"><span class="__cf_email__" data-cfemail="4e1d223b3d2f3c2d343725037f0e2d28602f2d603b25">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Magdalena++Slusarczyk">Magdalena Slusarczyk</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4707-7190" title="Orcid link">https://orcid.org/0000-0002-4707-7190</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michaela Serpi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michaela Serpi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiff University, School of Chemistry, Main Building, Park Place, Cardiff CF10 3AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michaela++Serpi">Michaela Serpi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Essam Ghazaly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Essam Ghazaly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Essam++Ghazaly">Essam Ghazaly</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Benson M. Kariuki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benson M. Kariuki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiff University, School of Chemistry, Main Building, Park Place, Cardiff CF10 3AT, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Benson+M.++Kariuki">Benson M. Kariuki</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8658-3897" title="Orcid link">https://orcid.org/0000-0002-8658-3897</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher McGuigan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher McGuigan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Redwood Building, Cardiff CF10 3NB, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher++McGuigan">Christopher McGuigan</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Chris Pepper</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chris Pepper</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Brighton and Sussex Medical School, University of Sussex, Medical Teaching Building, Brighton BN1 9PX, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +44 (0)1273 678644. Email: <a href="/cdn-cgi/l/email-protection#63204d3306131306112301100e104d02004d1608"><span class="__cf_email__" data-cfemail="1655384673666673645674657b6538777538637d">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chris++Pepper">Chris Pepper</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02194&amp;href=/doi/10.1021%2Facs.jmedchem.0c02194" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 8179–8193</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 4, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 December 2020</li><li><span class="item_label"><b>Published</b> online</span>4 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02194" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02194</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8179%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMagdalena%2BSlusarczyk%252C%2BMichaela%2BSerpi%252C%2BEssam%2BGhazaly%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D12%26contentID%3Dacs.jmedchem.0c02194%26title%3DSingle%2BDiastereomers%2Bof%2Bthe%2BClinical%2BAnticancer%2BProTide%2BAgents%2BNUC-1031%2Band%2BNUC-3373%2BPreferentially%2BTarget%2BCancer%2BStem%2BCells%2BIn%2BVitro%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8193%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02194"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">451</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02194" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells In Vitro&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Magdalena&quot;,&quot;last_name&quot;:&quot;Slusarczyk&quot;},{&quot;first_name&quot;:&quot;Michaela&quot;,&quot;last_name&quot;:&quot;Serpi&quot;},{&quot;first_name&quot;:&quot;Essam&quot;,&quot;last_name&quot;:&quot;Ghazaly&quot;},{&quot;first_name&quot;:&quot;Benson&quot;,&quot;last_name&quot;:&quot;M. Kariuki&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;McGuigan&quot;},{&quot;first_name&quot;:&quot;Chris&quot;,&quot;last_name&quot;:&quot;Pepper&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;8179-8193&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02194&quot;},&quot;abstract&quot;:&quot;A 3′-protected route toward the synthesis of the diastereomers of clinically active ProTides, NUC-1031 and NUC-3373, is described. The in vitro cytotoxic activities of the individual diastereomers were found to be similar to their diastereomeric mixtures. In the KG1a cell line, NUC-1031 and NUC-3373 have preferential cytotoxic effects on leukemic stem cells (LSCs). These effects were not diastereomer-specific and were not observed with the parental nucleoside analogues gemcitabine and FUDR, respectively. In addition, NUC-1031 preferentially targeted LSCs in primary AML samples and cancer stem cells in the prostate cancer cell line, LNCaP. Although the mechanism for this remains incompletely resolved, NUC-1031-treated cells showed increased levels of triphosphate in both LSC and bulk tumor fractions. As ProTides are not dependent on nucleoside transporters, it seems possible that the LSC targeting observed with ProTides may be caused, at least in part, by preferential accumulation of metabolized nucleos(t)ide &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02194&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02194" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02194&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02194" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02194&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02194" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02194&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02194&amp;href=/doi/10.1021/acs.jmedchem.0c02194" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02194" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02194" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02194%26sid%3Dliteratum%253Aachs%26pmid%3D34085825%26genre%3Darticle%26aulast%3DSlusarczyk%26date%3D2021%26atitle%3DSingle%2BDiastereomers%2Bof%2Bthe%2BClinical%2BAnticancer%2BProTide%2BAgents%2BNUC-1031%2Band%2BNUC-3373%2BPreferentially%2BTarget%2BCancer%2BStem%2BCells%2BIn%2BVitro%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D12%26spage%3D8179%26epage%3D8193%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291308" title="Nucleic acids">Nucleic acids</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292444" title="Molecular structure">Molecular structure</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A 3′-protected route toward the synthesis of the diastereomers of clinically active ProTides, NUC-1031 and NUC-3373, is described. The <i>in vitro</i> cytotoxic activities of the individual diastereomers were found to be similar to their diastereomeric mixtures. In the KG1a cell line, NUC-1031 and NUC-3373 have preferential cytotoxic effects on leukemic stem cells (LSCs). These effects were not diastereomer-specific and were not observed with the parental nucleoside analogues gemcitabine and FUDR, respectively. In addition, NUC-1031 preferentially targeted LSCs in primary AML samples and cancer stem cells in the prostate cancer cell line, LNCaP. Although the mechanism for this remains incompletely resolved, NUC-1031-treated cells showed increased levels of triphosphate in both LSC and bulk tumor fractions. As ProTides are not dependent on nucleoside transporters, it seems possible that the LSC targeting observed with ProTides may be caused, at least in part, by preferential accumulation of metabolized nucleos(t)ide analogues.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01561" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01561" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The phosphoramidate (ProTide) approach<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> applied to antiviral and anticancer nucleoside analogues (NAs), and more recently also to non-nucleoside compounds,<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7 ref8">(2−8)</a> continues to be of significant interest in the drug discovery field. This approach is used to overcome the limitations of NAs that are known to restrict their therapeutic potential. In the oncology arena, the application of ProTide technology to gemcitabine and floxuridine (FUDR) led to the discovery and clinical development of two anticancer agents, NUC-1031<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and NUC-3373<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The first-in-class agent, NUC-1031, was designed to overcome the cancer cell resistance mechanisms that limit the clinical utility of gemcitabine (dFdC). The three key resistance mechanisms involve down-regulation of nucleoside transporter proteins (hENT1); down-regulation of the key initial phosphorylating enzyme deoxycytidine kinase (dCK) that is required to activate dFdC to the 5′-monophosphate form dFdCMP; and up-regulation of the catabolizing enzyme cytidine deaminase (CDA).<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11−13)</a> NUC-1031 has been assessed in four completed clinical studies, including a Phase I study in patients with advanced solid tumors (PRO-001), a Phase Ib study in patients with recurrent ovarian cancer (PRO-002), a Phase Ib study in patients with locally advanced or metastatic biliary tract cancer (BTC) (ABC-08), and a Phase II study in patients with platinum-resistant ovarian cancer (PRO-105). Two clinical studies of NUC-1031 are currently ongoing: a Phase III study in metastatic pancreatic carcinoma (ACELARATE) and a Phase III study in locally advanced or metastatic BTC (NuTide:121). Results from PRO-001 revealed that NUC-1031 has a favorable pharmacokinetic profile with a long plasma half-life (8.3 h versus 1.5 h) and can generate intracellular levels of the active anticancer metabolite dFdCTP that are 217-times higher than those generated by gemcitabine. Furthermore, NUC-1031 achieved high levels of disease control (78%) in patients who had exhausted all other treatment options, including those with tumors relapsed/refractory to prior chemotherapy with gemcitabine.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> In June 2019, Acelarin, the NUC-1031_<i>S</i><sub>P</sub> isomer enriched API (98% <i>S</i><sub>P</sub>-isomer: 2% <i>R</i><sub>P</sub>-isomer), received orphan drug designation from the FDA for the treatment of BTC.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Currently, the <i>S</i><sub>P</sub> isomer of NUC-1031 is being investigated in all NUC-1031 clinical studies.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Phosphoramidate transformations of anticancer and FDA-approved antiviral nucleoside monophosph(on)ate analogues in the clinic and ongoing clinical studies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The second agent, NUC-3373, is a ProTide modification of FUDR, the fluorinated pyrimidine nucleoside derivative of 5-FU. These fluoropyrimidines are established clinical drugs used in the treatment of solid tumors including gastrointestinal, kidney, ovarian, and breast cancers.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The key resistance mechanisms that limit 5-FU and FUDR involve down-regulation of the activating enzyme, thymidine kinase (TK), required for the first phosphorylation step that transforms FUDR to the active anticancer metabolite (FdUMP); up-regulation of thymidylate synthase (TS), which is considered to be the main target for 5-FU and FUDR; up-regulation of the degradative enzyme thymidine phosphorylase (TP); and decreased expression of nucleoside/nucleobase transport proteins.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In addition, more than 85% of administered 5-FU is degraded by dihydropyrimidine dehydrogenase (DPD) before it has an opportunity to enter cancer cells and exert any therapeutic effect.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a><i>In vitro</i> data confirmed that NUC-3373 exerts its cytotoxic activity independently of thymidine kinase in TK-deficient tumor cell lines, and it is resistant to degradative action by catabolic enzymes including TP and DPD.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In addition, NUC-3373 was found to generate 366-fold higher intracellular levels of the active monophosphate form, FdUMP, in the human colorectal cancer cell line HT29 compared with 5-FU and achieved significantly greater tumor volume reduction than 5-FU in HT29 xenograft studies.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> NUC-3373, as a diastereomeric mixture, is currently being assessed in two ongoing clinical studies. Interim pharmacokinetic data from the first-in-human Phase I study of NUC-3373 in patients with advanced solid tumors (NuTide:301) demonstrated that NUC-3373 has a long plasma half-life (9.7 h versus 8–14 min) and the ability to completely deplete the pool of dTMP in patients PBMCs, compared to 5-FU. A three-part Phase I study of NUC-3373 in combination with standard agents used in colorectal cancer treatment (NuTide:302) is also ongoing and is designed to identify a recommended Phase II dose (RP2D) and schedule for NUC-3373 when combined with other agents.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Recently, a third anticancer agent, NUC-7738, the ProTide modification of 3′-deoxyadenosine (3′-dA; also known as cordycepin), entered a Phase I clinical study.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">NUC-1031 and NUC-3373 ProTides were obtained via a coupling reaction between 3′-Boc-protected gemcitabine or FUDR and phosphorylating agent (phosphorochloridate) in the presence of either Grignard reagent (<i>tert</i>-butyl magnesium chloride) or <i>N</i>-methylimidazole (NMI). In both cases, the formation of a pair of diastereomers at the phosphate center (1:1 ratio <i>S</i><sub>P</sub>/<i>R</i><sub>P</sub>) was achieved and, as such, NUC-1031 and NUC-3373 were further biologically evaluated.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Although NMI favors the phosphorylation of the primary hydroxyl group at the nucleoside’s 5′-position, the yield of the coupling reaction is usually low. On the contrary, the Grignard reagent is not selective, hence allowing the formation of a 5′-phosphoramidate along with undesired 3′- and 3′,5′-phosphoramidates. In order to prevent the formation of these byproducts, a selective 3′-protection of the nucleosides is required prior to the coupling reaction. This strategy involves an additional deprotection step at the 3′-positions in the obtained protected-phosphoramidates, as recently reviewed.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Because the yield of coupling reaction in the presence of the Grignard reagent is usually moderate to high, we adopted the hydroxyl groups protection as a strategy to prepare NUC-3373 with higher yield. In the case of gemcitabine, 3′-OH protection is more direct and selective due to the presence of fluorine atoms at the 2′-position in the sugar moiety. For FUDR, which lacks any substituents at the 2′-position, an initial protection of both 3′- and 5′-OH and subsequent selective 5′-deprotection was necessary. The 3′-OH protected FUDR was further used for a coupling reaction with a phosphorochloridate in the presence of the Grignard reagent to improve the overall yield of NUC-3373 synthesis. A variety of hydroxyl protecting groups can be used to prepare 3′-protected ProTides.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> A <i>tert</i>-butyl silyl group (TBDMS) was selected at first and was found to be the most optimal as a clear separation of two diastereomers of the 3′-protected NUC-3373 mixture was possible by normal-phase chromatography. Although a regioselective strategy to obtain the desired 5′-ProTides was published,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> during the course of the present study, we decided to proceed with our alternative methodology and to separate a mixture of two diastereomers at the level of 3′-protected ProTides. This alternative approach was of particular interest in light of the notable difference in activity between <i>S</i><sub>P</sub> and <i>R</i><sub>P</sub> isomers discovered for FDA-approved antiviral ProTide agents sofosbuvir<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (18-fold increase in potency against HCV for the <i>S</i><sub>P</sub> isomer)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and TAF<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> (10-fold increase in potency against HIV for the <i>S</i><sub>P</sub> isomer)<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In fact, chirality and chiral separation of racemic compounds are considered important topics in drug development. Most isomers of chiral drugs, including diastereomers, differ in their pharmacology, pharmacokinetics, metabolism, and biological activities.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> With this in mind, the current FDA recommendation is to assess activity of each isomer of racemic therapeutic agents.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Over the past decade, different diastereoselective methods for the synthesis of <i>P</i>-chirogenic phosphoramidates have been developed, including methods using a chiral auxiliary-bearing phosphoramidating reagent,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> diastereomerically pure phosphoramidating agent with <i>p</i>-nitro-phenyl or 2,3,4,5,6-pentafluorophenyl as leaving aryloxy groups,<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> or a method based on the process for the diastereomeric enrichment due to differences in solubility of <i>S</i><sub>P</sub> and <i>R</i><sub>P</sub> diastereomers in alcohols.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p">In our laboratory, we have focused on the development of diastereoselective synthetic methods via a copper-catalyzed reaction in the presence of different bases.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Additionally, methods for the separation of 3′-protected ProTides as a diastereomeric mixture, in general being very difficult to isolate as single diastereomers by standard chromatography (reverse-phase chromatography or crystallization), were probed.</div><div class="NLM_p last">Herein, we report an alternative synthetic procedure to obtain <i>S</i><sub>P</sub> and <i>R</i><sub>P</sub> isomers of the two clinical anticancer agents NUC-3373 and NUC-1031. A selective TBDMS-protection and deprotection manipulation of FUDR and gemcitabine was followed by a coupling reaction to give 3′-protected phosphoramidates which were separated to single diastereomers. Further removal of 3′-TBDMS group in each separated isomer yielded NUC-3373 and NUC-1031 as single isomers. NUC-1031 diastereomers were obtained upon column chromatography in crystalline form and the stereochemistry at the phosphorus center was assigned via X-ray crystallography. Moreover, for the first time, we disclose <i>in vitro</i> biological data for single <i>R</i><sub>P</sub> and <i>S</i><sub>P</sub> isomers of NUC-1031 and NUC-3373 (stereochemistry to be determined) as well as their ability to target cancer stem cells (CSC).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06483" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06483" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The selective protection and deprotection of hydroxyl groups in nucleoside analogues subjected to ProTide technology and the coupling reaction represents a solid strategy to improve the overall yield of phosphoramidate synthesis. This alternative approach may be considered as advantageous over the general method in which nonprotected nucleoside starting materials are used, as only the desired 5′-phosphorylated ProTides are formed. The alternative procedure for the preparation of clinical anticancer agents NUC-3373 and NUC-1031 from 3′-protected FUDR and gemcitabine, respectively, is depicted in general in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. In our approach to improve the efficiency of the route to obtain the desired 5′-ProTides, we selected the <i>tert</i>-butyldimethyl silyl group reported for its ability to be selectively cleaved from the primary TBDMS hydroxyl groups in the presence of their secondary equivalents.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Thus, first FUDR (<b>1</b>) was treated with TBDMS, imidazole, and DMAP at elevated temperature<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> to give the 5′,3′-TBDMS protected FUDR derivative (<b>3</b>) in 98% yield. Next, the FUDR intermediate <b>3</b> was subjected to different deprotection conditions to selectively remove the 5′-TBDMS moiety. The primary silyloxy groups are known to be cleaved under acidic conditions more efficiently in comparison with their secondary counterparts. Therefore, we investigated a variety of acidic conditions starting with a TFA/H<sub>2</sub>O/THF (1:1:4) mixture, reported by Zhu et al. as the most suitable for selective 5′-desilylation of the multisilylated nucleoside analogues.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> However, when compound <b>3</b> was treated under the above-mentioned conditions, 3′-TBDMS-FUDR derivative (<b>5</b>) was obtained in low yield (20%). Due to poor selectivity of trifluoroacetic acid toward 5′-desilylation, different acids such as <i>p</i>-toluenesulfonic acid (<i>p</i>-TsOH) or camphorsulfonic acid (CSA) were further tested as summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. No selectivity was observed when desilylation was performed with 0.6 equiv of <i>p</i>-TsOH in methanol at room temperature. After 1 h of reaction, a mixture of 3′- and 5′-monosilylated products in almost 1:1 ratio were detected along with a significant amount of starting material <b>3</b> (entry 1, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Decreasing the reaction temperature to −15 °C considerably improved the selectivity, and the desired product <b>5</b> was recovered in 45% yield after 4 h (entry 2, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Replacing MeOH with DCM drastically slowed down the reaction and significantly decreased the 5′-desilylation selectivity (data not reported). The yields were estimated by <sup>1</sup>H and <sup>19</sup>F NMR of the crude reaction mixture. Given the unsatisfactory result obtained with <i>p</i>-TsOH, we turned our attention to a new strategy with 10-camphorsulfonic acid (CSA), which has been reported in a few cases to be able to selectively deprotect primary silyl ether in multisilylated nucleosides to give free primary alcohol.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> Thus, when the reaction was carried out in a 1:1 mixture of DCM/MeOH at low temperature (0–5 °C), slow deprotection was detected; however, a remarkable selectivity was observed. The desired compound <b>5</b> was obtained in 38% crude yield as estimated by <sup>1</sup>H and <sup>19</sup>F NMR. By increasing the temperature to 25 °C, the selectivity toward 5′-desilylation was retained and the reaction was completed within 2.5 h, providing compound <b>5</b> with 37% yield (data not shown). A major improvement was obtained when only MeOH was employed as a solvent. In this case the reaction was accomplished much faster, and after 1 h the desired compound <b>5</b> was formed in 60% crude yield based on <sup>1</sup>H and <sup>19</sup>F NMR (entry 5, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Performing the reaction under the same conditions but at room temperature increased the rate of the deprotection. However, after 45 min, a significant amount of FUDR was formed, suggesting that meticulous monitoring is required (entry 7, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The best result was obtained when performing the reaction in MeOH with 1 equiv of CSA at room temperature in 10 min. Under these conditions the desired product <b>5</b> was recovered after work up in 60% yield (entry 8, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Additional attempts to improve the yield of 5′-TBDMS removal by changing solvents were unsuccessful (entries 9 and 10, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Strategy Toward 3′-TBDMS-Protected Nucleosides <b>5</b> and <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) imidazole (5.0 equiv), TBDMSCl (2.2 equiv), DMAP (0.3 equiv), DMF, 0 °C to rt, 1 h; (b) CSA (1.0 equiv), MeOH, rt, 10 min or TCA (28.0 equiv), THF, H<sub>2</sub>O, rt, 2 h.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Selective 5′-Desilylation of 3′,5′-TBDMS-FUDR (<b>3</b>) and 3′,5′-TBDMS-Gemcitabine (<b>4</b>): Conditions Optimization</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">entry</th><th class="colsep0 rowsep0" align="center">nucleoside analogue</th><th class="colsep0 rowsep0" align="center">acid/equiv</th><th class="colsep0 rowsep0" align="center">solvent</th><th class="colsep0 rowsep0" align="center">time/temp</th><th class="colsep0 rowsep0" align="center">yield<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">FUDR</td><td class="colsep0 rowsep0" align="left"><i>p</i>-TsOH/0.6</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">1 h/rt</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">FUDR</td><td class="colsep0 rowsep0" align="left"><i>p</i>-TsOH/1.0</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">4 h/–15 °C</td><td class="colsep0 rowsep0" align="left">45<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">FUDR</td><td class="colsep0 rowsep0" align="left"><i>p</i>-TsOH/1.0</td><td class="colsep0 rowsep0" align="left">DCM</td><td class="colsep0 rowsep0" align="left">6 h/15 °C–rt</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left">FUDR</td><td class="colsep0 rowsep0" align="left">CSA/0.6</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">30 min/0 °C</td><td class="colsep0 rowsep0" align="left">56<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">FUDR</td><td class="colsep0 rowsep0" align="left">CSA/0.6</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">1 h/0 °C</td><td class="colsep0 rowsep0" align="left">60<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="left">FUDR</td><td class="colsep0 rowsep0" align="left">CSA/0.5</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">25 min/rt</td><td class="colsep0 rowsep0" align="left">50<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="left">FUDR</td><td class="colsep0 rowsep0" align="left">CSA/0.6</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">45 min/rt</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="left">FUDR</td><td class="colsep0 rowsep0" align="left">CSA/1.0</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">10 min/rt</td><td class="colsep0 rowsep0" align="left">60<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="left">FUDR</td><td class="colsep0 rowsep0" align="left">CSA/1.0</td><td class="colsep0 rowsep0" align="left">AcCN</td><td class="colsep0 rowsep0" align="left">1 h/rt</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">FUDR</td><td class="colsep0 rowsep0" align="left">CSA/1.0</td><td class="colsep0 rowsep0" align="left">acetone</td><td class="colsep0 rowsep0" align="left">10 min/rt</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="left">gemcitabine</td><td class="colsep0 rowsep0" align="left">CSA/1.0</td><td class="colsep0 rowsep0" align="left">MeOH</td><td class="colsep0 rowsep0" align="left">10 min/rt</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="left">gemcitabine</td><td class="colsep0 rowsep0" align="left">TCA/28.0</td><td class="colsep0 rowsep0" align="left">THF/H<sub>2</sub>O</td><td class="colsep0 rowsep0" align="left">30 min/rt</td><td class="colsep0 rowsep0" align="left">82<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">5′-Desilylated product, calculated yield by <sup>1</sup>H and <sup>19</sup>F NMR.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Isolated yield.</p></div></div></div><div class="NLM_p">Next, the same conditions for protection and selective 5′-deprotection were applied to gemcitabine (<b>2</b>) to form the key intermediate <b>6</b>. However, instead of 3′-TBDMS-protected gemcitabine <b>6</b>, formation of its 5′-TBDMS-protected analogue was observed along with the starting bis-silylated compound <b>4</b>. While an attempt to selectively remove a silyl group from the 5′-position with oxalic acid (up to 3.0 equiv) was found unsuccessful (data not reported), the use of trichloroacetic acid (28 equiv) in a mixture of THF/H<sub>2</sub>O (3.5:1) gave the key intermediate <b>6</b> with 82% yield (entry 12, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_p">The key intermediate <b>5</b> was further subjected to the standard coupling conditions with <span class="smallcaps smallerCapital">l</span>-Ala-OBn-ONaph phosphorochloridate<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> in the presence of the Grignard reagent (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). 3′-TBDMS-protected compound <b>7</b> obtained as a mixture of diastereomers was purified using normal-phase chromatography to give single isomers: fast eluting (<b>7_isomer A</b>, <b>7a</b> or <b>7b</b>) and slow eluting (<b>7_isomer B</b>, <b>7a</b> or <b>7b</b>). A final deprotection of the 3′-silyl group in isomers <b>7a</b> and <b>7b</b> was performed with a 4:1:1 mixture of THF/TFA/H<sub>2</sub>O at 0 °C and yielded single diastereomers of NUC-3373, herein reported as NUC-3373_isoA (<b>9a</b> or <b>9b</b>) (obtained from <b>7_isoA</b>) and NUC-3373_isoB (<b>9a</b> or <b>9b</b>) (obtained from <b>7_isoB</b>) as stereochemistry at the phosphorus atom remained undetermined at the time of preparation of this manuscript. Attempts to crystallize NUC-3373_isoA (<b>9a</b> or <b>9b</b>) and NUC-3373_isoB (<b>9a</b> or <b>9b</b>) as well as their 3′-protected precursors (<b>7_isomer A</b> and <b>7_isomer B</b>) from various solvents including MeOH, 2-propanol, CHCl<sub>3</sub> and a combination of CHCl<sub>3</sub>/Et<sub>2</sub>O (1:1), and MeOH/CHCl<sub>3</sub> (3:1), CHCl<sub>3</sub>/H<sub>2</sub>O (1:1) were unsuccessful. In addition, the vapor diffusion method, using 2-propanol/hexane, MeOH/H<sub>2</sub>O and MeOH/petroleum ether as the binary solvent system, did not lead to formation of crystalline form. In parallel, a coupling reaction between <span class="smallcaps smallerCapital">l</span>-Ala-OBn-OPh phosphorochloridate<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and <b>6</b> gave 3′-TBDMS-protected NUC-1031 analogue <b>8</b>, further isolated as single isomers <b>8a</b> and <b>8b</b> via column chromatography. Removal of the 3′-TBDMS-group in separated diastereomers <b>8a</b> and <b>8b</b> under acidic conditions provided isomers of NUC-1031 <b>10a</b> and <b>10b</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>), which after normal-phase chromatography were obtained as a crystalline solid. The molecular structure and stereochemistry at the phosphate center was elucidated by single-crystal X-ray crystallography for the two isomers of NUC-1031 and determined to be <i>S</i><sub>P</sub> and <i>R</i><sub>P</sub> for diastereomers <b>10a</b> and <b>10b</b>, respectively (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Strategy Toward Separated Diastereomers of <b>NUC-3373</b> and <b>NUC-1031</b> (<b>9a</b>,<b>9b</b> and <b>10a</b>,<b>10b</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (ArO)(XOC(O)CHCH<sub>3</sub>NH)P(O)Cl (2.0 equiv), <i>tert-</i>BuMgCl, THF, rt, 16 h; (b) separation of diastereomers; and (c) THF/TFA/DCM (4:1:1), 0 °C for 2 h, then rt for 12 h.</p></p></figure><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structures of <b>10a</b> (NUC-1031_<i>S</i><sub>P</sub>) and <b>10b</b> (NUC-1031_<i>R</i><sub>P</sub>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> <i>In Vitro</i> Cytotoxic Activity</h3><div class="NLM_p">The single isomers of NUC-1031 and NUC-3373 were biologically evaluated for cytotoxic activity in a panel of solid tumor cell lines (Mia-Pa-Ca-2, Bx-PC-3, LNCaP, HT-29, HCT-116, MDA-MB-231, and SW-620), the acute myeloid leukemia (AML) cell line, KG1a, and primary AML blasts. The activity of the ProTides was compared with the corresponding diastereomeric mixtures NUC-3373 and NUC-1031 as well as with the parent nucleosides FUDR (<b>1</b>) and gemcitabine (<b>2</b>), respectively (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In the solid tumor cell lines, the LC<sub>50</sub> values for both NUC-3373 isomers were comparable to those of NUC-3373 and FUDR and ranged between 0.61–2.37 μM and 0.31–1.46 μM in HT-29 and SW-620 for NUC-3373_IsoA (<b>9a</b> or <b>9b</b>) and NUC-3373_IsoB (<b>9a</b> or <b>9b</b>), respectively. In comparison to 5-FU, a significant increase in potency was observed and ranged between 13 and 25-fold and 3–5-fold for NUC-3373_IsoA (<b>9a</b> or <b>9b</b>) and NUC-3373_IsoB (<b>9a</b> or <b>9b</b>), respectively, in HT-29 and SW-620 cell lines. The cytotoxic activity of the gemcitabine ProTide NUC-1031 and its isomers were similar, except for the NUC-1031_<i>S</i><sub>P</sub> isomer (<b>10a</b>) in the Mia-Pa-Ca-2 cell line, which was found to be 6-fold more potent than its <i>R</i><sub>P</sub> analogue <b>10b</b> (0.03 μM vs 0.19 μM) and 3-fold more potent than its diastereomeric mixture (0.03 μM vs 0.10 μM). In the HT-29 cancer cell line, the submicromolar LC<sub>50</sub> values for both <i>S</i><sub>P</sub> and <i>R</i><sub>P</sub> NUC-1031 isomers and NUC-1031 ranged between 0.34 and 0.74 μM, similar to the gemcitabine LC<sub>50</sub> value of 0.21 μM. NUC-1031 and both isomers were equipotent in the Bx-PC-3 tumor cell line. When considering the KG1a cell line, NUC-1031 was approximately 6-fold more potent than gemcitabine, again, with no significant difference between the diastereomers (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A–C). We went on to confirm that NUC-1031 was significantly more potent than gemcitabine in primary AML blasts (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>G,H). Similarly, NUC-3373 was approximately 23-fold more potent than FUDR with no significant difference between the diastereomers (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D–F).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Cytotoxicity of NUC-3373 and NUC-1031 as a Diastereomeric Mixture and Single Isomers <i>R</i><sub>P</sub> and <i>S</i><sub>P</sub> Reported as LC<sub>50</sub> (μM) Values<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="8" align="center" char=".">LC<sub>50</sub>(μM) ± SEM in different cell lines</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center" char=".">Mia-Pa-Ca-2<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">Bx-PC-3<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">LNCaP</th><th class="colsep0 rowsep0" align="center" char="±">HT-29</th><th class="colsep0 rowsep0" align="center" char="±">HCT-116</th><th class="colsep0 rowsep0" align="center" char=".">SW-620<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">MDA-MB-231</th><th class="colsep0 rowsep0" align="center" char="±">KG1a</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-FU</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">3.7 ± 0.7</td><td class="colsep0 rowsep0" align="char" char=".">7.98</td><td class="colsep0 rowsep0" align="char" char="±">12.6 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FUDR</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.4</td><td class="colsep0 rowsep0" align="char" char=".">1.55</td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">1.18 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NUC-3373</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.8</td><td class="colsep0 rowsep0" align="char" char=".">1.84</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">0.053 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NUC-3373_IsoA (<b>9a</b> or <b>9b</b>)</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 1.0</td><td class="colsep0 rowsep0" align="char" char=".">2.37</td><td class="colsep0 rowsep0" align="char" char="±">3.6 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">0.052 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NUC-3373_IsoB (<b>9a</b> or <b>9b</b>)</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.9</td><td class="colsep0 rowsep0" align="char" char=".">1.46</td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">0.055 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gemcitabine</td><td class="colsep0 rowsep0" align="char" char=".">0.01</td><td class="colsep0 rowsep0" align="char" char=".">0.74</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NUC-1031</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">2.29</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">0.28 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NUC-1031<b>_</b><i>S</i><sub>P</sub>(<b>10a</b>)</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">2.44</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">0.31 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NUC-1031_<i>R</i><sub>P</sub>(<b>10b</b>)</td><td class="colsep0 rowsep0" align="char" char=".">0.19</td><td class="colsep0 rowsep0" align="char" char=".">1.29</td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">0.25 ± 0.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup><sup>a</sup></sup><p class="last">LC<sub>50</sub> values (the concentration of drug required to induce 50% cell death) were calculated using an MTS assay performed in duplicate and tested in 9 serial concentrations from 198 μM to 0.0199 μM (data expressed as mean LC<sub>50</sub> values) or an Annexin V/7-AAD assay performed in triplicate (data expressed as mean LC<sub>50</sub> values ± SEM).</p></div></div></div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overlaid sigmoidal dose–response curves. (A) Comparison of gemcitabine and NUC-1031_mix (diasteromeric mixture) and (B) the separated diastereomers, NUC-1031_<i>S</i><sub>P</sub> (<b>10a</b>) and NUC-1031_<i>R</i><sub>P</sub> (<b>10b</b>). (C) Comparison of the LD<sub>50</sub> values for gemcitabine, NUC-1031_mix, NUC-1031_<i>S</i><sub>P</sub> (<b>10a</b>), NUC-1031_<i>R</i><sub>P</sub> (<b>10b</b>). (D) Comparison of FUDR and NUC-3373_mix (diasteromeric mixture) and (E) the separated diastereomers NUC-3373_isoA (<b>9a</b> or <b>9b</b>) and NUC-3373_isoB (<b>9a</b> or <b>9b</b>). (F) Comparison of the LD<sub>50</sub> values for 5-FU, FUDR, NUC-3373_mix, NUC-3373_isoA (<b>9a</b> or <b>9b</b>), and NUC-3373_isoB (<b>9a</b> or <b>9b</b>). All assays carried out using KG1a cells are presented as mean (±SEM) of five independent experiments. (G,H) Relative sensitivity of primary AML blasts to gemcitabine and NUC-1031_mix (<i>n</i> = 4).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The metabolic stability of NUC-3373, NUC-1031, and the separated diastereomers (<b>9a</b>, <b>9b</b> and <b>10a</b>,<b>10b</b>) was investigated by incubation with human hepatocytes. The half-lives and percentage of compounds remaining after 1 h were measured and are outlined in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. In human hepatocytes, NUC-3373_IsoA (<b>9a</b> or <b>9b</b>) was found to be slightly more stable than NUC-3373_IsoB (<b>9a</b> or <b>9b</b>) and its diastereomeric mixture NUC-3373, with a half-life of 53 min. In the case of the gemcitabine family, NUC-1031_<i>S</i><sub>P</sub> (<b>10a</b>) was found to have a shorter half-life of 37 min in human hepatocytes compared with NUC-1031_<i>R</i><sub>P</sub> (<b>10b</b>), which had a half-life >120 min. This intriguing discrepancy in half-life of both NUC-1031 isomers in human hepatocytes could potentially be explained by different carboxylesterases (CESs) substrate specificity also toward isomers. Mammalian carboxylesterases (CES1 and CES2), the crucial enzymes involved in the metabolism of endogenous esters and ester or amide-containing xenobiotics, may exhibit different hydrolysis rate between the <i>R</i>- and <i>S</i>-isomers. Thus, their reactivity might be affected by the conformational orientation into the active pocket of CESs.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Metabolic Stability of ProTides Incubated with Human Hepatocytes</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="3" align="center">intrinsic clearance (cryopreserved human hepatocytes)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center" char=".">half-life (min)</th><th class="colsep0 rowsep0" align="center" char=".">% compound remaining after 1 h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NUC-3373</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="char" char=".">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NUC-3373_IsoA (<b>9a</b> or <b>9b</b>)</td><td class="colsep0 rowsep0" align="char" char=".">53</td><td class="colsep0 rowsep0" align="char" char=".">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NUC-3373_IsoB (<b>9a</b> or <b>9b</b>)</td><td class="colsep0 rowsep0" align="char" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NUC-1031</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="char" char=".">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NUC-1031_<i>S</i><sub>P</sub> (<b>10a</b>)</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">NUC-1031_<i>R</i><sub>P</sub> (<b>10b</b>)</td><td class="colsep0 rowsep0" align="char" char=".">>120</td><td class="colsep0 rowsep0" align="char" char=".">97</td></tr></tbody></table></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Biological Activation: Carboxypeptidase Y Assay</h3><div class="NLM_p">The mechanism of activation of NUC-1031 and NUC-3373 in their diastereomeric forms was previously reported<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> and was confirmed to follow the commonly accepted putative route (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The activation pathway involves (i) carboxypeptidase-mediated hydrolysis of the ProTide ester moiety to form the intermediate <b>A</b>, (ii) displacement of the aryl moiety and spontaneous cyclization of <b>A</b> to form metabolite <b>B</b>, and (iii) spontaneous hydrolysis of cyclic anhydride <b>B</b> to the intermediate <b>C</b>. The latter metabolite would then be converted to the monophosphate <b>D</b> via P–N bond cleavage catalyzed by a phosphoramidase-type enzyme. In this work, we carried out an enzymatic assay for the two separated isomers NUC-3373_isoA (<b>9a</b> or <b>9b</b>) and NUC-3373_isoB (<b>9a</b> or <b>9b</b>) and for the gemcitabine ProTide NUC-1031_<i>S</i><sub>P</sub> (<b>10a</b>) and NUC-1031_<i>R</i><sub>P</sub> (<b>10b</b>) in the presence of carboxypeptidase Y according to the standard procedure.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Within 10 min of incubation (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), NUC-3373_isoA (<b>9a</b> or <b>9b</b>) was fully processed to metabolite <b>A</b>, as indicated by the lack of the single peak at δ 4.04 ppm ascribed to the NUC-3373_isoA (<b>9a</b> or <b>9b</b>) and appearance of a single peak at δ 5.16 ppm (metabolite <b>A</b>). During this time, a single peak at δ 6.80 ppm corresponding to achiral metabolite <b>C</b> was also detected. Slightly slower processing to metabolites <b>A</b> and <b>C</b> was observed for the isomer NUC-3373_isoB (<b>9a</b> or <b>9b</b>) within the first 10 min of incubation, during which 28% of NUC-3383_isoB remained unprocessed by the enzyme (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c02194/suppl_file/jm0c02194_si_002.pdf" class="ext-link">Figure S1a</a>).</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0009.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Metabolic Activation Pathway for NUC-3373 and NUC-1031 ProTides</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0004.jpeg" id="GRAPHIC-d7e2050-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) <sup>31</sup>P NMR spectra of NUC-3373_isoA (<b>9a</b> or <b>9b</b>) over time after enzymatic incubation with carboxypeptidase Y. (B) Chart representation of percentage of NUC-3373_isoA (<b>9a</b> or <b>9b</b>) and metabolites <b>A</b> and <b>C</b> over time after enzymatic incubation with carboxypeptidase Y. Conditions 202 MHz, 25 °C, <i>d</i><sub>6</sub>-acetone, 0.05 M Trizma buffer, pH 7.6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the case of the gemcitabine ProTide NUC-1031, only the <i>S</i><sub>P</sub> isomer (<b>10a</b>) was processed to its metabolites <b>A</b> (δ 4.51 ppm, 68%) and <b>C</b> (δ 6.80 ppm, 18%) within the first 10 min of incubation with carboxypeptidase Y. NUC-1031_<i>R</i><sub>P</sub> (<b>10b</b>) was converted to metabolite <b>C</b> (without metabolite <b>A</b> detection) within approximately 120 min (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c02194/suppl_file/jm0c02194_si_002.pdf" class="ext-link">Figure S1b,c</a>).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Cancer Stem Cell Targeting</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The putative existence of cancer stem cells (CSCs) has been suggested in many human cancers, including leukemias and solid tumors. The cancer stem cell hypothesis postulates that only a small subpopulation of tumor cells are responsible for tumor formation, maintenance of the bulk of the tumor, as well as its invasion and metastasis. In 1994, Lapidot and co-workers demonstrated that only a small percentage of acute myeloid leukemia cells had the capability to initiate leukemia in mice.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> These leukemic stem cells (LSCs) were shown to express similar cell surface markers (CD34<sup>+</sup>/CD38<sup>–</sup>) to normal hematopoietic stem cells implying that a similar hierarchical organization may occur in tumors. Subsequently, CSCs have been found in a wide range of solid tumors including breast, lung, colon, prostate, ovarian, skin, and pancreas.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> CSCs are also linked with the development of resistance to therapy and recurrence of cancer, as reported for human colon cancer cell resistance to 5-FU <i>in vitro</i><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and for human pancreatic adenocarcinoma resistance to gemcitabine.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Preferential Targeting of Cancer Stem Cells by ProTides</h3><div class="NLM_p">Given the growing interest in the treatment of cancer by targeting tumor stem cells, we assessed the relative abilities of NUC-1031_mix and NUC-3373_mix, their single diastereomers, and the parental nucleoside analogues to preferentially kill LSCs (as defined by the phenotype CD34<sup>+</sup>CD38<sup>–</sup>) in the acute myeloid leukemia cell line, KG1a, and in primary AML blasts.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a><a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B shows that gemcitabine did not significantly alter the percentage of LSCs in the KG1a cell cultures at concentrations ≤2.5 × 10<sup>–6</sup> M. In contrast, the NUC-1031 diastereomers significantly reduced the LSC fraction at concentrations ≥2.5 × 10<sup>–7</sup> M; both diastereomers had a similar effect (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Importantly, we were also able to demonstrate that NUC-1031_mix preferentially depleted LSCs in primary AML blasts (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). Furthermore, consistent with the results generated with gemcitabine, neither 5-FU nor FUDR showed any preferential toxic effect on LSCs when compared to the bulk tumor at concentrations ≤5 × 10<sup>–6</sup> M (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D). In contrast, both NUC-3373 diastereomers preferentially depleted the LSC compartment at concentrations ≥7 × 10<sup>–8</sup> M (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D). In order to establish whether this phenomenon was specific for KG1a cells and AML blasts, the prostate cancer cell line, LNCaP, was employed as an alternative cancer stem cell model. In this case, the cancer stem cells were identified by a CD44<sup>+</sup>CD133<sup>+</sup> phenotype; this population of cells accounted for just 1.4% of the cell line. Although the LC<sub>50</sub> values for gemcitabine and NUC-1031 were not significantly different (<i>P</i> = 0.24), NUC-1031 showed a preferential effect on cancer stem cell population when compared to gemcitabine at concentrations ≥2.5 × 10<sup>–6</sup> M (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E).</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Differential cytotoxic effects of nucleosides and ProTides on cancer stem cells. (A) Comparison of the viable fraction of KG1a cells exposed to gemcitabine and NUC-1031_mix for 48 h. (B) Both diastereomers of NUC-1031 caused a dose-dependent, statistically significant, reduction in the LSC (CD34<sup>+</sup>/CD38<sup>–</sup>) fraction of KG1a cells. In contrast, gemcitabine had no significant effect on the LSC compartment at concentrations ≤2.5 × 10<sup>–6</sup> M. (C) The diastereomeric mixture of NUC-1031 induced a dose-dependent decrease in the LSC fraction of primary AML blasts. (D) Both diastereomers of NUC-3373 caused a dose-dependent, statistically significant reduction in the LSC (CD34<sup>+</sup>/CD38<sup>–</sup>) fraction of KG1a cells. In contrast, 5-FU and FUDR had no significant effect on the LSC compartment at concentrations ≤5 × 10<sup>–6</sup> M. *<i>P</i> < 0.05, **<i>P</i> < 0.01. (E) A similar effect was observed in the prostate cancer cell line, LNCaP. NUC-1031 preferentially depleted the cancer stem cells (CD44<sup>+</sup>/CD133<sup>+</sup>) at concentrations ≥2.5 × 10<sup>–6</sup> M when compared with gemcitabine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Intracellular Triphosphate Accumulation and ABC Transporter Expression</h3><div class="NLM_p">LSC and bulk tumor fractions (5 × 10<sup>6</sup>) were isolated by high-speed cell sorting and were subsequently cultured for 1 h with either 1 μM gemcitabine or 1 μM NUC-1031_mix. The level of intracellular triphosphate was assessed using mass spectrometry and quantified by running defined concentrations of nucleoside through the mass spectrometer in order to construct a standard curve (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). In both fractions, NUC-1031 resulted in higher intracellular accumulation of the triphosphate when compared to the parental gemcitabine nucleoside (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Furthermore, the LSC fraction retained high levels of the triphosphate following treatment with NUC-1031_mix, which may contribute to the preferential depletion of these cells when exposed to ProTide. In contrast, LSCs treated with gemcitabine showed approximately a 30% reduction in intracellular triphosphate when compared with bulk tumor cells. Based on the intracellular triphosphate data, we next evaluated the expression of ABC transporters in LSC and bulk tumor fractions both at the level of protein and mRNA transcript. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C shows that LSCs show a trend toward higher expression of ABCB1 and significantly higher expression of ABCG2 in LSCs versus bulk tumor cells. Furthermore, at the level of transcript, ABCB1, ABCG2, ABCC4, and ABCC5 all showed significantly increased expression in LSCs versus bulk tumor cells (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D). A number of these transporters have been previously implicated in gemcitabine resistance.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a></div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Measurement of intracellular triphosphate ABC transporters in LSC and bulk tumor cell fractions from KG1a cells. (A) Defined concentrations of nucleoside were run through the mass spectrometer in order to construct a standard curve (B) Purified LSCs and bulk tumor cells were treated with 1 μM of gemcitabine or NUC-1031_mix for 1 h prior to cell lysis and mass spectrometry. Both LSC and bulk tumor fractions showed increased intracellular triphosphate following treatment with NUC-1031_mix. (C) Protein expression of ABCB1 and ABCG2 on purified bulk tumor (CD34<sup>+</sup>/CD38<sup>+</sup>) and LSCs (CD34<sup>+</sup>/CD38<sup>–</sup>). Cell sorted LSCs showed significantly higher levels of ABCG2 when compared with bulk tumor cells. (D) Relative gene transcription of ABC transporter genes in purified bulk tumor cells (solid bars) and LSCs (hatched bars). LSCs showed significantly increased relative transcription of ABCB1, ABCG2, and ABCC5 when compared with bulk tumor cells. All data are the mean (±SEM) of five independent experiments, performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77047" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77047" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The biological potencies and activities of single enantiomers or diastereomers of chiral compounds such as phosphoramidates (ProTides), with their stereocenter at the phosphorus atom, may differ markedly. In light of the FDA recommendation to assess activity of each isomer of racemic or diastereomeric mixtures, it became even more important to develop either stereoselective synthetic strategies or separation methods to obtain the desired isomers. Herein, we described an alternative synthesis of the two clinical anticancer agents NUC-1031 and NUC-3373 via a 3′,5′-hydroxyl group protection and 5′-deprotection strategy, which allowed separation of the single <i>S</i><sub>P</sub> and <i>R</i><sub>P</sub> diastereomers. Two diastereomers of NUC-1031 were obtained in crystalline form and their molecular structure and stereochemistry at the phosphate center was assigned via X-ray crystallography. The cytotoxic activities of <i>R</i><sub>P</sub> and <i>S</i><sub>P</sub> isomers of NUC-1031 were similar and there was no significant difference in the <i>in vitro</i> potency when compared to NUC-1031 as a diastereomeric mixture. Similarly, the <i>in vitro</i> potency of NUC-3373 and its single isomers NUC-3373_isoA and NUC-3373_isoB was comparable in the cancer cell lines tested. Attempts to crystallize two diastereomers of NUC-3373 were unsuccessful at the time of preparation of this manuscript. Both NUC-1031_mix and NUC-3373_mix and their separated diastereomers were shown to preferentially target leukemic cancer stem cells, whereas the parent nucleosides gemcitabine and FUDR did not. Mechanistically, increased intracellular accumulation of triphosphate may contribute to the preferential killing of CSCs by the ProTide in contrast to the parental analogue, but other factors may also be involved. Given that one of the gemcitabine resistance mechanisms has been associated with ABC transporter expression,<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> we investigated their expression in LSC and bulk tumor cells. LSCs showed significantly increased expression of ABCB1, ABCG2, ABCC4, and ABCC5 at the level of transcript and increased expression of ABCG2 at the level of protein. We postulate that the increased intracellular triphosphate in ProTide-treated cells is caused, at least in part, by the differential bioavailability of the ProTide versus the parental nucleoside analogue. As LSCs preferentially express ABC transporters, the increased intracellular accumulation of triphosphate in these cells, following treatment with ProTide, results in increased cell death of these LSCs. Importantly, the same effect was observed in cancer stem cells from a prostate cancer cell line (LNCaP). As such, ProTides may prove to be an important addition to the therapeutic repertoire, particularly in the context of eradication of cancer stem cells.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26857" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26857" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Materials and Methods</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Cell Lines</h4><div class="NLM_p last">KG1a, HT-29, HCT-116, LNCaP, and MDA-MB-231 cell lines were all purchased from DSMZ (Germany). All lines were initially expanded and then frozen down in aliquots (10<sup>7</sup> cells) at low passage number. Cell lines were never expanded beyond 8–10 passages and were routinely confirmed as mycoplasma-free to ensure the integrity of each cell line.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> MTS Cell Viability Assay</h4><div class="NLM_p last">The assay was contracted and carried-out by WuXi AppTec (Shanghai) Co., Ltd. The tumor cell lines Mia-PaCa-2, Bx-PC-3, HT-29, and SW620 were seeded at cell densities of 0.5 to 100 × 10<sup>3</sup> cells/well in a 96-well plate the day before drug incubation. Then the plates were incubated for 72 h with the different concentrations of compound to be tested. After the incubation period, 50 μL of MTS was added and the tumor cells were incubated for 4 h at 37 °C. The data were read and collected by a Spectra Max 340 absorbance microplate reader. The compounds were tested in duplicate with 9 serial concentrations (3.16-fold titrations with 198 μM as the highest concentration), and the data were analyzed by XL-fit software.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Annexin V/7-AAD Cell Viability Assay</h4><div class="NLM_p last">Cell lines were grown in T175 flasks until confluent. Cells were then aliquoted (10<sup>5</sup> cells/100 μL) into 96-well plates and were incubated at 37 °C in a humidified 5% CO<sub>2</sub> atmosphere for 72 h in the presence of tested compounds at the concentrations that were experimentally determined for each compound. In addition, control cultures were set up to which no drug was added. Cells were subsequently harvested by centrifugation and were analyzed by flow cytometry using the Annexin V/7-AAD assay. All experiments were performed in triplicate. LC<sub>50</sub> values (the concentration of compound required to kill 50% of the cells in culture) were calculated by nonlinear regression modeling using GraphPad Prism software and are shown as mean ± SEM for each replicate data set.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Metabolic Stability (Cryopreserved Hepatocytes, Human) Assay</h4><div class="NLM_p last">The assay was contracted and performed by Cerep (Seattle, WA, USA Laboratories, 15318 N. E. 95th Street Redmond, WA, 98052, U.S.) according to the published procedure (Cerep ref. 1432). Pooled cryopreserved hepatocytes were thawed, washed, and resuspended in Krebs–Heinslet buffer (pH 7.3). The reaction was initiated by adding the test compound (1 μM final concentration) into cell suspension and incubated in a final volume of 100 μL on a flat-bottom 96-well plate for 0 and 60 min, respectively, at 37 °C/5% CO<sub>2</sub>. The reaction was stopped by adding 100 μL of acetonitrile into the incubation mixture. Samples were then mixed gently and briefly on a plate shaker, transferred completely to a 0.8 mL V-bottom 96-well plate, and centrifuged at 2550<i>g</i> for 15 min at room temperature. Each supernatant (150 μL) was transferred to a clean cluster tube, followed by HPLC-MS/MS analysis on a Thermo Electron triple quadrupole system.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Carboxypeptidase Y (EC 3.4.16.1) Assay</h4><div class="NLM_p last">The experiment was carried out by dissolving ProTides (3.5 mg) in acetone-<i>d</i><sub>6</sub> (0.15 mL) followed by addition of 0.30 mL of Trizma buffer (pH 7.6). After recording the control <sup>31</sup>P NMR at 25 °C, a previously defrosted carboxypeptidase Y (0.1 mg dissolved in 0.15 mL of Trizma) was added to the sample, which was then immediately submitted to the <sup>31</sup>P NMR experiments (at 25 °C). The spectra were recorded with 64 scans every 7 min unless otherwise stated. <sup>31</sup>P NMR recorded data were processed and analyzed with the Bruker Topspin 2.1 program.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Cell Culture Conditions</h4><div class="NLM_p last">The acute myeloid leukemia (AML) KG1a cell line and the prostate cancer cell line, LNCaP, were maintained in RPMI medium (Invitrogen, Paisley, U.K.) supplemented with 100 units/mL penicillin, 100 μg/mL streptomycin, and 20% fetal calf serum. The colorectal cancer cell lines, HT-29 and HCT-116, and the breast cancer cell line, MDA-MB-231, were maintained in Dulbecco’s modified essential medium with high glucose supplemented with 100 units/mL penicillin, 100 μg/mL streptomycin, and 10% fetal calf serum.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Measurement of <i>In Vitro</i> Apoptosis</h4><div class="NLM_p last">Cultured cells were harvested by centrifugation and resuspended in 195 μL of calcium-rich buffer. Subsequently, 5 μL of Annexin V was added to the cell suspension and cells were incubated in the dark for 10 min prior to washing. Cells were finally resuspended in 190 μL of calcium-rich buffer together with 10 μL of propidium iodide. Apoptosis was assessed by dual-color immunofluorescent flow cytometry<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> as described previously. Subsequently LC<sub>50</sub> values (the doses required to kill 50% of the cells in culture) were calculated for each nucleoside analogue and ProTide.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Immunophenotypic Identification of the Cancer Stem Cells</h4><div class="NLM_p last">KG1a cells or LNCaP cells were cultured for 72 h in the presence of a wide range of concentrations of each nucleoside analogue and their respective ProTides. Cells were then harvested, and KG1a cells were labeled with anti-CD34 (FITC) and anti-CD38 (PE) and LNCaP cells were labeled with anti-CD44 (APC) and anti-CD133 (Alexa 488). The subpopulations expressing a cancer stem cell (CSC) phenotype were subsequently identified and were expressed as a percentage of all viable cells left in the culture. The percentages of stem cells remaining were then plotted on a dose–response graph, and the proportion of cancer stem cells was compared across the various concentrations of ProTides and their respective parental nucleoside in order to determine if they preferentially target cancer stem cells.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Cell Sorting</h4><div class="NLM_p last">KG1a cells were cultured until confluent in order to generate 10<sup>8</sup> cells. Subsequently, 5 × 10<sup>6</sup> of CD34<sup>+</sup>/CD38<sup>–</sup> LSCs and CD34<sup>+</sup>/CD38<sup>+</sup> bulk tumor cells were purified by high-speed cell sorting using a FACS Melody cell sorter (Becton Dickenson) and were placed back into culture prior to the addition of 1 μM gemcitabine or the ProTide NUC-1031_mix.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Mass Spectrometry Assessment of Intracellular Nucleoside/ProTide</h4><div class="NLM_p last">Defined concentrations of nucleoside were run through the mass spectrometer in order to construct a standard curve (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). This was used to quantify the levels of nucleoside/ProTide triphosphate in each of the samples provided. KG1a cells (5 × 10<sup>6</sup>), cultured in DMEM + 10% FCS, were exposed to 1 μM of gemcitabine or NUC-1031_mix for 1 h prior to harvesting by centrifugation. Cells were then FACS sorted into LSC (CD34+/CD38-) and bulk tumor cell fractions (CD34+/CD38+). Purified cells were then pelleted prior to lysis and mass spectrometry analysis for intracellular triphosphate content of gemcitabine or NUC-1031.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Immunopheotypic Expression of ABCB1 and ABCG2</h4><div class="NLM_p last">KG1a cells were harvested from culture and labeled with anti-CD34 (FITC) and anti-CD38 (PE) to identify the LSC and bulk tumor fractions. In addition, they were labeled with anti-ABCB1 (Alexa 647) and anti-ABCG2 (APC). Subsequently, the LSC and bulk tumor fractions were gated and the expression levels of the two ABC transporters were quantified using mean fluorescence intensity values.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Transcription of ABC Transporter Genes</h4><div class="NLM_p last">A volume of 1 mL of TRIzol was added to each pellet of 2 × 10<sup>5</sup> harvested bulk tumor or LSC cells. A volume of 200 μL of chloroform was added and centrifuged at 8000<i>g</i> for 15 min at 4 °C. The aqueous layer was gently removed and added to an equal volume of 70% ethanol. A volume of 700 μL of the sample was then added to an RNeasy spin column, and the RNeasy Mini Kit protocol was followed. The elution step used 50 μL of RNase-free water, and RNA quantification was assessed using a Nanodrop:1000 spectrophotometer. Duplicate 1 μL samples were evaluated, and the RNA concentration, A260/280 ratio, and A260/A230 ratios were obtained. Aliquots of 0.5 μg of RNA were then added to 0.5 mL microfuge tubes containing 10 μL of master mix and made up to 20 μL with sterile RNase-free water. Samples were added to the thermal cycler and run as per the kit’s protocol. Once the run was complete, 20 μL of newly converted cDNA was diluted 5:1 with sterile DNA and RNase-free water to give a working concentration of 2.5 ng/μL. Samples were stored at −20 °C. The TaqMan Fast Advanced Master Mix kit protocol was followed. Samples were run in triplicate, including a minus RT sample and a minus cDNA sample. Samples were run on a 96-well plate with a running volume 10 μL per well. This was composed of 2.5 μL of thawed cDNA, 0.5 μL of forward and reverse primers (ABC transporter gene or GAPDH as a housekeeping control; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c02194/suppl_file/jm0c02194_si_002.pdf" class="ext-link">Table S1</a>, Supporting Information), 5 μL of TaqMan master mix, and 2 μL of RNase-free water. Samples were run on a ViiA7 real-time PCR system using the TaqMan FAST program. Results were analyzed using the Thermo Fisher Cloud software using the Relative Quantification qPCR application.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Statistical Analysis</h4><div class="NLM_p last">The data obtained in these experiments were evaluated using one-way ANOVA. All data was confirmed as Gaussian or a Gaussian approximation using the omnibus K2 test. LC<sub>50</sub> values were calculated from the nonlinear regression and line of best-fit analysis of the sigmoidal dose–response curves. Values are shown as mean ± SEM from each replicate data set. All statistical analyses were performed using Graphpad Prism 6.0 software (GraphPad Software Inc., San Diego, CA).</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Crystal Structure Determination</h4><div class="NLM_p last">Single-crystal XRD data were collected on an Agilent SuperNova Dual Atlas diffractometer with a mirror monochromator using Cu (λ = 1.5418 Å) . Crystal structures were solved and refined using SHELX (see <a href="/doi/suppl/10.1021/acs.jmedchem.0c02194/suppl_file/jm0c02194_si_002.pdf" class="ext-link">Table S2</a>, Supporting Information).<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> Geometric restraints were applied during refinement of orientationally disordered components. Non-hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atoms were inserted in idealized positions, and a riding model was used.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> General Methods</h4><div class="NLM_p last">All solvents and reagents were used as obtained from commercial sources unless otherwise indicated. All reactions were performed under a nitrogen atmosphere. The <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Varian spectrometer operating at 500 MHz for <sup>1</sup>H and 125 MHz for <sup>13</sup>C. Deuterated chloroform was used as the solvent for NMR experiments, unless otherwise stated. <sup>1</sup>H chemical shifts values (δ) are referenced to the residual nondeuterated components of the NMR solvents (δ = 7.26 ppm for CHCl<sub>3</sub>, etc.). The <sup>13</sup>C chemical shifts (δ) are referenced to CDCl<sub>3</sub> (central peak, δ = 77.0 ppm). Fluorine chemical shifts are referenced to CFCl<sub>3</sub>. Mass spectra were measured in positive mode electrospray ionization (ESI). Thin layer chromatography (TLC) was performed on silica gel 60 F254 plastic sheets. Column chromatography was performed using silica gel (35–75 mesh). Purity of prepared compounds was determined by high-pressure liquid chromatography-ultraviolet (HPLC-UV) analysis (Thermo HPLC connected with UV detector). The purity of all final compounds was determined to be >95% by reversed phase-high-pressure liquid chromatography (RP-HPLC) using the eluents water (eluent A), acetonitrile (eluent B), and the following conditions: Varian Pursuit XS, 4.6 mm × 150 mm, 5.0 μm, 1.0 mL/min, gradient 30 min 10% → 100% eluent B in eluent A (method 1). The purity of the intermediates was >90%, unless otherwise stated.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> General Procedure 1 for the Preparation of 3′,5′-TBDMS Protected FUDR (<b>3</b>) and of 3′,5′-TBDMS Protected Gemcitabine (<b>4</b>)</h4><div class="NLM_p">TBDMSCl (2.2 equiv) was added to a stirred solution of nucleoside (1.0 equiv), imidazole (5.0 equiv), and DMAP (0.3 equiv) in DMF (10 mL) at 0 °C, and the mixture was allowed to warm to 25 °C and stirred for 1 h. The reaction was quenched with saturated aqueous solution of ammonium chloride, followed by extraction with EtOAc (3 × 5 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under vacuum to give a crude product as an oil used for the next step without further purification.</div><div class="NLM_p">2′-Deoxy-5-fluoro-3′,5′-bis(<i>O</i>-<i>tert</i>-butyldimethylsilyl-uridine (<b>3</b>) was obtained from FUDR (2.0 g, 8.10 mmol), imidazole (40.62 mmol, 2.76 g), DMAP (2.43 mmol, 0.297 g), and TBDMSCl (17.87 mmol, 2.70 g) in DMF (15 mL) as an oil. Yield, 83% (3.20 g). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ<sub>H</sub> 8.02 (d, <i>J</i> = 6.5 Hz, 1H, <i>H</i>-6), 6.30 (t, <i>J</i> = 7.50, 1H, <i>H</i>-1′), 4.40 (q, <i>J</i> = 3.5 Hz, 1H, <i>H</i>-3′), 3.97–3.86 (m, 2H, <i>H</i>-4′, <i>H</i>-5′), 3.74 (dd, 1H, <i>J</i> = 12.0, 3.5 Hz, <i>H</i>-5′), 2.40–2.31 (m, 1H, <i>H</i>-2′), 2.10–2.00 (m, 1H, <i>H</i>-2′), 0.93, 0.92 (2<i>s</i>, 18H, C(C<i>H</i><sub>3</sub>)<sub>3</sub>), 0.12, 0.11 (2<i>s</i>, 12H, Si(C<i>H</i><sub>3</sub>)<sub>2</sub>). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ<sub>C</sub> 157.23 (d,<sup>2</sup><i>J</i><sub>C–F</sub> = 26.0 Hz, <i>C</i>-4), 149.17 (<i>C</i>-2), 141.54 (d,<sup>1</sup><i>J</i><sub>C–F</sub> = 235.0 Hz, <i>C</i>-5), 124.12 (d,<sup>2</sup><i>J</i><sub>C–F</sub> = 33.7 Hz, <i>C</i>-6), 87.98 (<i>C</i>-4′), 85.46 (<i>C</i>-1′), 71.38 (<i>C</i>-3′), 62.58 (<i>C</i>-5′), 41.73 (<i>C</i>-2′), 25.65 (C(<i>C</i>H<sub>3</sub>)<sub>3</sub>), 18.37, 18.06 (<i>C</i>(CH<sub>3</sub>)<sub>3</sub>), −4.67, −4.93 (Si(<i>C</i>H<sub>3</sub>)<sub>2</sub>).</div><div class="NLM_p last">2′-Deoxy-2′,2′-difluoro-3′,5′-bis(<i>O</i>-<i>tert-</i>butyldimethylsilyl-<span class="smallcaps smallerCapital">d</span>-cytidine (<b>4</b>) was obtained from gemcitabine (2.0 g, 7.59 mmol), imidazole (2.58 g, 37.95 mmol), DMAP (0.278 g, 2.27 mmol), and TBDMSCl (2.52 g, 16.69 mmol) in DMF (15 mL) as an oil. Yield 82% (3.05 g). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ<sub>H</sub> 7.74 (d, <i>J</i> = 8.0 Hz, 1H, <i>H</i>-6), 6.27 (dd, <i>J</i><sub>H–F</sub> = 9.50, 5.50 Hz, 1H, <i>H</i>-1′), 5.77 (d, <i>J</i> = 7.5 Hz, 1H, <i>H</i>-5), 4.38–4.28 (m, 1H, <i>H</i>-3′), 4.02 (dd, 1H, <i>J</i> = 11.5, 3.5 Hz, <i>H</i>-5′a), 3.92–3.88 (m, 1H, <i>H</i>-4′), 3.80 (dd, 1H, <i>J</i> = 2.0, 11.5 Hz, <i>H</i>-5′b), 0.93, 0.92 (2<i>s</i>, 18H, C(C<i>H</i><sub>3</sub>)<sub>3</sub>), 0.12, 0.11 (2<i>s</i>, 12H, Si(C<i>H</i><sub>3</sub>)<sub>2</sub>).</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2′-Deoxy-5-fluoro-3′-(<i>O</i>-<i>tert-</i>butyldimethylsilyl-uridine (<b>5</b>)</h4><div class="NLM_p last">CSA (6.74 mmol, 1.56 g) was added to 2′-deoxy-5-fluoro-3′,5′-bis(<i>O</i>-<i>tert</i>-butyldimethylsilyl-uridine (<b>3</b>) (6.74 mmol, 3.20 g) dissolved in MeOH (15 mL), at 0 °C and the reaction mixture was stirred under an argon atmosphere for 10 min. After the reaction was completed, the solvent was removed under reduced pressure to yield the crude residue that was purified by silica gel column chromatography with a gradient of MeOH (1% to 10%) in DCM as an eluent to afford <b>5</b> as a white solid. Yield, 60% (1.45 g). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 8.22 (d, <i>J</i><sub>H–F</sub> = 8.0 Hz, 1H, <i>H</i>-6), 6.25 (td, <i>J</i> = 7.5, 2.0 Hz 1H, <i>H</i>-1′), 5.20 (t, <i>J</i> = 3.0 Hz, 1H, 5′-O<i>H</i>), 4.53 (q, <i>J</i> = 3.5 Hz, 1H, <i>H</i>-3′), 3.92 (qr, <i>J</i> = 3.5 Hz, 1H, <i>H</i>-4′), 3.80 (dd, <i>J</i> = 12.0, 3.5 Hz, 1H, <i>H</i>-5′), 3.73 (dd, <i>J</i> = 12.0, 3.5 Hz, 1H, <i>H</i>-5′), 2.26–2.21 (m, 2H, <i>H</i>-2′), 0.94 (s, 9H, C(C<i>H</i><sub>3</sub>)<sub>3</sub>), 0.15 (s, 6H, Si(C<i>H</i><sub>3</sub>)<sub>2</sub>). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ<sub>C</sub> 159.46 (d,<sup>2</sup><i>J</i><sub>C–F</sub> = 26.2 Hz, <i>C</i>-4), 150.83 (<i>C</i>-2), 141.87 (d,<sup>1</sup><i>J</i><sub>C–F</sub> = 231.0 Hz, <i>C</i>-5), 126.24 (d,<sup>2</sup><i>J</i><sub>C–F</sub> = 35.0 Hz, <i>C</i>-6), 89.58 (<i>C</i>-4′), 86.83 (<i>C</i>-1′), 73.46 (<i>C</i>-3′), 62.38 (<i>C</i>-5′), 41.99 (<i>C</i>-2′), 26.41 (C(<i>C</i>H<sub>3</sub>)<sub>3</sub>), 18.84 (<i>C</i>(CH<sub>3</sub>)<sub>3</sub>), −4.65 (d,<sup>1</sup><i>J</i><sub>C–Si</sub> = 18.7 Hz, (Si(<i>C</i>H<sub>3</sub>)<sub>2</sub>). MS (MSI+): <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>25</sub>FN<sub>2</sub>O<sub>5</sub>Si: 360.45 [M]<sup>+</sup>; found 383.149 [M + Na]<sup>+</sup>.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2′-Deoxy-2′,2′-difluoro-3′-(<i>O</i>-<i>tert</i>-butyldimethylsilyl)-<span class="smallcaps smallerCapital">d</span>-cytidine (<b>6</b>)</h4><div class="NLM_p last">A solution of trichloroacetic acid (113.88 mmol, 11.42 mmol) in 8.7 mL of water was added to a solution of compound <b>4</b> (2.0 g, 4.06 mmol) in THF (38 mL) at 0 °C. The reaction mixture was stirred for 2 h at rt, and then the reaction solution was neutralized with solid NaHCO<sub>3</sub> until evolution of gas was finished. Next, 100 mL of water was added to the reaction mixture, followed by extraction with EtOAc (3 × 50 mL). The volatiles were concentrated under reduced pressure to afford the title compound <b>6</b> as a white solid. Yield, 82% (1.25 g). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ<sub>H</sub> 7.54 (d, <i>J</i> = 7.5 Hz, 1H, <i>H</i>-6), 7.55, 7.53 (2 × bs, 2H, NH<sub>2</sub>), 6.03 (t, <i>J</i><sub>H–F</sub> = 8.0 Hz, 1H, <i>H</i>-1′), 5.68 (d, <i>J</i> = 7.5 Hz, 1H, <i>H</i>-5), 5.15 (bs, 1H, O<i>H</i>-5′), 4.25–4.18 (m, 1H, <i>H</i>-3′), 3.71–3.64 (m, 2H, <i>H</i>-4′, <i>H</i>-5′a), 3.46 (dd, <i>J</i> = 12.5, 3.5 Hz, 1H, <i>H</i>-5′b), 0.77 (s, 9H, C(C<i>H</i><sub>3</sub>)<sub>3</sub>), 0.00, −0.02 (2<i>s</i>, 6H, Si(C<i>H</i><sub>3</sub>)<sub>2</sub>). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ<sub>C</sub> 165.99 (<i>C</i>–NH<sub>2</sub>), 156.16 (<i>C</i>═O base), 140.43 (<i>C</i>H–base), 122.61 (t,<sup>1</sup><i>J</i><sub>C–F</sub> = 256 Hz, <i>C</i>F<sub>2</sub>), 95.16 (<i>C</i>H–base), 84.35 (t,<sup>2</sup><i>J</i><sub>C–F</sub> = 31.7 Hz, <i>C</i>-1′), 80.67 (t,<sup>3</sup><i>J</i><sub>C–F</sub> = 4.0 Hz, <i>C</i>-4′), 68.39 (t,<sup>2</sup><i>J</i><sub>C–F</sub> = 22.8 Hz, <i>C</i>-3′), 60.35 (<i>C</i>-5′), 25.09, 24.92 (C(<i>C</i>H<sub>3</sub>)<sub>3</sub>), 17.92 (<i>C</i>(CH<sub>3</sub>)<sub>3</sub>), −6.65 (d,<sup>1</sup><i>J</i><sub>C–Si</sub> = 12.9 Hz, Si(<i>C</i>H<sub>3</sub>)<sub>2</sub>).</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> General Procedure 2 for a Preparation of 3′-TBDMS-Protected ProTides</h4><div class="NLM_p"><i>tert</i>-BuMgCl (1.0 M solution in THF, 1.2 equiv) was added to a solution of 3′-O-(<i>tert</i>-butyldimethylsilyl)-protected nucleoside (1.0 equiv) in dry THF (10 mL), in one portion followed by addition of an appropriate phosphorochloridate (2.0 equiv) dissolved in anhydrous THF (3 mL). The reaction mixture was stirred for 16 h and then evaporated under reduced pressure to give a crude residue that was purified either by silica gel column chromatography, eluting with a gradient of MeOH (0–2%) in DCM or with a gradient of MeOH (3–6%) in a mixture of EtOAc (15%) and DCM as an eluent, followed by TLC preparative purification unless stated otherwise to afford 3′-TBDMS-protected ProTides as single diastereoisomers.</div><div class="NLM_p">2′-Deoxy-5-fluoro-3′-<i>O</i>-<i>tert-</i>butyl-dimethylsilyl-<span class="smallcaps smallerCapital">d</span>-uridine-5′-<i>O</i>-[naphthyl-(benzyloxy-<span class="smallcaps smallerCapital">l</span>-alaninyl)] phosphate (<b>7</b>) was prepared according to general procedure 2 from 2′-deoxy-5-fluoro-3′-(<i>O</i>-<i>tert-</i>butyldimethylsilyl-uridine (<b>5</b>) (2.77 mmol, 1.0 g) and <span class="smallcaps smallerCapital">l</span>-Ala-OBn-ONaph phosphorochloridate<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> (5.55 mmol, 2.24 g), (3.33 mmol, 3.33 mL) in THF (15 mL). The crude mixture was purified by silica column chromatography with a slow gradient of MeOH (0–2%) in DCM as an eluent to give the fast eluting isomer A (<b>7a</b>,<i>S</i><sub>P</sub>) or (<b>7b</b>,<i>R</i><sub>P</sub>) and the slow eluting isomer B (<b>7a</b>, <i>S</i><sub>P</sub>) or (<b>7b</b>,<i>R</i><sub>P</sub>).</div><div class="NLM_p">2′-Deoxy-5-fluoro-3′-<i>O</i>-(<i>tert</i>-butyl-dimethylsilyl)-<span class="smallcaps smallerCapital">d</span>-uridine-5′-<i>O</i>-[naphthyl-(benzyloxy-<span class="smallcaps smallerCapital">l</span>-alaninyl)] phosphate (<b>7_Isomer A</b>) was the fast eluting fraction obtained as a white solid. Yield, 9% (0.19 g) <sup>31</sup>P NMR (202 MHz, CD<sub>3</sub>OD): δ<sub>P</sub> 4.64. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ<sub>H</sub> 8.15 (d, <i>J</i> = 8.0 Hz, 1H, Ar-<i>H</i>), 7.89 (d, <i>J</i> = 8.0 Hz, 1H, <i>H</i>-Ar), 7.73 (d, <i>J</i><sub>H–F</sub> = 8.0 Hz, 1H, <i>H</i>-6), 7.65 (d, <i>J</i> = 6.5 Hz, 1H, Ar-<i>H</i>), 7.54–7.50 (m, 3H, Ar-<i>H</i>), 7.43. (t, <i>J</i> = 8.0 Hz, 1H, Ar-<i>H</i>), 7.34–7.28 (m, 5H, Ar-<i>H</i>), 6.08 (t, <i>J</i> = 6.5 Hz 1H, <i>H</i>-1′), 5.06 (ABq, <i>J</i><sub>A-B</sub> = 12.0 Hz, 2H, OC<i>H</i><sub>2</sub>Ph), 4.30–4.28 (m, 3H, 2 × <i>H</i>-5′, <i>H</i>-3′), 4.15–4.11 (m, 1H, C<i>H</i>CH<sub>3</sub>), 3.97–3.95 (m, 1H, <i>H</i>-4′), 1.96 (ddd, <i>J</i> = 13.5, 5.5, 2.5 Hz, 1H, <i>H</i>-2′), 1.55–1.50 (m, 1H, <i>H</i>-2′), 1.38 (d, <i>J</i> = 7.0 Hz, 3H, CHC<i>H</i><sub>3</sub>), 0.89 (s, 9H, C(C<i>H</i><sub>3</sub>)<sub>3</sub>), 0.01 (d,<sup>2</sup><i>J</i><sub>Si–H</sub> = 5.5 Hz, 6H, Si(C<i>H</i><sub>3</sub>)<sub>2</sub>). MS (MSI<sup>+</sup>): <i>m</i>/<i>z</i> calcd for C<sub>35</sub>H<sub>43</sub>FN<sub>3</sub>O<sub>9</sub>PSi: 727.78 [M]<sup>+</sup>; found 750.25 [M + Na]<sup>+</sup>.</div><div class="NLM_p">2′-Deoxy-5-fluoro-3′-<i>O</i>-(<i>tert</i>-butyl-dimethylsilyl)-<span class="smallcaps smallerCapital">d</span>-uridine-5′-<i>O</i>-[naphthyl-(benzyloxy-<span class="smallcaps smallerCapital">l</span>-alaninyl)] phosphate (<b>7_Isomer B</b>) was the slow eluting fraction obtained as a white solid. Yield, 12% (0.25 g). <sup>31</sup>P NMR (202 MHz, CD<sub>3</sub>OD): δ<sub>P</sub> 4.28. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ<sub>H</sub> 8.17–8.14 (m, 1H, <i>H</i>-Ar), 7.88–7.86 (m, 1H, <i>H</i>-Ar), 7.70 (d, <i>J</i><sub>H–F</sub> = 6.5 Hz, 1H, <i>H</i>-6), 7.60 (d, <i>J</i> = 8.5 Hz, 1H, <i>H</i>-Ar), 7.54–7.50 (m, 3H, <i>H</i>-Ar), 7.37 (t, <i>J</i> = 8.0 Hz, 1H, <i>H</i>-Ar), 7.33–7.27 (m, 5H, <i>H</i>-Ar), 6.06 (t, <i>J</i> = 7.5 Hz 1H, <i>H</i>-1′), 5.06 (apparent s, 2H, OC<i>H</i><sub>2</sub>Ph), 4.32–4.27 (m, 2H, <i>H</i>-3′, <i>H</i>-5′), 4.23–4.19 (m, 1H, <i>H</i>-5′), 4.15–4.11 (m, 1H, C<i>H</i>CH<sub>3</sub>), 3.99–3.97 (m, 1H, <i>H</i>-4′), 1.98 (ddd, <i>J</i> = 13.5, 5.5, 2.5 Hz, 1H, <i>H</i>-2′), 1.59–1.54 (m, 1H, <i>H</i>-2′), 1.38 (d, <i>J</i> = 7.0 Hz, 3H, CHC<i>H</i><sub>3</sub>), 0.87 (s, 9H, C(C<i>H</i><sub>3</sub>)<sub>3</sub>), 0.04 (d,<sup>2</sup><i>J</i><sub>Si–H</sub> = 5.5 Hz, 6H, Si(C<i>H</i><sub>3</sub>)<sub>2</sub>). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ<sub>C</sub> 173.08 (d,<sup>3</sup><i>J</i><sub><i>C–P</i></sub> = 4.8 Hz, <i>C</i>═O, ester), 157.95 (d,<sup>2</sup><i>J</i><sub><i>C–F</i></sub> = 26.2 Hz, <i>C</i>-4), 149.12 (<i>C</i>-2), 146.41 (d,<sup>2</sup><i>J</i><sub><i>C–P</i></sub> = 7.8 Hz, O<i>C</i>-Naph), 140.32 (d,<sup>1</sup><i>J</i><sub><i>C–F</i></sub> = 232.0 Hz, <i>C</i>-5), 135.74, 134.90 (<i>C</i>-Ar), 128.19, 127.96, 127.89, 127.60, 126.51 (<i>C</i>H–Ar), 126.47, 126.42 (<i>C</i>-Ar), 126.20, 125.17, 124.84 (<i>C</i>H–Ar), 124.28 (d,<sup>2</sup><i>J</i><sub>C–F</sub> = 34.1 Hz, <i>C</i>-6), 121.20 (<i>C</i>H-Ar), 115.17 (d,<sup>3</sup><i>J</i><sub><i>C–P</i></sub> = 3.2 Hz, <i>C</i>H–Ar), 85.77 (d,<sup>3</sup><i>J</i><sub><i>C–P</i></sub> = 7.7 Hz, <i>C</i>-4′), 85.55 (<i>C</i>-1′), 72.10 (<i>C</i>-3′), 66.63 (O<i>C</i>H<sub>2</sub>Ph), 66.11 (d,<sup>2</sup><i>J</i><sub><i>C–P</i></sub> = 5.5 Hz, <i>C</i>-5′), 50.46 (<i>C</i>HCH<sub>3</sub>), 39.80 (<i>C</i>-2′), 24.81 (C(<i>C</i>H<sub>3</sub>)<sub>3</sub>), 18.99 (d,<sup>3</sup><i>J</i><sub><i>C–P</i></sub> = 6.9 Hz, CH<i>C</i>H<sub>3</sub>), 17.34 (<i>C</i>(CH<sub>3</sub>)<sub>3</sub>), −6.06 (d,<sup>1</sup><i>J</i><sub>C–Si</sub> = 14.2 Hz, Si(<i>C</i>H<sub>3</sub>)<sub>2</sub>). MS (MSI+): <i>m</i>/<i>z</i> calcd for C<sub>35</sub>H<sub>43</sub>FN<sub>3</sub>O<sub>9</sub>PSi: 727.78 [M]<sup>+</sup>; found 750.25 [M + Na]<sup>+</sup>.</div><div class="NLM_p">2′-Deoxy-2′,2′-difluoro-3′-<i>O</i>-(<i>tert-</i>butyl-dimethylsilyl)-<span class="smallcaps smallerCapital">d</span>-cytidine-5′-<i>O</i>-[phenyl(benzyloxy-<span class="smallcaps smallerCapital">l</span>-alaninyl)] phosphate (<b>8</b>) was obtained from 3′-<i>O</i>-(<i>tert</i>-butyldimethylsilyl)-gemcitabine <b>6</b> (2.66 mmol, 1.0 g) in dry THF (14 mL), <i>tert</i>-BuMgCl (2.90 mmol, 2.9 mL), and <span class="smallcaps smallerCapital">l</span>-Ala-OBn-OPh phosphorochloridate<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> (3.97 mmol, 1.40 g) dissolved in anhydrous THF (5 mL). The reaction mixture was stirred for 16 h and then evaporated in vacuum to give a crude residue that was purified by column chromatography on silica gel, eluting with a gradient of DCM/EtOAc/MeOH (82%/15%/3%) to (79%/15%/6%) to afford <b>8b</b> as the fast eluting fraction and <b>8a</b> as the slow eluting fraction.</div><div class="NLM_p">2′-Deoxy-2′,2′-difluoro-3′-<i>tert</i>-butylsilyl-<span class="smallcaps smallerCapital">d</span>-cytidine-5′-<i>O</i>-[phenyl(benzyloxy-<span class="smallcaps smallerCapital">l</span>-alaninyl)] phosphate (<b>8a</b>) was the slow eluting fraction obtained as a white solid. Yield, 30% (0.55 g). <sup>31</sup>P NMR (202 MHz, CD<sub>3</sub>OD): δ<sub>P</sub> 3.56. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ<sub>H</sub> 7.40 (d, <i>J</i> = 7.5 Hz, 1H, <i>H</i>-6), 7.22–7.16 (m, 7H, Ar-<i>H</i>), 7.09–7.04 (m, 3H, Ar-<i>H</i>), 6.07 (t, <i>J</i><sub>H–F</sub> = 8.5 Hz 1H, <i>H</i>-1′), 5.71 (d, <i>J</i> = 7.5 Hz, 1H, <i>H</i>-5), 5.00, 4.96 (AB q, <i>J</i><sub>AB</sub> = 12.0, 9.0 Hz, 2H, OC<i>H</i><sub>2</sub>Ph), 4.31–4.27 (m, 1H, <i>H</i>-3′), 4.22–4.16 (m, 1H, <i>H</i>-4′), 4.13–4.08 (m, 1H, <i>H</i>-5′), 3.89–3.83 (m, 2H, <i>H</i>-5′, C<i>H</i>CH<sub>3</sub>), 1.23 (dd, <i>J</i> = 7.0, 1.5 Hz, 3H, CHC<i>H</i><sub>3</sub>), 0.78 (s, 9H, C(C<i>H</i><sub>3</sub>)<sub>3</sub>), 0.0 (s, 6H, Si(C<i>H</i><sub>3</sub>)<sub>2</sub>). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ<sub>C</sub> 173.07 (d,<sup>3</sup><i>J</i><sub>C–P</sub> = 5.3 Hz, <i>C</i>═O, ester), 166.26 (<i>C</i>-NH<sub>2</sub>), 156.28 (<i>C</i>═O base), 150.68 (d,<sup>2</sup><i>J</i><sub>C–P</sub> = 3.3 Hz, <i>C</i>-Ar), 141.11 (<i>C</i>H-base), 135.79 (<i>C</i>-Ar), 129.50, 128.22, 127.98, 127.88, 124.94 (<i>C</i>H-Ar), 122.83 (d,<sup>1</sup><i>J</i><sub>C–F</sub> = 258 Hz, <i>C</i>F<sub>2</sub>), 120.02, 119.98 (<i>C</i>H-Ar), 95.28 (<i>C</i>H-base), 79.39 (broad signal, <i>C</i>-1′), 79.35 (<i>C</i>-4′), 71.05 (apparent t,<sup>2</sup><i>J</i><sub>C–F</sub> = 26.1 Hz, <i>C</i>-3′), 66.60 (O<i>C</i>H<sub>2</sub>Ph), 64.02 (d,<sup>2</sup><i>J</i><sub>C–P</sub> = 4.9 Hz, <i>C</i>-5′), 50.29 (<i>C</i>HCH<sub>3</sub>), 24.63 (C(<i>C</i>H<sub>3</sub>)<sub>3</sub>), 19.02 (d,<sup>3</sup><i>J</i><sub>C–P</sub> = 6.8 Hz, CH<i>C</i>H<sub>3</sub>), 17.47 (<i>C</i>(CH<sub>3</sub>)<sub>3</sub>), −6.20 (d,<sup>1</sup><i>J</i><sub>C–Si</sub> = 29.1 Hz, Si(<i>C</i>H<sub>3</sub>)<sub>2</sub>). MS (ESI+) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>41</sub>F<sub>2</sub>N<sub>4</sub>O<sub>8</sub>PSi: 694.73 [M<sup>+</sup>]; found 717.45 [M + Na] <sup>+</sup>.</div><div class="NLM_p last">2′-Deoxy-2′,2′-difluoro-3′-<i>tert</i>-butylsilyl-<span class="smallcaps smallerCapital">d</span>-cytidine-5′-<i>O</i>-[phenyl(benzyloxy-<span class="smallcaps smallerCapital">l</span>-alaninyl)] phosphate (<b>8b</b>), the fast eluting fraction, was obtained as a white solid. Yield, 25% (0.45 g). <sup>31</sup>P NMR (202 MHz, CD<sub>3</sub>OD): δ<sub>P</sub> 3.71. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ<sub>H</sub> 7.45 (d, <i>J</i> = 7.5 Hz, 1H, <i>H</i>-6), 7.24–7.18 (m, 7H, Ar-<i>H</i>), 7.09–7.07 (m, 3H, Ar-<i>H</i>), 6.12 (t, <i>J</i><sub>H–F</sub> = 8.5 Hz 1H, <i>H</i>-1′), 5.78 (d, <i>J</i> = 7.5 Hz, 1H, <i>H</i>-5), 5.04, 5.01 (AB q, <i>J</i><sub>AB</sub> = 12.5, 3.0 Hz, 2H, OC<i>H</i><sub>2</sub>Ph), 4.39–4.36 (m, 1H, <i>H</i>-3′), 4.23–4.13 (m, 2H, <i>H</i>-5′, <i>H</i>-4′), 3.93–3.87 (m, 2H, <i>H</i>-5′, C<i>H</i>CH<sub>3</sub>), 1.24 (dd, <i>J</i> = 7.0, 1.5 Hz, 3H, CHC<i>H</i><sub>3</sub>), 0.80 (s, 9H, C(C<i>H</i><sub>3</sub>)<sub>3</sub>), 0.0 (s, 6H, Si(C<i>H</i><sub>3</sub>)<sub>2</sub>). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ<sub>C</sub> 173.35 (d,<sup>3</sup><i>J</i><sub>C–P</sub> = 4.2 Hz, <i>C</i>═O, ester), 166.26 (<i>C</i>-NH<sub>2</sub>), 156.26 (<i>C</i>═O base), 150.63 (d,<sup>2</sup><i>J</i><sub>C–P</sub> = 2.4 Hz, <i>C</i>-Ar), 140.89 (<i>C</i>H-base), 135.82 (<i>C</i>-Ar), 129.47, 128.21, 127.98, 127.92, 125.57 (<i>C</i>H–Ar), 123.90 (d,<sup>1</sup><i>J</i><sub>C–F</sub> = 266 Hz, <i>C</i>F<sub>2</sub>), 120.11, 120.07 (<i>C</i>H-Ar), 95.38 (<i>C</i>H-base), 79.24 (broad signal, <i>C</i>-1′), 75.23 (broad signal, <i>C</i>-4′), 70.94 (broad signal, <i>C</i>-3′), 66.59 (O<i>C</i>H<sub>2</sub>Ph), 63.59 (d,<sup>2</sup><i>J</i><sub>C–P</sub> = 5.0 Hz, <i>C</i>-5′), 50.47 (<i>C</i>HCH<sub>3</sub>), 24.62 (C(<i>C</i>H<sub>3</sub>)<sub>3</sub>), 18.82 (d,<sup>3</sup><i>J</i><sub><i>C–P</i></sub> = 7.7 Hz, CH<i>C</i>H<sub>3</sub>), 17.47 (<i>C</i>(CH<sub>3</sub>)<sub>3</sub>), −6.21 (d,<sup>1</sup><i>J</i><sub>C–Si</sub> = 28.1 Hz, Si(<i>C</i>H<sub>3</sub>)<sub>2</sub>). MS (ESI+) <i>m</i>/<i>z</i> calcd for C<sub>31</sub>H<sub>41</sub>F<sub>2</sub>N<sub>4</sub>O<sub>8</sub>PSi: 694.73 [M<sup>+</sup>]; found 717.45 [M + Na] <sup>+</sup>.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> General Procedure 3 for the 3′-Desilylation of 3′-TBDMS-Protected ProTides <b>7a</b>, <b>7b</b> and <b>8a</b>, <b>8b</b></h4><div class="NLM_p">The separated diastereoisomer of 3′-TBDMS-protected ProTide (<b>7a</b>, <b>7b</b>, <b>8a</b>, and <b>8b</b>) was treated with a mixture of THF/TFA/DCM (4:1:1) at 0 °C. The resulting reaction mixture was stirred at 0 °C for 2 h and then at room temperature for 12 h. After the reaction was completed, the solvents were evaporated, and the residue was purified on silica gel with a gradient of MeOH (2–8%) in DCM as an eluent.</div><div class="NLM_p">2′-Deoxy-5-fluoro-<span class="smallcaps smallerCapital">d</span>-uridine-5′-<i>O</i>-[naphthyl-(benzyloxy-<span class="smallcaps smallerCapital">l</span>-alaninyl)] phosphate (<b>9a</b> or <b>9b</b>, NUC-3373_IsoA) was obtained from the fast eluting <b>7_isomer A</b> (<b>7a</b> or <b>7b</b>) (0.19 g, 0.26 mmol) as a white solid. Yield, 75% (0.12 g). <sup>31</sup>P NMR (202 MHz, CD<sub>3</sub>OD): δ<sub>P</sub> 4.60. <sup>19</sup>F NMR (470 MHz, CD<sub>3</sub>OD): δ<sub>F</sub> – 167.05. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ<sub>H</sub> 8.14 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H, Ar-<i>H</i>), 7.87 (d, <i>J</i> = 7.0 Hz, 1H, <i>H</i>-Ar), 7.72 (apparent s, 1H, Ar-<i>H</i>), 7.69 (d, <i>J</i><sub>H–F</sub> = 6.5 Hz, 1H, <i>H</i>-6), 7.54–7.49 (m, 3H, Ar-<i>H</i>), 7.42 (t, <i>J</i> = 8.0 Hz, 1H, Ar-<i>H</i>), 7.34–7.28 (m, 5H, Ar-<i>H</i>), 6.14 (t, <i>J</i> = 6.0 Hz 1H, <i>H</i>-1′), 5.10 (ABq, <i>J</i><sub>A-B</sub> = 12.5 Hz, 2H, OC<i>H</i><sub>2</sub>Ph), 4.35–4.33 (m, 2H, <i>H</i>-3′, <i>H</i>-5′), 4.30–4.28 (m, 1H, <i>H</i>-5′), 4.14–4.08 (m, 1H, C<i>H</i>CH<sub>3</sub>), 4.07–4.05 (m, 1H, <i>H</i>-4’), 2.11 (ddd, <i>J</i> = 14.0, 6.0, 3.0 Hz, 1H, <i>H</i>-2’), 1.73–1.68 (m, 1H, <i>H</i>-2’), 1.33 (dd, <i>J</i> = 7.5, 1.5 Hz, 3H, CHC<i>H</i><sub>3</sub>). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ<sub>C</sub> 174.92 (d,<sup>3</sup><i>J</i><sub><i>C–P</i></sub> = 3.9 Hz, <i>C</i>═O, ester), 159.27 (d,<sup>2</sup><i>J</i><sub><i>C–F</i></sub> = 25.9 Hz, <i>C</i>-4), 150.52 (<i>C</i>-2), 147.90 (d,<sup>2</sup><i>J</i><sub><i>C–P</i></sub> = 7.3 Hz, O<i>C</i>-Naph), 141.73 (d,<sup>1</sup><i>J</i><sub><i>C–F</i></sub> = 232.3 Hz, <i>C</i>-5), 137.19, 136.29 (<i>C</i>-Ar), 129.59, 129.36, 128.91, 127.90 (<i>C</i>H-Ar), 127.85, 127.80 (<i>C</i>-Ar), 127.60 (<i>C</i>H-Ar), 126.50 (d,<sup>3</sup><i>J</i><sub>C–P</sub> = 1.4 Hz, <i>C</i>H-Naph), 126.18 (<i>C</i>H-Ar), 125.53 (d,<sup>2</sup><i>J</i><sub>C–F</sub> = 34.0 Hz, <i>C</i>-6), 122.64 (<i>C</i>H-Ar), 116.30 (d,<sup>3</sup><i>J</i><sub><i>C–P</i></sub> = 3.12 Hz, <i>C</i>H-Ar), 86.93 (<i>C</i>-1′), 86.88 (d,<sup>3</sup><i>J</i><sub><i>C–P</i></sub> = 8.0 Hz, <i>C</i>-4′), 72.18 (<i>C</i>-3′), 68.10 (O<i>C</i>H<sub>2</sub>Ph), 67.86 (d,<sup>2</sup><i>J</i><sub><i>C–P</i></sub> = 5.2 Hz, <i>C</i>-5′), 51.96 (<i>C</i>HCH<sub>3</sub>), 40.84 (<i>C</i>-2′), 20.24 (d,<sup>3</sup><i>J</i><sub><i>C–P</i></sub> = 7.5 Hz, CH<i>C</i>H<sub>3</sub>). MS (MSI+): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>9</sub>P: 613.53 [M]<sup>+</sup>; found 636.15 [M + Na]<sup>+</sup>. Reverse HPLC eluting with (H<sub>2</sub>O/AcCN from 100/0 to 0/100) in 30 min, <i>t</i><sub>R</sub> 16.61 min.</div><div class="NLM_p">2′-Deoxy-5-fluoro-<span class="smallcaps smallerCapital">d</span>-uridine-5′-<i>O</i>-[naphthyl-(benzyloxy-<span class="smallcaps smallerCapital">l</span>-alaninyl)] phosphate (<b>9a</b> or <b>9b</b>, NUC-3373_IsoB) was obtained from the slow eluting <b>7_isomer B</b> (<b>7a</b> or <b>7b</b>) (0.24 g, 0.36 mmol) (0.19 g, 0.26 mmol) as a white solid. Yield, 75% (0.15 g). <sup>31</sup>P NMR (202 MHz, CD<sub>3</sub>OD): δ<sub>P</sub> 4.26. <sup>19</sup>F NMR (470 MHz, CD<sub>3</sub>OD): δ<sub>F</sub> −167.31. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ<sub>H</sub> 8.17–8.14 (m, 1H, Ar-<i>H</i>), 7.90–7.87 (m, 1H, Ar-<i>H</i>), 7.72 (apparent s, 1H, Ar-<i>H</i>), 7.69 (d, <i>J</i><sub>H–F</sub> = 6.0 Hz, 1H, <i>H</i>-6), 7.54–7.48 (m, 3H, Ar-<i>H</i>), 7.38 (t, <i>J</i> = 8.0 Hz, 1H, Ar-<i>H</i>), 7.34–7.28 (m, 5H, Ar-<i>H</i>), 6.10 (t, <i>J</i> = 6.0 Hz 1H, <i>H</i>-1′), 5.12 (s, 2H, OC<i>H</i><sub>2</sub>Ph), 4.36–4.25 (m, 3H, <i>H</i>-3′, 2 × <i>H</i>-5′), 4.14–4.08 (m, 1H, C<i>H</i>CH<sub>3</sub>), 4.05 (apparent q, <i>J</i> = 2.5 Hz, 1H, <i>H</i>-4′), 2.14 (ddd, <i>J</i> = 14.0, 6.0, 3.0 Hz, 1H, <i>H</i>-2′), 1.75–1.69 (m, 1H, <i>H</i>-2′), 1.36 (dd, <i>J</i> = 7.0, 0.5 Hz, 3H, CHC<i>H</i><sub>3</sub>). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ<sub>C</sub> 174.57 (d,<sup>3</sup><i>J</i><sub><i>C–P</i></sub> = 4.5 Hz, <i>C</i>═O, ester), 159.38 (d,<sup>2</sup><i>J</i><sub><i>C–F</i></sub> = 26.0 Hz, <i>C</i>-4), 150.48 (<i>C</i>-2), 147.80 (d,<sup>2</sup><i>J</i><sub><i>C–P</i></sub> = 7.3 Hz, O<i>C</i>-Naph), 141.67 (d,<sup>1</sup><i>J</i><sub><i>C–F</i></sub> = 232.0 Hz, <i>C</i>-5), 137.15, 136.27 (<i>C</i>-Ar), 129.63, 129.40, 129.36, 128.97, 127.89 (<i>C</i>H-Ar), 127.86, 127.81 (<i>C</i>-Ar), 127.59 (<i>C</i>H-Ar), 126.56 (d,<sup>3</sup><i>J</i><sub>C–P</sub> = 1.4 Hz, <i>C</i>H-Naph), 126.22 (<i>C</i>H-Ar), 125.62 (d,<sup>2</sup><i>J</i><sub>C–F</sub> = 34.1 Hz, <i>C</i>-6), 122.63 (<i>C</i>H-Ar), 116.56 (d,<sup>3</sup><i>J</i><sub><i>C–P</i></sub> = 3.0 Hz, <i>C</i>H-Ar), 86.98 (<i>C</i>-1′), 86.68 (d,<sup>3</sup><i>J</i><sub><i>C–P</i></sub> = 7.6 Hz, <i>C</i>-4′), 72.02 (<i>C</i>-3′), 68.08 (O<i>C</i>H<sub>2</sub>Ph), 67.85 (d,<sup>2</sup><i>J</i><sub><i>C–P</i></sub> = 5.5 Hz, <i>C</i>-5′), 51.84 (<i>C</i>HCH<sub>3</sub>), 40.90 (<i>C</i>-2′), 20.44 (d,<sup>3</sup><i>J</i><sub><i>C–P</i></sub> = 6.7 Hz, CH<i>C</i>H<sub>3</sub>). MS (MSI+): <i>m</i>/<i>z</i> calcd for C<sub>29</sub>H<sub>29</sub>FN<sub>3</sub>O<sub>9</sub>P: 613.53 [M]<sup>+</sup>; found 636.15 [M + Na]<sup>+</sup>. Reverse HPLC eluting with (H<sub>2</sub>O/AcCN from 100/0 to 0/100) in 30 min, <i>t</i><sub>R</sub> 16.03 min.</div><div class="NLM_p">2′-Deoxy-2′,2′-difluoro-<span class="smallcaps smallerCapital">d</span>-cytidine-5′-<i>O</i>-[phenyl(benzyloxy-<span class="smallcaps smallerCapital">l</span>-alaninyl)] phosphate (<b>10a</b>, NUC-1031_<i>S</i><sub>P</sub>) obtained from <b>8a</b> (0.55 g, 0.79 mmol) as a white, crystalline solid. Yield, 76% (0.35 g). <sup>31</sup>P NMR (202 MHz, CD<sub>3</sub>OD): δ<sub>P</sub> 3.66. <sup>19</sup>F NMR (470 MHz, CD<sub>3</sub>OD): δ<sub>F</sub> −118.0 (d, <i>J</i> = 241 Hz, <i>F</i>), −120.24 (broad d, <i>J</i> = 241 Hz, <i>F</i>). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ<sub>H</sub> 7.58 (d, <i>J</i> = 7.5 Hz, 1H, <i>H-</i>6), 7.38–7.32 (m, 7H, Ar-<i>H</i>), 7.26–7.20 (m, 3H, Ar-<i>H</i>), 6.24 (t, <i>J</i> = 7.5 Hz, 1H, <i>H-</i>1′), 5.84 (d, <i>J</i> = 7.5 Hz, 1H, <i>H-</i>5), 5.20 (AB q, <i>J</i><sub>AB</sub> = 12.0, 7.2 Hz, 2H, OC<i>H</i><sub>2</sub>Ph), 4.46–4.43 (m, 1H, <i>H-</i>5′), 4.36–4.31 (m, 1H, <i>H-</i>5′), 4.25–4.19 (m, 1H, <i>H-</i>3′), 4.07–4.00 (m, 2H, <i>H-</i>4′, C<i>H</i>CH<sub>3</sub>), 1.38 (d, <i>J</i> = 7.2 Hz, 3H, CHC<i>H</i><sub>3</sub>). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ<sub>C</sub> 174.61 (d,<sup>3</sup><i>J</i><sub>C–P</sub> = 5.0 Hz, <i>C</i>═O, ester), 167.64 (<i>C</i>-NH<sub>2</sub>), 157.74 (<i>C</i>═O base), 152.10 (d,<sup>2</sup><i>J</i><sub>C–P</sub> = 7.0 Hz, <i>C</i>-Ar), 142.41 (<i>C</i>H-base), 137.22 (<i>C</i>-Ar), 130.91, 129.64, 129.40, 129.33, 126.33 (<i>C</i>H-Ar), 124.51 (d,<sup>1</sup><i>J</i><sub>C–F</sub> = 257 Hz, <i>C</i>F<sub>2</sub>), 121.47, 121.44 (<i>C</i>H–Ar), 96.67 (<i>C</i>H-base), 86.08 (broad signal, <i>C</i>-1′), 80.32 (<i>C</i>-4′), 71.27 (apparent t,<sup>2</sup><i>J</i><sub>C–F</sub> = 23.7 Hz, <i>C</i>-3′), 68.04 (O<i>C</i>H<sub>2</sub>Ph), 65.74 (d,<sup>2</sup><i>J</i><sub>C–P</sub> = 5.30 Hz, <i>C</i>-5′), 51.67 (<i>C</i>HCH<sub>3</sub>), 20.44 (d,<sup>3</sup><i>J</i><sub>C–P</sub> = 6.25 Hz, CH<i>C</i>H<sub>3</sub>). (ESI+) <i>m/z,</i> found: (M + Na<sup>+</sup>) 603.14. C<sub>25</sub>H<sub>27</sub>F<sub>2</sub>N<sub>4</sub>O<sub>8</sub>NaP required: (M<sup>+</sup>) 580.47. Reverse HPLC, eluting with H<sub>2</sub>O/MeOH from 100/0 to 0/100 in 35 min, <i>t</i><sub>R</sub> = 18.32 min.</div><div class="NLM_p last">2′-Deoxy-2′,2′-difluoro-<span class="smallcaps smallerCapital">d</span>-cytidine-5′-<i>O</i>-[phenyl(benzyloxy-<span class="smallcaps smallerCapital">l</span>-alaninyl)] phosphate (<b>10b</b>, NUC-1031_<i>R</i><sub>P</sub>) was obtained from <b>8b</b> (0.45 g, 0.65 mmol) as a white, crystalline solid. Yield, 78% (0.29 g). <sup>31</sup>P NMR (202 MHz, CD<sub>3</sub>OD): δ<sub>P</sub> 3.83. <sup>19</sup>F NMR (470 MHz, CD<sub>3</sub>OD): δ<sub>F</sub> −118.3 (d, <i>J</i> = 241 Hz, <i>F</i>), −120.38 (broad d, <i>J</i> = 241 Hz, <i>F</i>). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ<sub>H</sub> 7.56 (d, <i>J</i> = 7.5 Hz, 1H, <i>H-</i>6), 7.38–7.31 (m, 7H, Ar-<i>H</i>), 7.23–7.19 (m, 3H, Ar-<i>H</i>), 6.26 (t, <i>J</i> = 7.5 Hz, 1H, <i>H-</i>1′), 5.88 (d, <i>J</i> = 7.5 Hz, 1H, <i>H-</i>5), 5.20 (s, 2H, OC<i>H</i><sub>2</sub>Ph), 4.49–4.46 (m, 1H, <i>H-</i>5′), 4.38–4.34 (m, 1H, <i>H-</i>5′), 4.23–4.17 (m, 1H, <i>H-</i>3′), 4.07–4.01 (m, 2H, <i>H-</i>4′, C<i>H</i>CH<sub>3</sub>), 1.38 (d, <i>J</i> = 7.2 Hz, 3H, CHC<i>H</i><sub>3</sub>). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ<sub>C</sub> 174.65 (d,<sup>3</sup><i>J</i><sub>C–P</sub> = 5.0 Hz, <i>C</i>═O, ester), 167.65 (<i>C</i>-NH<sub>2</sub>), 157.75 (<i>C</i>═O base), 152.10 (d,<sup>2</sup><i>J</i><sub>C–P</sub> = 7.0 Hz, <i>C</i>-Ar), 142.28 (<i>C</i>H-base), 137.50 (<i>C</i>-Ar), 130.86, 129.63, 129.40, 129.32, 126.31 (<i>C</i>H-Ar), 123.73 (d,<sup>1</sup><i>J</i><sub>C–F</sub> = 252 Hz, <i>C</i>F<sub>2</sub>), 121.44, 121.40 (<i>C</i>H-Ar), 96.67 (<i>C</i>H-base), 85.90 (broad signal, <i>C</i>-1′), 80.27 (<i>C</i>-4′), 71.02 (apparent t,<sup>2</sup><i>J</i><sub>C–F</sub> = 23.7 Hz, <i>C</i>-3′), 68.04 (O<i>C</i>H<sub>2</sub>Ph), 65.52 (d,<sup>2</sup><i>J</i><sub>C–P</sub> = 5.30 Hz, <i>C</i>-5′), 51.85 (<i>C</i>HCH<sub>3</sub>), 20.23 (d,<sup>3</sup><i>J</i><sub>C–P</sub> = 7.5 Hz, CH<i>C</i>H<sub>3</sub>). (ESI+) <i>m/z</i>, found: (M + Na<sup>+</sup>) 603.14. C<sub>25</sub>H<sub>27</sub>F<sub>2</sub>N<sub>4</sub>O<sub>8</sub>NaP required: (M<sup>+</sup>) 580.47. Reverse HPLC, eluting with H<sub>2</sub>O/MeOH from 100/0 to 0/100 in 35 min, <i>t</i><sub>R</sub> = 19.15 min.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> General Method for Crystallization of <b>7_isoB</b> from the Column Purified Amorphous <b>7_isoB</b> Using the Modified Procedure<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></h4><div class="NLM_p last">The chromatographed fraction containing the compound <b>7_isoB</b> (50 mg, 97%) was dissolved in 5 mL of 2-propanol and diluted with hexane until cloudy. The solution was seeded and stirred at room temperature for 5 h. The resulting solid was filtered, washed with hexane (2 × 2 mL), and dried under a high vacuum. The obtained solid was not suitable for single crystal X-ray analysis. Multiple attempts to crystallize <b>7_isoA</b>, <b>7_isoB</b>, <b>9_isoA</b>, and <b>9_isoB</b> by slow evaporation of MeOH, 2-propanol, CHCl<sub>3</sub>, and a combination of CHCl<sub>3</sub>/Et<sub>2</sub>O (1/1, v/v), and MeOH/CHCl<sub>3</sub> (3/1, v/v), CHCl<sub>3</sub>/H<sub>2</sub>O (1/1, v/v) also failed to give crystals of sufficient quality for single crystal X-ray analysis.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02194" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14677" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14677" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02194?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02194</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Compound molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02194/suppl_file/jm0c02194_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Carboxypeptidase Y assay for NUC-3373_isoB, <b>10a</b>, and <b>10b</b> (Figures S1a–c); list of primers used for RT-PCR (Table S1); compound purity analyses; and crystal data and structure refinement for the compounds <b>10a</b> and <b>10b</b> (Table S2) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02194/suppl_file/jm0c02194_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02194/suppl_file/jm0c02194_si_001.csv">jm0c02194_si_001.csv (2.14 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02194/suppl_file/jm0c02194_si_002.pdf">jm0c02194_si_002.pdf (9.83 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">CCDC 2049153 and 2049154 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <a href="http://www.ccdc.cam.ac.uk/structures" class="extLink">www.ccdc.cam.ac.uk/structures</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c02194" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33411" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33411" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Magdalena Slusarczyk</span> - <span class="hlFld-Affiliation affiliation">Cardiff
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Redwood Building, Cardiff CF10 3NB, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4707-7190" title="Orcid link">https://orcid.org/0000-0002-4707-7190</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0d5e61787e6c7f6e777466403c4d6e6b236c6e237866"><span class="__cf_email__" data-cfemail="37645b42445645544d4e5c7a0677545119565419425c">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chris Pepper</span> - <span class="hlFld-Affiliation affiliation">Brighton
and Sussex Medical School, University of
Sussex, Medical Teaching
Building, Brighton BN1 9PX, U.K.</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#15563b45706565706755776678663b74763b607e"><span class="__cf_email__" data-cfemail="baf994eadfcacadfc8fad8c9d7c994dbd994cfd1">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michaela Serpi</span> - <span class="hlFld-Affiliation affiliation">Cardiff
University, School of Chemistry, Main Building, Park Place, Cardiff CF10 3AT, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Essam Ghazaly</span> - <span class="hlFld-Affiliation affiliation">Centre
for Haemato-Oncology, Barts Cancer Institute,
Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benson M. Kariuki</span> - <span class="hlFld-Affiliation affiliation">Cardiff
University, School of Chemistry, Main Building, Park Place, Cardiff CF10 3AT, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8658-3897" title="Orcid link">https://orcid.org/0000-0002-8658-3897</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher McGuigan</span> - <span class="hlFld-Affiliation affiliation">Cardiff
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Redwood Building, Cardiff CF10 3NB, U.K.</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65506" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65506" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank NuCana plc for funding part of the research work described in this manuscript and Andrew William Gibbs for technical assistance.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BTC</td><td class="NLM_def"><p class="first last">biliary tract cancer</p></td></tr><tr><td class="NLM_term">CDA</td><td class="NLM_def"><p class="first last">cytidine deaminase</p></td></tr><tr><td class="NLM_term">CSA</td><td class="NLM_def"><p class="first last">camphorsulfonic acid</p></td></tr><tr><td class="NLM_term">dCK</td><td class="NLM_def"><p class="first last">deoxycytidine kinase</p></td></tr><tr><td class="NLM_term">DPD</td><td class="NLM_def"><p class="first last">dihydropyrimidine dehydrogenase</p></td></tr><tr><td class="NLM_term">hENT1</td><td class="NLM_def"><p class="first last">human equilibrative nucleoside transporter 1</p></td></tr><tr><td class="NLM_term">TP</td><td class="NLM_def"><p class="first last">thymidine phosphorylase</p></td></tr><tr><td class="NLM_term">TS</td><td class="NLM_def"><p class="first last">thymidylate synthase</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67044" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67044" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 50 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cahard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Aryloxy phosphoramidate triesters as pro-tides</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.2174/1389557043403936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.2174%2F1389557043403936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=15134540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1yju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=371-381&author=D.+Cahardauthor=C.+McGuiganauthor=J.+Balzarini&title=Aryloxy+phosphoramidate+triesters+as+pro-tides&doi=10.2174%2F1389557043403936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Aryloxy phosphoramidate triesters as protides</span></div><div class="casAuthors">Cahard, Dominique; McGuigan, Christopher; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-381</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  We herein describe the development of aryloxy phosphoramidate triesters as an effective pro-tide motif for the intracellular delivery of charged bio-active antiviral nucleoside monophosphates.  The review covers the discovery of such aryl phosphoramidates, their mechanism of action and structure-activity relationships.  The application of this strategy to a range of antiviral nucleosides is highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPXB7nTgdhDLVg90H21EOLACvtfcHk0lgHrW5c0YogyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1yju7Y%253D&md5=ed98f170152c0406185126200a28a40e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F1389557043403936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043403936%26sid%3Dliteratum%253Aachs%26aulast%3DCahard%26aufirst%3DD.%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DAryloxy%2520phosphoramidate%2520triesters%2520as%2520pro-tides%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D371%26epage%3D381%26doi%3D10.2174%2F1389557043403936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serpi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibbo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caterson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibert, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verson, C. R. A.</span></span> <span> </span><span class="NLM_article-title">Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5807</span>– <span class="NLM_lpage">5812</span>, <span class="refDoi"> DOI: 10.1021/jm800594c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800594c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVeit7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5807-5812&author=C.+McGuiganauthor=M.+Serpiauthor=R.+Bibboauthor=H.+Robertsauthor=C.+Hughesauthor=B.+Catersonauthor=A.+T.+Gibertauthor=C.+R.+A.+Verson&title=Phosphate+prodrugs+derived+from+N-acetylglucosamine+have+enhanced+chondroprotective+activity+in+explant+cultures+and+represent+a+new+lead+in+antiosteoarthritis+drug+discovery&doi=10.1021%2Fjm800594c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphate Prodrugs Derived from N-Acetylglucosamine Have Enhanced Chondroprotective Activity in Explant Cultures and Represent a New Lead in Antiosteoarthritis Drug Discovery</span></div><div class="casAuthors">McGuigan, Christopher; Serpi, Michaela; Bibbo, Rita; Roberts, Helen; Hughes, Clare; Caterson, Bruce; Gibert, Ana Torrent; Verson, Carlos Raul Alez</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5807-5812</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the application of the phosphoramidate ProTide approach, developed by us for antiviral nucleosides, to sugar derivs. with potential chondro-protection against osteoarthritis.  In particular, N-acetylglucosamine was converted to a series of 06 arylaminoacyl phosphoramidates with ester and amino acid variation.  Compds. were prepd. by two routes, with or without sugar protection, and were isolated as phosphate diastereoisomers.  The compds. were assayed for cellular toxicity and for inhibition of IL-1 induced glycosaminoglycan (GAG) release (i.e., proteoglycan degrdn.) from bovine articular cartilage in vitro explant cultures.  By comparison to the N-acetyl glucosamine parent, some of the analogs show a significant enhancement in efficacy in the inhibition of inflammatory cytokine-induced proteoglycan degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpclksqSYf6v7Vg90H21EOLACvtfcHk0lgHrW5c0YogyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVeit7fJ&md5=0a73f4bc96da9eae18b87d16bc3d3267</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm800594c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800594c%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DSerpi%26aufirst%3DM.%26aulast%3DBibbo%26aufirst%3DR.%26aulast%3DRoberts%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DC.%26aulast%3DCaterson%26aufirst%3DB.%26aulast%3DGibert%26aufirst%3DA.%2BT.%26aulast%3DVerson%26aufirst%3DC.%2BR.%2BA.%26atitle%3DPhosphate%2520prodrugs%2520derived%2520from%2520N-acetylglucosamine%2520have%2520enhanced%2520chondroprotective%2520activity%2520in%2520explant%2520cultures%2520and%2520represent%2520a%2520new%2520lead%2520in%2520antiosteoarthritis%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5807%26epage%3D5812%26doi%3D10.1021%2Fjm800594c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serpi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibbo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caterson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibert, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">Novel phosphoramidate prodrugs of N-acetyl-(D)- glucosamine with antidegenerative activity on bovine and human cartilage explants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4629</span>– <span class="NLM_lpage">4639</span>, <span class="refDoi"> DOI: 10.1021/jm300074y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300074y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFKltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4629-4639&author=M.+Serpiauthor=R.+Bibboauthor=S.+Ratauthor=H.+Robertsauthor=C.+Hughesauthor=B.+Catersonauthor=M.+J.+Alcarazauthor=A.+T.+Gibertauthor=C.+R.+Versonauthor=C.+McGuigan&title=Novel+phosphoramidate+prodrugs+of+N-acetyl-%28D%29-+glucosamine+with+antidegenerative+activity+on+bovine+and+human+cartilage+explants&doi=10.1021%2Fjm300074y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Phosphoramidate Prodrugs of N-Acetyl-(d)-Glucosamine with Antidegenerative Activity on Bovine and Human Cartilage Explants</span></div><div class="casAuthors">Serpi, Michaela; Bibbo, Rita; Rat, Stephanie; Roberts, Helen; Hughes, Claire; Caterson, Bruce; Alcaraz, Maria Jose; Gibert, Anna Torrent; Verson, Carlos Raul Alaez; McGuigan, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4629-4639</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(d)-Glucosamine and other nutritional supplements have emerged as safe alternative therapies for osteoarthritis (OA), a chronic and degenerative articular joint disease.  In our preceding paper, a series of novel O-6 phosphate N-acetyl (d)-glucosamine prodrugs aimed at improving the oral bioavailability of N-acetyl-(d)-glucosamine as its putative bioactive phosphate form were shown to have greater chondroprotective activity in vitro when compared to the parent agent.  In order to extend the SAR studies, this work focuses on the O-3 and O-4 phosphate prodrugs of N-acetyl-(d)-glucosamine bearing a 4-methoxy Ph group and different amino acid esters on the phosphate moiety.  Among the compds., the (l)-proline amino acid-contg. prodrugs proved to be the most active of the series, more effective than the prior O-6 compds., and well processed in chondrocytes in vitro.  Data on human cartilage support the notion that these novel O-3 and O-4 regioisomers may represent novel promising leads for drug discovery for osteoarthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcKi2AVqV3arVg90H21EOLACvtfcHk0lgSn2MiRIln6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFKltb0%253D&md5=49363bc5c1b86096d9f79c28ed45584a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm300074y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300074y%26sid%3Dliteratum%253Aachs%26aulast%3DSerpi%26aufirst%3DM.%26aulast%3DBibbo%26aufirst%3DR.%26aulast%3DRat%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DC.%26aulast%3DCaterson%26aufirst%3DB.%26aulast%3DAlcaraz%26aufirst%3DM.%2BJ.%26aulast%3DGibert%26aufirst%3DA.%2BT.%26aulast%3DVerson%26aufirst%3DC.%2BR.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DNovel%2520phosphoramidate%2520prodrugs%2520of%2520N-acetyl-%2528D%2529-%2520glucosamine%2520with%2520antidegenerative%2520activity%2520on%2520bovine%2520and%2520human%2520cartilage%2520explants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4629%26epage%3D4639%26doi%3D10.1021%2Fjm300074y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintiliani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of prodrugs of 2-fluoro-2-deoxyribose-1-phosphate and 2,2-difluoro-2-deoxyribose-1-phosphate</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2555</span>– <span class="NLM_lpage">2559</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1016%2Fj.bmcl.2013.02.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=23541671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVCis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2555-2559&author=N.+Hamonauthor=M.+Quintilianiauthor=J.+Balzariniauthor=C.+McGuigan&title=Synthesis+and+biological+evaluation+of+prodrugs+of+2-fluoro-2-deoxyribose-1-phosphate+and+2%2C2-difluoro-2-deoxyribose-1-phosphate&doi=10.1016%2Fj.bmcl.2013.02.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of prodrugs of 2-fluoro-2-deoxyribose-1-phosphate and 2,2-difluoro-2-deoxyribose-1-phosphate</span></div><div class="casAuthors">Hamon, Nadege; Quintiliani, Maurizio; Balzarini, Jan; McGuigan, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2555-2559</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report in this Letter the synthesis of prodrugs of 2-fluoro-2-deoxyarabinose-1-phosphates, e.g. I, and 2,2-difluoro-2-deoxyribose-1-phosphates.  We demonstrate the difficulty of realizing a phosphorylation step on the anomeric position of 2-deoxyribose, and we discover that introduction of fluorine atoms on the 2 position of 2-deoxyribose enables the phosphorylation step: in fact, the stability of the prodrugs increases with the degree of 2-fluorination.  Stability studies of prodrugs of 2-fluoro-2-deoxyribose-1-phosphate and 2,2-difluoro-2-deoxyribose-1-phosphate in acidic and neutral conditions were conducted to confirm our observation.  Biol. evaluation of prodrugs of 2,2-difluoro-2-deoxyribose-1-phosphate for antiviral and cytotoxic activity is reported.  Unfortunately, biol. evaluation of the prodrugs of the 2,2-difluoro-2-deoxyribose-1-phosphate showed that they had no inhibitory activity against a variety of virus infections and cancer cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg7v3zBd-uu7Vg90H21EOLACvtfcHk0lgSn2MiRIln6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVCis7Y%253D&md5=c6410cece574c67b8f1d32bb166c127f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.117%26sid%3Dliteratum%253Aachs%26aulast%3DHamon%26aufirst%3DN.%26aulast%3DQuintiliani%26aufirst%3DM.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520prodrugs%2520of%25202-fluoro-2-deoxyribose-1-phosphate%2520and%25202%252C2-difluoro-2-deoxyribose-1-phosphate%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2555%26epage%3D2559%26doi%3D10.1016%2Fj.bmcl.2013.02.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serpi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of phosphoramidate prodrugs of two analogues of 2-deoxy-D-ribose-1-phosphate directed to the discovery of two carbasugars as new potential anti-HIV leads</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.12.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1016%2Fj.bmc.2014.12.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=25616343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVClsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=829-838&author=N.+Hamonauthor=M.+Slusarczykauthor=M.+Serpiauthor=J.+Balzariniauthor=C.+McGuigan&title=Synthesis+and+biological+evaluation+of+phosphoramidate+prodrugs+of+two+analogues+of+2-deoxy-D-ribose-1-phosphate+directed+to+the+discovery+of+two+carbasugars+as+new+potential+anti-HIV+leads&doi=10.1016%2Fj.bmc.2014.12.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of phosphoramidate prodrugs of two analogues of 2-deoxy-D-ribose-1-phosphate directed to the discovery of two carbasugars as new potential anti-HIV leads</span></div><div class="casAuthors">Hamon, Nadege; Slusarczyk, Magdalena; Serpi, Michaela; Balzarini, Jan; McGuigan, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">829-838</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">2-Deoxy-α-D-ribose-1-phosphate is of great interest as it is involved in the biosynthesis and/or catabolic degrdn. of several nucleoside analogs of biol. and therapeutic relevance.  However due to the lack of a stabilizing group at its 2-position, it is difficult to synthesize stable prodrugs of this compd.  In order to overcome this lack of stability, the synthesis of carbasugar analogs of 2-deoxyribose-1-phosphate was envisioned.  Herein the prepn. of a series of prodrugs of two carbocyclic analogs of 2-deoxyribose-1-phosphate using the phosphoramidate ProTide technol., along with their biol. evaluation against HIV and cancer cell proliferation, is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsBev09xhLN7Vg90H21EOLACvtfcHk0lgSn2MiRIln6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVClsA%253D%253D&md5=93ef3df511600da958e43d895ea72237</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.039%26sid%3Dliteratum%253Aachs%26aulast%3DHamon%26aufirst%3DN.%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DSerpi%26aufirst%3DM.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520phosphoramidate%2520prodrugs%2520of%2520two%2520analogues%2520of%25202-deoxy-D-ribose-1-phosphate%2520directed%2520to%2520the%2520discovery%2520of%2520two%2520carbasugars%2520as%2520new%2520potential%2520anti-HIV%2520leads%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D829%26epage%3D838%26doi%3D10.1016%2Fj.bmc.2014.12.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">James, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertusati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">Kinase-independent phosphoramidate S1P1 receptor agonist benzyl ether derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1371</span>– <span class="NLM_lpage">1378</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1016%2Fj.bmcl.2017.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=28236593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVCksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1371-1378&author=E.+Jamesauthor=F.+Pertusatiauthor=A.+Brancaleauthor=C.+McGuigan&title=Kinase-independent+phosphoramidate+S1P1+receptor+agonist+benzyl+ether+derivatives&doi=10.1016%2Fj.bmcl.2017.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-independent phosphoramidate S1P1 receptor agonist benzyl ether derivs.</span></div><div class="casAuthors">James, Edward; Pertusati, Fabrizio; Brancale, Andrea; McGuigan, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1371-1378</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previously published S1P receptor modulator benzyl ether derivs. have shown potential as being viable therapeutics for the treatment of neurodegenerative diseases, however, two of the most S1P1-selective compds. are reported as being poorly phosphorylated by kinases in vivo.  Phosphoramidates of BED compds. (2a, 2b) were synthesized with the aim of producing kinase-independent S1P receptor modulators.  Carboxypeptidase, human serum and cell lysate processing expts. were conducted.  ProTide BED analogs were found to have an acceptable level of stability in acidic and basic conditions and in vitro metabolic processing expts. showed that they are processed to the desired pharmacol. active monophosphate.  The research describes the development of an entirely novel family of therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGOe6jnvJ69rVg90H21EOLACvtfcHk0ljHRXa-YUjtKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVCksbc%253D&md5=58fbcab904a69659a33ab20298e7c83b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DE.%26aulast%3DPertusati%26aufirst%3DF.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DKinase-independent%2520phosphoramidate%2520S1P1%2520receptor%2520agonist%2520benzyl%2520ether%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D1371%26epage%3D1378%26doi%3D10.1016%2Fj.bmcl.2017.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osgerby, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalfitano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Duff, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabeen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miccoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muqit, M. M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehellou, Y.</span></span> <span> </span><span class="NLM_article-title">Kinetin riboside and its protides activate the Parkinson’s disease associated PTEN-induced putative kinase 1 (PINK1) independent of mitochondrial depolarization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3518</span>– <span class="NLM_lpage">3524</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01897</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01897" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslKlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3518-3524&author=L.+Osgerbyauthor=Y.-C.+Laiauthor=P.+J.+Thorntonauthor=J.+Amalfitanoauthor=C.+S.+Le+Duffauthor=I.+Jabeenauthor=H.+Kadriauthor=A.+Miccoliauthor=J.+H.+R.+Tuckerauthor=M.+M.+K.+Muqitauthor=Y.+Mehellou&title=Kinetin+riboside+and+its+protides+activate+the+Parkinson%E2%80%99s+disease+associated+PTEN-induced+putative+kinase+1+%28PINK1%29+independent+of+mitochondrial+depolarization&doi=10.1021%2Facs.jmedchem.6b01897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetin Riboside and Its ProTides Activate the Parkinson's Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial Depolarization</span></div><div class="casAuthors">Osgerby, Laura; Lai, Yu-Chiang; Thornton, Peter J.; Amalfitano, Joseph; Le Duff, Cecile S.; Jabeen, Iqra; Kadri, Hachemi; Miccoli, Ageo; Tucker, James H. R.; Muqit, Miratul M. K.; Mehellou, Youcef</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3518-3524</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since loss of function mutations of PINK1 lead to early onset Parkinson's disease, there has been growing interest in the discovery of small mols. that amplify the kinase activity of PINK1.  We herein report the design, synthesis, serum stability, and hydrolysis of four kinetin riboside ProTides.  These ProTides, along with kinetin riboside, activated PINK1 in cells independent of mitochondrial depolarization.  This highlights the potential of modified nucleosides and their phosphate prodrugs as treatments for neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE0IJ5gXFDs7Vg90H21EOLACvtfcHk0ljHRXa-YUjtKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslKlt7s%253D&md5=bc90c5fa151f4c8e63d4a96a1297bc3a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01897%26sid%3Dliteratum%253Aachs%26aulast%3DOsgerby%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DY.-C.%26aulast%3DThornton%26aufirst%3DP.%2BJ.%26aulast%3DAmalfitano%26aufirst%3DJ.%26aulast%3DLe%2BDuff%26aufirst%3DC.%2BS.%26aulast%3DJabeen%26aufirst%3DI.%26aulast%3DKadri%26aufirst%3DH.%26aulast%3DMiccoli%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DJ.%2BH.%2BR.%26aulast%3DMuqit%26aufirst%3DM.%2BM.%2BK.%26aulast%3DMehellou%26aufirst%3DY.%26atitle%3DKinetin%2520riboside%2520and%2520its%2520protides%2520activate%2520the%2520Parkinson%25E2%2580%2599s%2520disease%2520associated%2520PTEN-induced%2520putative%2520kinase%25201%2520%2528PINK1%2529%2520independent%2520of%2520mitochondrial%2520depolarization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3518%26epage%3D3524%26doi%3D10.1021%2Facs.jmedchem.6b01897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davey, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malde, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mykura, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taher, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Duff, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willcox, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehellou, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of (E)-4-hydroxy-3-methylbut-2-enyl phosphate (HMBP) aryloxy triester phosphoramidate prodrugs as activators of Vγ9/Vδ2 T-cell immune responses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2111</span>– <span class="NLM_lpage">2117</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01824</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01824" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2111-2117&issue=5&author=M.+S.+Daveyauthor=R.+Maldeauthor=R.+C.+Mykuraauthor=A.+T.+Bakerauthor=T.+E.+Taherauthor=C.+S.+Le+Duffauthor=B.+E.+Willcoxauthor=Y.+Mehellou&title=Synthesis+and+biological+evaluation+of+%28E%29-4-hydroxy-3-methylbut-2-enyl+phosphate+%28HMBP%29+aryloxy+triester+phosphoramidate+prodrugs+as+activators+of+V%CE%B39%2FV%CE%B42+T-cell+immune+responses&doi=10.1021%2Facs.jmedchem.7b01824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of (E)-4-Hydroxy-3-methylbut-2-enyl Phosphate (HMBP) Aryloxy Triester Phosphoramidate Prodrugs as Activators of Vγ9/Vδ2 T-Cell Immune Responses</span></div><div class="casAuthors">Davey, Martin S.; Malde, Roshni; Mykura, Rory C.; Baker, Alfie T.; Taher, Taher E.; Le Duff, Cecile S.; Willcox, Benjamin E.; Mehellou, Youcef</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2111-2117</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The aryloxy triester phosphoramidate prodrug approach has been used with success in drug discovery.  Herein, we describe the first application of this prodrug technol. to the monophosphate deriv. of the phosphoantigen HMBPP and one of its analogs.  Some of these prodrugs exhibited specific and potent activation of Vγ9/Vδ2 T-cells, which were then able to lyse bladder cancer cells in vitro.  This work highlights the promise of this prodrug technol. in the discovery of novel immunotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM4h5SljO2ArVg90H21EOLACvtfcHk0ljHRXa-YUjtKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCntL8%253D&md5=a67679dcb0dcd5b81b0fc0b9e70df5ad</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01824%26sid%3Dliteratum%253Aachs%26aulast%3DDavey%26aufirst%3DM.%2BS.%26aulast%3DMalde%26aufirst%3DR.%26aulast%3DMykura%26aufirst%3DR.%2BC.%26aulast%3DBaker%26aufirst%3DA.%2BT.%26aulast%3DTaher%26aufirst%3DT.%2BE.%26aulast%3DLe%2BDuff%26aufirst%3DC.%2BS.%26aulast%3DWillcox%26aufirst%3DB.%2BE.%26aulast%3DMehellou%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520%2528E%2529-4-hydroxy-3-methylbut-2-enyl%2520phosphate%2520%2528HMBP%2529%2520aryloxy%2520triester%2520phosphoramidate%2520prodrugs%2520as%2520activators%2520of%2520V%25CE%25B39%252FV%25CE%25B42%2520T-cell%2520immune%2520responses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D5%26spage%3D2111%26epage%3D2117%26doi%3D10.1021%2Facs.jmedchem.7b01824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghazaly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">Application of protide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1531</span>– <span class="NLM_lpage">1542</span>, <span class="refDoi"> DOI: 10.1021/jm401853a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401853a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1531-1542&author=M.+Slusarczykauthor=M.+H.+Lopezauthor=J.+Balzariniauthor=M.+Masonauthor=W.+G.+Jiangauthor=S.+Blagdenauthor=E.+Thompsonauthor=E.+Ghazalyauthor=C.+McGuigan&title=Application+of+protide+technology+to+gemcitabine%3A+a+successful+approach+to+overcome+the+key+cancer+resistance+mechanisms+leads+to+a+new+agent+%28NUC-1031%29+in+clinical+development&doi=10.1021%2Fjm401853a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development</span></div><div class="casAuthors">Slusarczyk, Magdalena; Lopez, Monica Huerta; Balzarini, Jan; Mason, Malcolm; Jiang, Wen G.; Blagden, Sarah; Thompson, Emely; Ghazaly, Essam; McGuigan, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1531-1542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Gemcitabine is a nucleoside analog commonly used in cancer therapy but with limited efficacy due to a high susceptibility to cancer cell resistance.  The addn. of a phosphoramidate motif to the gemcitabine can protect it against many of the key cancer resistance mechanisms.  We have synthesized a series of gemcitabine phosphoramidate prodrugs, e.g. I, and screened for cytostatic activity in a range of different tumor cell lines.  Among the synthesized compds., one in particular (NUC-1031, I) was shown to be potent in vitro.  Importantly, compared with gemcitabine, I activation was significantly less dependent on deoxycytidine kinase and on nucleoside transporters, and it was resistant to cytidine deaminase-mediated degrdn.  Moreover, I showed a significant redn. in tumor vols. in vivo in pancreatic cancer xenografts.  The ProTide I is now in clin. development with encouraging efficacy signals in a Phase I/II study, which strongly supports the ProTide approach to generate promising new anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2UbxkazAxBbVg90H21EOLACvtfcHk0linyLOjGoFUqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCntbs%253D&md5=981fde9daf27a1e4d9fa59d1d15cfc08</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm401853a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401853a%26sid%3Dliteratum%253Aachs%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DM.%2BH.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DMason%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DW.%2BG.%26aulast%3DBlagden%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DE.%26aulast%3DGhazaly%26aufirst%3DE.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DApplication%2520of%2520protide%2520technology%2520to%2520gemcitabine%253A%2520a%2520successful%2520approach%2520to%2520overcome%2520the%2520key%2520cancer%2520resistance%2520mechanisms%2520leads%2520to%2520a%2520new%2520agent%2520%2528NUC-1031%2529%2520in%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1531%26epage%3D1542%26doi%3D10.1021%2Fjm401853a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murziani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonczy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vande Voorde, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liekens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Phosphoramidate protides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7247</span>– <span class="NLM_lpage">7258</span>, <span class="refDoi"> DOI: 10.1021/jm200815w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200815w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eru7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7247-7258&author=C.+McGuiganauthor=P.+Murzianiauthor=M.+Slusarczykauthor=B.+Gonczyauthor=J.+Vande+Voordeauthor=S.+Liekensauthor=J.+Balzarini&title=Phosphoramidate+protides+of+the+anticancer+agent+FUDR+successfully+deliver+the+preformed+bioactive+monophosphate+in+cells+and+confer+advantage+over+the+parent+nucleoside&doi=10.1021%2Fjm200815w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoramidate ProTides of the Anticancer Agent FUDR Successfully Deliver the Preformed Bioactive Monophosphate in Cells and Confer Advantage over the Parent Nucleoside</span></div><div class="casAuthors">McGuigan, Christopher; Murziani, Paola; Slusarczyk, Magdalena; Gonczy, Blanka; Vande Voorde, Johan; Liekens, Sandra; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7247-7258</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The fluorinated pyrimidine family of nucleosides continues to represent major current chemotherapeutic agents for treating solid tumors.  We herein report their phosphate prodrugs, ProTides, as promising new derivs., which partially bypass the dependence of the current drugs on active transport and nucleoside kinase-mediated activation.  They are also resistant to metabolic deactivation by phosphorolytic enzymes.  We report 39 ProTides of the fluorinated pyrimidine FUDR with variation in the aryl, ester, and amino acid regions.  Notably, only certain ProTide motifs are successful in delivering the nucleoside monophosphate into intact cells.  We also find that the ProTides retain activity in mycoplasma infected cells, unlike FUDR.  Data suggest these compds. to be worthy of further progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppOiNKgrQqyLVg90H21EOLACvtfcHk0linyLOjGoFUqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eru7zP&md5=dbc6dde916700391cbd0b13b5d0c116c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm200815w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200815w%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DMurziani%26aufirst%3DP.%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DGonczy%26aufirst%3DB.%26aulast%3DVande%2BVoorde%26aufirst%3DJ.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DPhosphoramidate%2520protides%2520of%2520the%2520anticancer%2520agent%2520FUDR%2520successfully%2520deliver%2520the%2520preformed%2520bioactive%2520monophosphate%2520in%2520cells%2520and%2520confer%2520advantage%2520over%2520the%2520parent%2520nucleoside%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7247%26epage%3D7258%26doi%3D10.1021%2Fjm200815w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cass, C. E.</span></span> <span> </span><span class="NLM_article-title">Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4349</span>– <span class="NLM_lpage">4357</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=9766663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADyaK1cXmsVyqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=4349-4357&author=J.+R.+Mackeyauthor=R.+S.+Maniauthor=M.+Selnerauthor=D.+Mowlesauthor=J.+D.+Youngauthor=J.+A.+Beltauthor=C.+R.+Crawfordauthor=C.+E.+Cass&title=Functional+nucleoside+transporters+are+required+for+gemcitabine+influx+and+manifestation+of+toxicity+in+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines</span></div><div class="casAuthors">Mackey, John R.; Mani, Rajam S.; Selner, Milada; Mowles, Delores; Young, James D.; Belt, Judith A.; Crawford, Charles R.; Cass, Carol E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4349-4357</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Gemcitabine (2',2'-difluorodeoxycytidine) is a novel pyrimidine nucleoside drug with clin. efficacy in several common epithelial cancers.  We have proposed that gemcitabine requires nucleoside transporter (NT) proteins to permeate the plasma membrane and to exhibit pharmacol. activity.  In humans, there are seven reported distinct NT activities varying in substrate specificity, sodium dependence, and sensitivity to inhibition by nitrobenzylthioinosine (NBMPR) and dipyridamole.  To det. which NTs are required for gemcitabine-dependent growth inhibition, cultures from a panel of 12 cell lines with defined plasma membrane NT activities were incubated with different concns. of gemcitabine.  Cell proliferation was assessed by the sulforhodamine B assay and cell enumeration to identify the concns. of gemcitabine that inhibited cell replication by 50% (IC50s).  NT activity was a prerequisite for growth inhibition in vitro because: (a) the nucleoside transport-deficient cells were highly resistant to gemcitabine; and (b) treatment of cells that exhibited only equilibrative NT activity with NBMPR or dipyridamole increased resistance to gemcitabine by 39- to 1800-fold.  These data suggested that the type of NT activities possessed by a cell may be an important determinant of its sensitivity to gemcitabine and that NT deficiency may confer significant gemcitabine resistance.  We analyzed the uptake kinetics of [3H]gemcitabine by each of five human NT activities in cell lines that exhibited a single NT activity in isolation; transient transfection of the cDNAs encoding the human concentrative NT proteins (hCNT1 and hCNT2) was used to study the cit and cif activities, resp.  The efficiency of gemcitabine uptake varied markedly among the cell lines with single NTs: es ≃ cit > ei > cib >>> cif.  The transportability of [3H]gemcitabine was demonstrated by reconstitution of the human es NT in proteoliposomes, confirming that gemcitabine permeation is a protein-mediated process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEu51WE2MjmrVg90H21EOLACvtfcHk0linyLOjGoFUqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsVyqsbo%253D&md5=44abf3f52c97ef2a5cbf04f59b97a58f</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMackey%26aufirst%3DJ.%2BR.%26aulast%3DMani%26aufirst%3DR.%2BS.%26aulast%3DSelner%26aufirst%3DM.%26aulast%3DMowles%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DJ.%2BD.%26aulast%3DBelt%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DC.%2BR.%26aulast%3DCass%26aufirst%3DC.%2BE.%26atitle%3DFunctional%2520nucleoside%2520transporters%2520are%2520required%2520for%2520gemcitabine%2520influx%2520and%2520manifestation%2520of%2520toxicity%2520in%2520cancer%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D4349%26epage%3D4357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gourdeau, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolivet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafrenière, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cass, C. E.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7217</span>– <span class="NLM_lpage">7224</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=11585758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsVeht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=7217-7224&author=H.+Gourdeauauthor=M.+L.+Clarkeauthor=F.+Ouelletauthor=D.+Mowlesauthor=M.+Selnerauthor=A.+Richardauthor=N.+Leeauthor=J.+R.+Mackeyauthor=J.+D.+Youngauthor=J.+Jolivetauthor=R.+G.+Lafreni%C3%A8reauthor=C.+E.+Cass&title=Mechanisms+of+uptake+and+resistance+to+troxacitabine%2C+a+novel+deoxycytidine+nucleoside+analogue%2C+in+human+leukemic+and+solid+tumor+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines</span></div><div class="casAuthors">Gourdeau, Henriette; Clarke, Marilyn L.; Ouellet, France; Mowles, Delores; Selner, Milada; Richard, Annie; Lee, Nola; Mackey, John R.; Young, James D.; Jolivet, Jacques; Lafreniere, Ronald G.; Cass, Carol E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7217-7224</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Troxacitabine (Troxatyl; BCH-4556; (-)-2'-deoxy-3'-oxacytidine), a deoxycytidine analog with an unusual dioxolane structure and nonnatural L-configuration, has potent antitumor activity in animal models and is in clin. trials against human malignancies.  The current work was undertaken to identify potential biochem. mechanisms of resistance to troxacitabine and to det. whether there are differences in resistance mechanisms between troxacitabine, gemcitabine, and cytarabine in human leukemic and solid tumor cell lines.  The CCRF-CEM leukemia cell line was highly sensitive to the antiproliferative effects of troxacitabine, gemcitabine, and cytarabine with inhibition of proliferation by 50% obsd. at 160, 20, and 10 nM, resp., whereas a deoxycytidine kinase (dCK)-deficient variant (CEM/dCK-) was resistant to all three drugs.  In contrast, a nucleoside transport-deficient variant (CEM/ARAC8C) exhibited high levels of resistance to cytarabine (1150-fold) and gemcitabine (432-fold) but only minimal resistance to troxacitabine (7-fold).  Anal. of troxacitabine transportability by the five molecularly characterized human nucleoside transporters [human equilibrative nucleoside transporters 1 and 2, human concentrative nucleoside transporter (hCNT) 1, hCNT2, and hCNT3] revealed that short- and long-term uptake of 10-30 μM [3H]troxacitabine was low and unaffected by the presence of either nucleoside transport inhibitors or high concns. of nonradioactive troxacitabine.  These results, which suggested that the major route of cellular uptake of troxacitabine was passive diffusion, demonstrated that deficiencies in nucleoside transport were unlikely to impart resistance to troxacitabine.  A troxacitabine-resistant prostate cancer subline (DU145R; 6300-fold) that exhibited reduced uptake of troxacitabine was cross-resistant to both gemcitabine (350-fold) and cytarabine (300-fold).  DCK activity toward deoxycytidine in DU145R cell lysates was <20% of that in DU145 cell lysates, and no activity was detected toward troxacitabine.  Sequence anal. of cDNAs encoding dCK revealed a mutation of a highly conserved amino acid (Trp92→Leu) in DU145R dCK, providing a possible explanation for the reduced phosphorylation of troxacitabine in DU145R lysates.  Reduced deamination of deoxycytidine was also obsd. in DU145R relative to DU145 cells, and this may have contributed to the overall resistance phenotype.  These results, which demonstrated a different resistance profile for troxacitabine, gemcitabine, and cytarabine, suggest that troxacitabine may have an advantage over gemcitabine and cytarabine in human malignancies that lack or have low nucleoside transport activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphoDIwz8UhC7Vg90H21EOLACvtfcHk0lhQHxSegvXO4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsVeht7g%253D&md5=816052844c3dff95c6a7feb4123f4fd1</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGourdeau%26aufirst%3DH.%26aulast%3DClarke%26aufirst%3DM.%2BL.%26aulast%3DOuellet%26aufirst%3DF.%26aulast%3DMowles%26aufirst%3DD.%26aulast%3DSelner%26aufirst%3DM.%26aulast%3DRichard%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DMackey%26aufirst%3DJ.%2BR.%26aulast%3DYoung%26aufirst%3DJ.%2BD.%26aulast%3DJolivet%26aufirst%3DJ.%26aulast%3DLafreni%25C3%25A8re%26aufirst%3DR.%2BG.%26aulast%3DCass%26aufirst%3DC.%2BE.%26atitle%3DMechanisms%2520of%2520uptake%2520and%2520resistance%2520to%2520troxacitabine%252C%2520a%2520novel%2520deoxycytidine%2520nucleoside%2520analogue%252C%2520in%2520human%2520leukemic%2520and%2520solid%2520tumor%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D7217%26epage%3D7224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz van Haperen, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veerman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boven, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmann, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermorken, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinedo, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span> <span> </span><span class="NLM_article-title">Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4138</span>– <span class="NLM_lpage">4143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=8033147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADyaK2cXlsVynu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1994&pages=4138-4143&author=V.+W.+Ruiz+van+Haperenauthor=G.+Veermanauthor=S.+Erikssonauthor=E.+Bovenauthor=A.+P.+Stegmannauthor=M.+Hermsenauthor=J.+B.+Vermorkenauthor=H.+M.+Pinedoauthor=G.+J.+Peters&title=Development+and+molecular+characterization+of+a+2%E2%80%B2%2C2%E2%80%B2-difluorodeoxycytidine-resistant+variant+of+the+human+ovarian+carcinoma+cell+line+A2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780</span></div><div class="casAuthors">Ruiz van Haperen, Veronique W. T.; Veerman, Gijsbert; Eriksson, Staffan; Boven, Epie; Stegmann, Alexander P. A.; Hermsen, Mario; Vermorken, Jan B.; Pinedo, Herbert M.; Peters, Godefridus J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4138-43</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">2',2'-Difluorodeoxycytidine (gemcitabine, dFdCyd) is a deoxycytidine analog with promising antitumor activity.  In order to be active it must be phosphorylated by deoxycytidine kinase (dCK).  The authors induced resistance to dFdCyd in the human ovarian carcinoma cell line A2780 by exposure to increasing concns. of dFdCyd.  The IC50, defined as the concn. of dFdCyd causing 50% growth inhibition, at 72 h exposure increased from 0.6 nM dFdCyd in A2780 to 92 μM in the resistant variant, named AG6000.  Although the resistant cell line is routinely cultured in 6 μM dFdCyd, the resistant phenotype can be maintained for at least 10 passages without dFdCyd.  AG6000 is cross-resistant to other drugs which require activation by dCK, such as 1-β-D-arabinofuranosylcytosine, 5-aza-2'-deoxycytidine, and 2-chlorodeoxyadenosine.  There was no specific dCK activity in exts. from AG6000 cells.  Western blot anal. using a polyclonal anti-dCK antibody did not reveal any dCK protein in AG6000 cell exts.  Reverse-transcribed and PCR-amplified mRNA, using specific dCK primers, demonstrated that AG6000 expressed a normal length amplicon of 701 base pairs, besides an aberrant amplicon of 500 base pairs.  Chromosome spreads from the cell lines showed no major differences between A2780 and AG6000.  The latter cell line was also cross-resistant to 2',2'-difluorodeoxyuridine, the deamination product of dFdCyd.  Addnl., cross-resistance to the multidrug resistance drugs doxorubicin and vincristine was obsd.  This was not assocd. with the induction of P-glycoprotein, as detd. by the RNase protection assay.  Injection of AG6000 cells s.c. into nude mice demonstrated that the cell line had retained its tumorigenicity; AG6000 xenografts were not sensitive to dFdCyd treatment, in contrast to the parental A2780 tumors.  No dFdCyd triphosphate accumulation was found in the resistant tumors, in contrast to the parental A2780 tumors.  These results indicate that the dFdCyd resistance phenotype is stable, and mainly due to dCK deficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7vUGzO626KLVg90H21EOLACvtfcHk0lhQHxSegvXO4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsVynu7w%253D&md5=41070986d07e3bbeef310f568683605f</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz%2Bvan%2BHaperen%26aufirst%3DV.%2BW.%26aulast%3DVeerman%26aufirst%3DG.%26aulast%3DEriksson%26aufirst%3DS.%26aulast%3DBoven%26aufirst%3DE.%26aulast%3DStegmann%26aufirst%3DA.%2BP.%26aulast%3DHermsen%26aufirst%3DM.%26aulast%3DVermorken%26aufirst%3DJ.%2BB.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26atitle%3DDevelopment%2520and%2520molecular%2520characterization%2520of%2520a%25202%25E2%2580%25B2%252C2%25E2%2580%25B2-difluorodeoxycytidine-resistant%2520variant%2520of%2520the%2520human%2520ovarian%2520carcinoma%2520cell%2520line%2520A2780%26jtitle%3DCancer%2520Res.%26date%3D1994%26volume%3D54%26spage%3D4138%26epage%3D4143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kroep, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loves, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Wilt, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talianidis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boven, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braakhuis, B. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Groeningen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinedo, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span> <span> </span><span class="NLM_article-title">Pretreatment deoxycytidine kinase levels predict <i>in vivo</i> gemcitabine sensitivity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">376</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=12477049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1yqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=371-376&author=J.+R.+Kroepauthor=W.+J.+Lovesauthor=C.+L.+van+der%0AWiltauthor=E.+Alvarezauthor=I.+Talianidisauthor=E.+Bovenauthor=B.+J.+M.+Braakhuisauthor=C.+J.+van+Groeningenauthor=H.+M.+Pinedoauthor=G.+J.+Peters&title=Pretreatment+deoxycytidine+kinase+levels+predict+in+vivo+gemcitabine+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity</span></div><div class="casAuthors">Kroep, Judith R.; Loves, Willem J. P.; Van der Wilt, Clasina L.; Alvarez, Enrique; Talianidis, Iannis; Boven, Epie; Braakhuis, Boudewijn J. M.; Van Groeningen, Cornelis J.; Pinedo, Herbert M.; Peters, Godefridus J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">371-376</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deoxycytidine kinase (dCK) is essential for the phosphorylation of gemcitabine (2',2'-difluorodeoxycytidine), a deoxycytidine analog active against various solid tumors.  Cytidine deaminase (CDA) catalyzes the degrdn. of gemcitabine.  We detd. whether dCK and/or CDA levels would predict response to gemcitabine.  Activities of dCK and CDA were measured in a panel of eight gemcitabine-sensitive and -resistant tumors of a different origin (pancreas, lung, colon, ovary, and head and neck) grown as s.c. tumors in mice.  Sensitivity to gemcitabine was expressed as treated vs. control (tumor vol. treated mice/control mice).  Gemcitabine was given on days 0, 3, 6, and 9 (q3dx4) at its max. tolerated dose.  In addn., we measured the mRNA expression and protein levels of dCK in seven human tumor xenografts.  DCK activity (mean ± SE) ranged from 3.3±0.3 to 18.4±1.2 nmol/h/mg protein.  Sensitivity to gemcitabine, expressed as treated vs. control, ranged from 0.98 to 0.02, and the activity of CDA varied from 2±2 to 411±4 nmol/h/mg protein.  In contrast to CDA, dCK activity was clearly related to gemcitabine sensitivity (p = -0.93; P < 0.001).  This indicates that dCK might be an important prognostic marker for gemcitabine sensitivity.  Protein levels were significantly related to both dCK activity (r = 0.96; P < 0.001) and gemcitabine sensitivity (p = -0.96; P < 0.001).  DCK expression as detd. by competitive template reverse transcriptase PCR was significantly related with the dCK activity (r = 0.88; P = 0.025) and protein levels (p = 0.80; P = 0.052) but not with gemcitabine sensitivity, suggesting a post-translational regulation of dCK.  In conclusion, the clear correlation between dCK levels and gemcitabine sensitivity in various murine tumors and human tumor xenografts may be a prognostic parameter when considering gemcitabine therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtmGyuXKsGQbVg90H21EOLACvtfcHk0lhQHxSegvXO4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1yqs78%253D&md5=d624932f2fbcbe7597badefc154dcbcf</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKroep%26aufirst%3DJ.%2BR.%26aulast%3DLoves%26aufirst%3DW.%2BJ.%26aulast%3Dvan%2Bder%2BWilt%26aufirst%3DC.%2BL.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DTalianidis%26aufirst%3DI.%26aulast%3DBoven%26aufirst%3DE.%26aulast%3DBraakhuis%26aufirst%3DB.%2BJ.%2BM.%26aulast%3Dvan%2BGroeningen%26aufirst%3DC.%2BJ.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26atitle%3DPretreatment%2520deoxycytidine%2520kinase%2520levels%2520predict%2520in%2520vivo%2520gemcitabine%2520sensitivity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2002%26volume%3D1%26spage%3D371%26epage%3D376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Galmarini, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordheim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cros, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span> <span> </span><span class="NLM_article-title">Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene</span>. <i>BMC Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.1186/1471-2210-4-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1186%2F1471-2210-4-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=15157282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A280%3ADC%252BD2czgt1Wlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=8&author=C.+M.+Galmariniauthor=M.+L.+Clarkeauthor=L.+Jordheimauthor=C.+L.+Santosauthor=E.+Crosauthor=J.+R.+Mackeyauthor=C.+Dumontet&title=Resistance+to+gemcitabine+in+a+human+follicular+lymphoma+cell+line+is+due+to+partial+deletion+of+the+deoxycytidine+kinase+gene&doi=10.1186%2F1471-2210-4-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene</span></div><div class="casAuthors">Galmarini Carlos Maria; Clarke Marilyn L; Jordheim Lars; Santos Cheryl L; Cros Emeline; Mackey John R; Dumontet Charles</div><div class="citationInfo"><span class="NLM_cas:title">BMC pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Gemcitabine is an analogue of deoxycytidine with activity against several solid tumors.  In order to elucidate the mechanisms by which tumor cells become resistant to gemcitabine, we developed the resistant subline RL-G from the human follicular lymphoma cell line RL-7 by prolonged exposure of parental cells to increasing concentrations of gemcitabine.  RESULTS:  In vitro, the IC50 increased from 0.015 microM in parental RL-7 cells to 25 microM in the resistant variant, RL-G.  Xenografts of both cell lines developed in nude mice were treated with repeated injections of gemcitabine.  Under conditions of gemcitabine treatment which totally inhibited the development of RL-7 tumors, RL-G derived tumors grew similarly to those of untreated animals, demonstrating the in vivo resistance of RL-G cells to gemcitabine.  HPLC experiments showed that RL-G cells accumulated and incorporated less gemcitabine metabolites into DNA and RNA than RL-7 cells.  Gemcitabine induced an S-phase arrest in RL-7 cells but not in RL-G cells.  Exposure to gemcitabine induced a higher degree of apoptosis in RL-7 than in RL-G cells, with poly-(ADP-ribose) polymerase cleavage in RL-7 cells.  No modifications of Bcl-2 nor of Bax expression were observed in RL-7 or RL-G cells exposed to gemcitabine.  These alterations were associated with the absence of the deoxycytidine kinase mRNA expression observed by quantitative RT-PCR in RL-G cells.  PCR amplification of desoxycytidine kinase gene exons showed a partial deletion of the dCK gene in RL-G cells.  CONCLUSIONS:  These results suggest that partial deletion of the dCK gene observed after selection in the presence of gemcitabine is involved with resistance to this agent both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-7XXrs8c5MevW160gIxP_fW6udTcc2eZ75OTRzbbuV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czgt1Wlsw%253D%253D&md5=6f3ab048027d98416786a04a71bcf649</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1186%2F1471-2210-4-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2210-4-8%26sid%3Dliteratum%253Aachs%26aulast%3DGalmarini%26aufirst%3DC.%2BM.%26aulast%3DClarke%26aufirst%3DM.%2BL.%26aulast%3DJordheim%26aufirst%3DL.%26aulast%3DSantos%26aufirst%3DC.%2BL.%26aulast%3DCros%26aufirst%3DE.%26aulast%3DMackey%26aufirst%3DJ.%2BR.%26aulast%3DDumontet%26aufirst%3DC.%26atitle%3DResistance%2520to%2520gemcitabine%2520in%2520a%2520human%2520follicular%2520lymphoma%2520cell%2520line%2520is%2520due%2520to%2520partial%2520deletion%2520of%2520the%2520deoxycytidine%2520kinase%2520gene%26jtitle%3DBMC%2520Pharmacol.%26date%3D2004%26volume%3D4%26spage%3D8%26doi%3D10.1186%2F1471-2210-4-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Beumer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiseman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parise, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egorin, M. J.</span></span> <span> </span><span class="NLM_article-title">Modulation of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3529</span>– <span class="NLM_lpage">3535</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-4885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1158%2F1078-0432.CCR-07-4885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=18519786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslygtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=3529-3535&author=J.+H.+Beumerauthor=J.+L.+Eisemanauthor=R.+A.+Pariseauthor=E.+Josephauthor=J.+M.+Coveyauthor=M.+J.+Egorin&title=Modulation+of+gemcitabine+%282%E2%80%B2%2C2%E2%80%B2-difluoro-2%E2%80%B2-deoxycytidine%29+pharmacokinetics%2C+metabolism%2C+and+bioavailability+in+mice+by+3%2C4%2C5%2C6-tetrahydrouridine&doi=10.1158%2F1078-0432.CCR-07-4885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of Gemcitabine (2',2'-Difluoro-2'-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine</span></div><div class="casAuthors">Beumer, Jan H.; Eiseman, Julie L.; Parise, Robert A.; Joseph, Erin; Covey, Joseph M.; Egorin, Merrill J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3529-3535</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: In vivo, 2',2'-difluoro-2'-deoxycytidine (dFdC) is rapidly inactivated by gut and liver cytidine deaminase (CD) to 2',2'-difluoro-2'-deoxyuridine (dFdU).  Consequently, dFdC has poor oral bioavailability and is administered i.v., with assocd. costs and limitations in administration schedules. 3,4,5,6-Tetrahydrouridine (THU) is a potent CD inhibitor with a 20% oral bioavailability.  We investigated the ability of THU to decrease elimination and first-pass effect by CD, thereby enabling oral dosing of dFdC.  Exptl. Design: A liq. chromatog.-tandem mass spectrometry assay was developed for plasma dFdC and dFdU.  Mice were dosed with 100 mg/kg dFdC i.v. or orally with or without 100 mg/kg THU i.v. or orally.  At specified times between 5 and 1,440 min, mice (n = 3) were euthanized. dFdC, dFdU, and THU concns. were quantitated in plasma and urine.  RESULTS: THU i.v. and orally produced concns. >4 μg/mL for 3 and 2 h, resp., whereas concns. of >1 μg/mL have been assocd. with near-complete inhibition of CD in vitro.  THU i.v. decreased plasma dFdU concns. but had no effect on dFdC plasma area under the plasma concn. vs. time curve after i.v. dFdC dosing.  Both THU i.v. and orally substantially increased oral bioavailability of dFdC.  Absorption of dFdC orally was 59%, but only 10% passed liver and gut CD and eventually reached the systemic circulation.  Coadministration of THU orally increased dFdC oral bioavailability from 10% to 40%.  CONCLUSIONS: Coadministration of THU enables oral dosing of dFdC and warrants clin. testing.  Oral dFdC treatment would be easier and cheaper, potentially prolong dFdC exposure, and enable exploration of administration schedules considered impractical by the i.v. route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc1H9aRg7karVg90H21EOLACvtfcHk0lgjogWnbOD_vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslygtrY%253D&md5=744bee3dc79923eccdedef29434c098c</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4885%26sid%3Dliteratum%253Aachs%26aulast%3DBeumer%26aufirst%3DJ.%2BH.%26aulast%3DEiseman%26aufirst%3DJ.%2BL.%26aulast%3DParise%26aufirst%3DR.%2BA.%26aulast%3DJoseph%26aufirst%3DE.%26aulast%3DCovey%26aufirst%3DJ.%2BM.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26atitle%3DModulation%2520of%2520gemcitabine%2520%25282%25E2%2580%25B2%252C2%25E2%2580%25B2-difluoro-2%25E2%2580%25B2-deoxycytidine%2529%2520pharmacokinetics%252C%2520metabolism%252C%2520and%2520bioavailability%2520in%2520mice%2520by%25203%252C4%252C5%252C6-tetrahydrouridine%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D3529%26epage%3D3535%26doi%3D10.1158%2F1078-0432.CCR-07-4885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobili, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caciagli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzei, T.</span></span> <span> </span><span class="NLM_article-title">Cellular pharmacology of gemcitabine</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">v7</span>– <span class="NLM_lpage">v12</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdj941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1093%2Fannonc%2Fmdj941" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=16807468" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=v7-v12&author=E.+Miniauthor=S.+Nobiliauthor=B.+Caciagliauthor=I.+Landiniauthor=T.+Mazzei&title=Cellular+pharmacology+of+gemcitabine&doi=10.1093%2Fannonc%2Fmdj941"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdj941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdj941%26sid%3Dliteratum%253Aachs%26aulast%3DMini%26aufirst%3DE.%26aulast%3DNobili%26aufirst%3DS.%26aulast%3DCaciagli%26aufirst%3DB.%26aulast%3DLandini%26aufirst%3DI.%26aulast%3DMazzei%26aufirst%3DT.%26atitle%3DCellular%2520pharmacology%2520of%2520gemcitabine%26jtitle%3DAnn.%2520Oncol.%26date%3D2006%26volume%3D17%26spage%3Dv7%26epage%3Dv12%26doi%3D10.1093%2Fannonc%2Fmdj941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzuto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suppiah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukumaran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharwani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabra, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Bahrawy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habib, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghazaly, E.</span></span> <span> </span><span class="NLM_article-title">Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1038/s41416-018-0244-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1038%2Fs41416-018-0244-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=30206366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSrs7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=815-822&author=S.+P.+Blagdenauthor=I.+Rizzutoauthor=P.+Suppiahauthor=D.+O%E2%80%99Sheaauthor=M.+Patelauthor=L.+Spiersauthor=A.+Sukumaranauthor=N.+Bharwaniauthor=A.+Rockallauthor=H.+Gabraauthor=M.+El-Bahrawyauthor=H.+Wasanauthor=R.+Leonardauthor=N.+Habibauthor=E.+Ghazaly&title=Anti-tumour+activity+of+a+first-in-class+agent+NUC-1031+in+patients+with+advanced+cancer%3A+results+of+a+phase+I+study&doi=10.1038%2Fs41416-018-0244-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study</span></div><div class="casAuthors">Blagden, Sarah P.; Rizzuto, Ivana; Suppiah, Puvan; O'Shea, Daniel; Patel, Markand; Spiers, Laura; Sukumaran, Ajithkumar; Bharwani, Nishat; Rockall, Andrea; Gabra, Hani; El-Bahrawy, Mona; Wasan, Harpreet; Leonard, Robert; Habib, Nagy; Ghazaly, Essam</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">815-822</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Gemcitabine is used to treat a wide range of tumors, but its efficacy is limited by cancer cell resistance mechanisms.  NUC-1031, a phosphoramidate modification of gemcitabine, is the first anti-cancer ProTide to enter the clinic and is designed to overcome these key resistance mechanisms.  Sixty-eight patients with advanced solid tumors who had relapsed after treatment with std. therapy were recruited to a dose escalation study to det. the recommended Phase II dose (RP2D) and assess the safety of NUC-1031.  Pharmacokinetics and anti-tumor activity was also assessed.  Sixty-eight patients received treatment, 50% of whom had prior exposure to gemcitabine.  NUC-1031 was well tolerated with the most common Grade 3/4 adverse events of neutropenia, lymphopenia and fatigue occurring in 13 patients each (19%).  In 49 response-evaluable patients, 5 (10%) achieved a partial response and 33 (67%) had stable disease, resulting in a 78% disease control rate.  Cmax levels of the active intracellular metabolite, dFdCTP, were 217-times greater than those reported for equimolar doses of gemcitabine, with minimal toxic metabolite accumulation.  The RP2D was detd. as 825 mg/m2 on days 1, 8 and 15 of a 28-day cycle.  NUC-1031 was well tolerated and demonstrated clin. significant anti-tumor activity, even in patients with prior gemcitabine exposure and in cancers not traditionally perceived as gemcitabine-responsive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzqXWvBd6VLbVg90H21EOLACvtfcHk0lgJ-u1JCZ4cSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSrs7jM&md5=5cf90783188268b2b884a6e45c8f12f6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fs41416-018-0244-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-018-0244-1%26sid%3Dliteratum%253Aachs%26aulast%3DBlagden%26aufirst%3DS.%2BP.%26aulast%3DRizzuto%26aufirst%3DI.%26aulast%3DSuppiah%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DSpiers%26aufirst%3DL.%26aulast%3DSukumaran%26aufirst%3DA.%26aulast%3DBharwani%26aufirst%3DN.%26aulast%3DRockall%26aufirst%3DA.%26aulast%3DGabra%26aufirst%3DH.%26aulast%3DEl-Bahrawy%26aufirst%3DM.%26aulast%3DWasan%26aufirst%3DH.%26aulast%3DLeonard%26aufirst%3DR.%26aulast%3DHabib%26aufirst%3DN.%26aulast%3DGhazaly%26aufirst%3DE.%26atitle%3DAnti-tumour%2520activity%2520of%2520a%2520first-in-class%2520agent%2520NUC-1031%2520in%2520patients%2520with%2520advanced%2520cancer%253A%2520results%2520of%2520a%2520phase%2520I%2520study%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D119%26spage%3D815%26epage%3D822%26doi%3D10.1038%2Fs41416-018-0244-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><a href="http://www.nucana.com/downloads/NuCana12June2019.pdf" class="extLink">http://www.nucana.com/downloads/NuCana12June2019.pdf</a> (accessed 2019-07-22).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.nucana.com%2Fdownloads%2FNuCana12June2019.pdf+%28accessed+2019-07-22%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grem, J. L.</span></span> <span> </span><span class="NLM_article-title">5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1023/A:1006416410198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1023%2FA%3A1006416410198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=11081567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotFCqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=299-313&author=J.+L.+Grem&title=5-Fluorouracil%3A+forty-plus+and+still+ticking.+A+review+of+its+preclinical+and+clinical+development&doi=10.1023%2FA%3A1006416410198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development</span></div><div class="casAuthors">Grem, Jean L.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">299-313</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review with 128 refs.  5-Fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FdUrd) are pyrimidine analogs that have been part of the therapeutic armamentarium for a variety of solid tumors for over forty years.  5-FU has customarily required i.v. administration due to poor and erratic oral bioavailability, while FdUrd has generally been employed for regional administration to the liver or the peritoneal cavity.  A great deal of knowledge has been gained concerning the cellular pharmacol. and mechanism of action of 5-FU since it was first synthesized in the late 1950's.  A more thorough understanding of the factors influencing the metabolic activation of 5-FU and its cellular effects has generated considerable interest in combining it with both modulatory agents such as leucovorin and methotrexate that enhance its metab. or cytotoxic effects.  In addn., 5-FU has also been employed to enhance the therapeutic activity of other antineoplastic agents or modalities such as cisplatin and ionizing radiation with which it can synergize.  Appreciation of the clin. pharmacol. of 5-FU and FdUrd have led to a variety of schedules that are clin. useful.  The preclin. and clin. pharmacol. of 5-FU is reviewed to provide a basis for exploring the novel approaches to permit oral administration of 5-FU or its prodrugs that will be described in other articles in this issue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjbb7VzAKqwrVg90H21EOLACvtfcHk0lgJ-u1JCZ4cSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotFCqurc%253D&md5=26b5129a0f45b59de973de3e13b153e6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1023%2FA%3A1006416410198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1006416410198%26sid%3Dliteratum%253Aachs%26aulast%3DGrem%26aufirst%3DJ.%2BL.%26atitle%3D5-Fluorouracil%253A%2520forty-plus%2520and%2520still%2520ticking.%2520A%2520review%2520of%2520its%2520preclinical%2520and%2520clinical%2520development%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2000%26volume%3D18%26spage%3D299%26epage%3D313%26doi%3D10.1023%2FA%3A1006416410198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-S.</span></span> <span> </span><span class="NLM_article-title">5-Fluorouracil: mechanisms of resistance and reversal strategies</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1569</span>, <span class="refDoi"> DOI: 10.3390/molecules13081551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.3390%2Fmolecules13081551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=18794772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCju7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=1551-1569&author=N.+Zhangauthor=Y.+Yinauthor=S.-J.+Xuauthor=W.-S.+Chen&title=5-Fluorouracil%3A+mechanisms+of+resistance+and+reversal+strategies&doi=10.3390%2Fmolecules13081551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">5-fluorouracil: mechanisms of resistance and reversal strategies</span></div><div class="casAuthors">Zhang, Ning; Yin, Ying; Xu, Sheng-Jie; Chen, Wei-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1551-1569</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  The purpose of this work is to review the published studies on the mechanisms of action and resistance of 5-fluorouracil.  The review is divided into 3 main sections: mechanisms of anti-tumor action, studies of the resistance to the drug, and procedures for the identification of new genes involved in resistance with microarray techniques.  The details of the induction and reversal of the drug resistance are also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIZm3-MGMwO7Vg90H21EOLACvtfcHk0lgJ-u1JCZ4cSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCju7jK&md5=de07c1be5c5995b8361805b28f237027</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.3390%2Fmolecules13081551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules13081551%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DS.-J.%26aulast%3DChen%26aufirst%3DW.-S.%26atitle%3D5-Fluorouracil%253A%2520mechanisms%2520of%2520resistance%2520and%2520reversal%2520strategies%26jtitle%3DMolecules%26date%3D2008%26volume%3D13%26spage%3D1551%26epage%3D1569%26doi%3D10.3390%2Fmolecules13081551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jetté, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissoon-Haqqani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Francois, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maroun, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnboim, C.</span></span> <span> </span><span class="NLM_article-title">Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by mycoplasma infection</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2175</span>– <span class="NLM_lpage">2180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=18751392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVaku7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=2175-2180&author=L.+Jett%C3%A9author=S.+Bissoon-Haqqaniauthor=B.+Le+Francoisauthor=J.+A.+Marounauthor=C.+Birnboim&title=Resistance+of+colorectal+cancer+cells+to+5-FUdR+and+5-FU+caused+by+mycoplasma+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by mycoplasma infection</span></div><div class="casAuthors">Jette, Lucie; Bissoon-Haqqani, Seema; Le Francois, Brice; Maroun, Jean A.; Birnboim, H. Chaim</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4B</span>),
    <span class="NLM_cas:pages">2175-2180</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: 5-Fluorouracil (5-FU) is an antineoplastic drug that targets thymidylate synthase (TS).  Tumor cells can develop resistance to anti-TS drugs by a variety of mechanisms including up-regulation of TS protein and alterations in drug uptake and degrdn.  The possible mechanisms of the obsd. rapid development of resistance to the pyrimidine analogs 5-FUdR and 5-FU in cultured HCT116 colon cancer cells were investigated.  Materials and Methods: Cell survival was detd. in resistant and control HCT116 cells treated with 5-FUdR and 5-FU for 7 days.  The ability of the cells to take up and metabolize these drugs was detd. by Western blotting and [3H]thymidine incorporation.  Results and Conclusion: Resistant HCT116 cells were 5- and 100-fold more resistant to killing by 5-FU and 5-FUdR, resp., than the parental cells and exhibited impaired uptake.  Although the HCT116R cells were initially Mycoplasma free, a low level of Mycoplasma contamination was found in these cells after several weeks in culture.  Sensitivity to 5-FUdR was restored by treatment with an anti-Mycoplasma antibiotic.  Our observations emphasize the need for frequent testing for Mycoplasma contamination in any cell line under investigation for resistance to anti-TS drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4LxTWP_ygQrVg90H21EOLACvtfcHk0lgJ-u1JCZ4cSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVaku7%252FN&md5=020dbae6d351ca5244e82d3eb3177533</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJett%25C3%25A9%26aufirst%3DL.%26aulast%3DBissoon-Haqqani%26aufirst%3DS.%26aulast%3DLe%2BFrancois%26aufirst%3DB.%26aulast%3DMaroun%26aufirst%3DJ.%2BA.%26aulast%3DBirnboim%26aufirst%3DC.%26atitle%3DResistance%2520of%2520colorectal%2520cancer%2520cells%2520to%25205-FUdR%2520and%25205-FU%2520caused%2520by%2520mycoplasma%2520infection%26jtitle%3DAnticancer%2520Res.%26date%3D2008%26volume%3D28%26spage%3D2175%26epage%3D2180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diasio, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, B. E.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacology of 5-fluorouracil</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.2165/00003088-198916040-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.2165%2F00003088-198916040-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=2656050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADyaL1MXkslSisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1989&pages=215-237&author=R.+B.+Diasioauthor=B.+E.+Harris&title=Clinical+pharmacology+of+5-fluorouracil&doi=10.2165%2F00003088-198916040-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacology of 5-fluorouracil</span></div><div class="casAuthors">Diasio, Robert B.; Harris, Barry E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">215-37</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    </div><div class="casAbstract">A review with 150 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon2q3qcBdt77Vg90H21EOLACvtfcHk0lh4blDMvuv6Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkslSisr4%253D&md5=ac71baf8afc1cd77a33d14c4fff5fe9e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2165%2F00003088-198916040-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-198916040-00002%26sid%3Dliteratum%253Aachs%26aulast%3DDiasio%26aufirst%3DR.%2BB.%26aulast%3DHarris%26aufirst%3DB.%2BE.%26atitle%3DClinical%2520pharmacology%2520of%25205-fluorouracil%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1989%26volume%3D16%26spage%3D215%26epage%3D237%26doi%3D10.2165%2F00003088-198916040-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Voorde, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liekens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murziani, P. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2’-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2011.05.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1016%2Fj.bcp.2011.05.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=21658373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1ehsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2011&pages=441-452&author=J.+Vande%0AVoordeauthor=S.+Liekensauthor=C.+McGuiganauthor=P.+G.+S.+Murzianiauthor=M.+Slusarczykauthor=J.+Balzarini&title=The+cytostatic+activity+of+NUC-3073%2C+a+phosphoramidate+prodrug+of+5-fluoro-2%E2%80%99-deoxyuridine%2C+is+independent+of+activation+by+thymidine+kinase+and+insensitive+to+degradation+by+phosphorolytic+enzymes&doi=10.1016%2Fj.bcp.2011.05.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2'-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes</span></div><div class="casAuthors">Vande Voorde, Johan; Liekens, Sandra; McGuigan, Christopher; Murziani, Paola G. S.; Slusarczyk, Magdalena; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel phosphoramidate nucleotide prodrug of the anticancer nucleoside analog 5-fluoro-2'-deoxyuridine (5-FdUrd) was synthesized and evaluated for its cytostatic activity.  Whereas 5-FdUrd substantially lost its cytostatic potential in thymidine kinase (TK)-deficient murine leukemia L1210 and human lymphocyte CEM cell cultures, NUC-3073 markedly kept its antiproliferative activity in TK-deficient tumor cells, and thus is largely independent of intracellular TK activity to exert its cytostatic action.  NUC-3073 was found to inhibit thymidylate synthase (TS) in the TK-deficient and wild-type cell lines at drug concns. that correlated well with its cytostatic activity in these cells.  NUC-3073 does not seem to be susceptible to inactivation by catabolic enzymes such as thymidine phosphorylase (TP) and uridine phosphorylase (UP).  These findings are in line with our observations that 5-FdUrd, but not NUC-3073, substantially loses its cytostatic potential in the presence of TP-expressing mycoplasmas in the tumor cell cultures.  Therefore, we propose NUC-3073 as a novel 5-FdUrd phosphoramidate prodrug that (i) may circumvent potential resistance mechanisms of tumor cells (e.g. decreased TK activity) and (ii) is not degraded by catabolic enzymes such as TP which is often upregulated in tumor cells or expressed in mycoplasma-infected tumor tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0BkUUtRLZTrVg90H21EOLACvtfcHk0lh4blDMvuv6Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1ehsrw%253D&md5=50b53ced366a86c9180e178456b902d8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2011.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2011.05.024%26sid%3Dliteratum%253Aachs%26aulast%3DVande%2BVoorde%26aufirst%3DJ.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DMurziani%26aufirst%3DP.%2BG.%2BS.%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DThe%2520cytostatic%2520activity%2520of%2520NUC-3073%252C%2520a%2520phosphoramidate%2520prodrug%2520of%25205-fluoro-2%25E2%2580%2599-deoxyuridine%252C%2520is%2520independent%2520of%2520activation%2520by%2520thymidine%2520kinase%2520and%2520insensitive%2520to%2520degradation%2520by%2520phosphorolytic%2520enzymes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D82%26spage%3D441%26epage%3D452%26doi%3D10.1016%2Fj.bcp.2011.05.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghazaly, E.</span>; <span class="NLM_string-name">Woodcock, V. K.</span>; <span class="NLM_string-name">Spilipoulou, P.</span>; <span class="NLM_string-name">Spiers, L.</span>; <span class="NLM_string-name">Moschandreas, J.</span>; <span class="NLM_string-name">Griffiths, L.</span>; <span class="NLM_string-name">Gnanaranjan, C.</span>; <span class="NLM_string-name">Harrison, D. J.</span>; <span class="NLM_string-name">Evans, T. R. J.</span>; <span class="NLM_string-name">Blagden, S.</span></span> <i>42nd ESMO Congress 2017</i>, Madrid, Spain, September 8–12, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">385-P</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=385-P&author=E.+Ghazaly&author=V.+K.+Woodcock&author=P.+Spilipoulou&author=L.+Spiers&author=J.+Moschandreas&author=L.+Griffiths&author=C.+Gnanaranjan&author=D.+J.+Harrison&author=T.+R.+J.+Evans&author=S.+Blagden&title=42nd+ESMO+Congress+2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGhazaly%26aufirst%3DE.%26jtitle%3D42nd%2520ESMO%2520Congress%25202017%26date%3D2017%26spage%3D385-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03428958" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03428958</a> (accessed 2019-03-28).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03428958+%28accessed+2019-03-28%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03829254" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03829254</a> (accessed 2019-08-28).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03829254+%28accessed+2019-08-28%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pradere, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnier-Amblard, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amblard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis of nucleoside phosphate and phosphonate prodrugs</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">9154</span>– <span class="NLM_lpage">9218</span>, <span class="refDoi"> DOI: 10.1021/cr5002035</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr5002035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=9154-9218&author=U.+Pradereauthor=E.+C.+Garnier-Amblardauthor=S.+J.+Coatsauthor=F.+Amblardauthor=R.+F.+Schinazi&title=Synthesis+of+nucleoside+phosphate+and+phosphonate+prodrugs&doi=10.1021%2Fcr5002035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23aR"><div class="casContent"><span class="casTitleNuber">23a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs</span></div><div class="casAuthors">Pradere, Ugo; Garnier-Amblard, Ethel C.; Coats, Steven J.; Amblard, Franck; Schinazi, Raymond F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">9154-9218</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we review the most important mono-, di-, and triphosphate and phosphonate prodrug approaches applied to nucleoside analogs from a chem. point of view, detailing the strengths and limitations of each approach.  We will focus on the various synthetic pathways discussing: (1) the chem. variation of the biolabile phosphonate masking groups; (2) the reliability of using P(III) and/or P(V) chem. for both phosphate and phosphonate prodrug synthesis; (3) the influence of the masking group(s) introduction conditions (solvent, temp., stoichiometry) on the overall outcome for each method; (4) the various protection/deprotection strategies used to impart improved yield and regioselectivity relative to the nature of the nucleobase and the sugar; and (5) the influence of reaction conditions or protective groups on the stereoselectivity (Rp/Sp) obsd. at the phosphorus center as well as the methods employed to sep. both Rp and Sp isomers along with the asym. strategies for the synthesis of predominantly single diastereoisomers at the phosphorus center.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2UgEs4_SnUrVg90H21EOLACvtfcHk0ljOk_cGNzyShg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsL7J&md5=115175a0c31890dd5b7b9f4ae9a9191f</span></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1021%2Fcr5002035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr5002035%26sid%3Dliteratum%253Aachs%26aulast%3DPradere%26aufirst%3DU.%26aulast%3DGarnier-Amblard%26aufirst%3DE.%2BC.%26aulast%3DCoats%26aufirst%3DS.%2BJ.%26aulast%3DAmblard%26aufirst%3DF.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26atitle%3DSynthesis%2520of%2520nucleoside%2520phosphate%2520and%2520phosphonate%2520prodrugs%26jtitle%3DChem.%2520Rev.%26date%3D2014%26volume%3D114%26spage%3D9154%26epage%3D9218%26doi%3D10.1021%2Fcr5002035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serpi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertusati, F.</span></span> <span> </span><span class="NLM_article-title">Phosphoramidates and phosphonamidates (protides) with antiviral activity</span>. <i>Antivir. Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1177/2040206618775243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1177%2F2040206618775243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=29792071" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+Slusarczykauthor=M.+Serpiauthor=F.+Pertusati&title=Phosphoramidates+and+phosphonamidates+%28protides%29+with+antiviral+activity&doi=10.1177%2F2040206618775243"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1177%2F2040206618775243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040206618775243%26sid%3Dliteratum%253Aachs%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DSerpi%26aufirst%3DM.%26aulast%3DPertusati%26aufirst%3DF.%26atitle%3DPhosphoramidates%2520and%2520phosphonamidates%2520%2528protides%2529%2520with%2520antiviral%2520activity%26jtitle%3DAntivir.%2520Chem.%2520Chemother.%26date%3D2018%26doi%3D10.1177%2F2040206618775243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klapars, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, S. M.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based solution to the protide synthesis problem: selective access to sofosbuvir, acelarin, and INX-08189</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2218</span>– <span class="NLM_lpage">2221</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.7b00469</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.7b00469" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFCmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=2218-2221&author=B.+Simmonsauthor=Z.+Liuauthor=A.+Klaparsauthor=A.+Bellomoauthor=S.+M.+Silverman&title=Mechanism-based+solution+to+the+protide+synthesis+problem%3A+selective+access+to+sofosbuvir%2C+acelarin%2C+and+INX-08189&doi=10.1021%2Facs.orglett.7b00469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-Based Solution to the ProTide Synthesis Problem: Selective Access to Sofosbuvir, Acelarin, and INX-08189</span></div><div class="casAuthors">Simmons, Bryon; Liu, Zhuqing; Klapars, Artis; Bellomo, Ana; Silverman, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2218-2221</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A general and efficient method for the synthesis of pro-nucleotide (ProTide) 5'-phosphoramidate mono-esters is reported.  This method consists of a highly stereoselective 5'-phosphorylation mediated by dimethylaluminum chloride to afford the desired target ProTides in excellent yields without employing 3'-protection strategies.  The application of this methodol. to the synthesis of a no. of pharmaceutically relevant compds. currently marketed or under investigation in clin. research is demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDuwgFmGkb3LVg90H21EOLACvtfcHk0ljOk_cGNzyShg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFCmtr4%253D&md5=8cb5b9d994fcd83db7393e376a336bea</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.7b00469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.7b00469%26sid%3Dliteratum%253Aachs%26aulast%3DSimmons%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DKlapars%26aufirst%3DA.%26aulast%3DBellomo%26aufirst%3DA.%26aulast%3DSilverman%26aufirst%3DS.%2BM.%26atitle%3DMechanism-based%2520solution%2520to%2520the%2520protide%2520synthesis%2520problem%253A%2520selective%2520access%2520to%2520sofosbuvir%252C%2520acelarin%252C%2520and%2520INX-08189%26jtitle%3DOrg.%2520Lett.%26date%3D2017%26volume%3D19%26spage%3D2218%26epage%3D2221%26doi%3D10.1021%2Facs.orglett.7b00469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natt, N.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir: A novel treatment option for chronic hepatitis C infection</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.4103/0976-500X.142464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.4103%2F0976-500X.142464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=25422576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFahtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=278-282&author=H.+Singhauthor=H.+Bhatiaauthor=N.+Grewalauthor=N.+Natt&title=Sofosbuvir%3A+A+novel+treatment+option+for+chronic+hepatitis+C+infection&doi=10.4103%2F0976-500X.142464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir: a novel treatment option for chronic hepatitis C infection</span></div><div class="casAuthors">Bhatia, Harmeet Kaur; Singh, Harmanjit; Grewal, Nipunjot; Natt, Navreet Kaur</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">278-284, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPPOGN</span>;
        ISSN:<span class="NLM_cas:issn">0976-500X</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications and Media Pvt. Ltd.</span>)
        </div><div class="casAbstract">Hepatitis C currently infects more than 170 million people around the world, leading to significant morbidity and mortality.  The current std. of care for HCV infection, including one of the two protease inhibitors, telaprevir or boceprevir, for 12-32 wk, along with pegylated interferon alfa-2a (PEG-IFN-α) and ribavirin for up to 48 wk, is unsatisfactory in many cases, either because of lack of efficacy or because of treatment-related adverse effects.  There is an urgent need of new drugs with improved efficacy as well as a safety profile.  Sofosbuvir, a recently approved nucleotide analog, is a highly potent inhibitor of the NS5B polymerase in the Hepatitis C virus (HCV), and has shown high efficacy in combination with several other drugs, with and without PEG-INF, against HCV.  It offers many advantages due to its high potency, low side effects, oral administration, and high barrier to resistance.  The efficacy and safety were demonstrated in many large and well-designed phase 2 and phase 3 clin. trials like NEUTRINO, PROTON, ELECTRON, ATOMIC, COSMOS, FUSION, FISSION, NUCLEAR, POSITRON, and the like.  It is generally well-tolerated.  Adverse events that occurred include: Headache, insomnia, fatigue, nausea, dizziness, pruritis, upper respiratory tract infections, rash, back pain, grade 1 anemia, and grade 4 lymphopenia; however, the exact safety profile can only be judged when this drug is actually used on a large scale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiw8rejud7ubVg90H21EOLACvtfcHk0ljOk_cGNzyShg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFahtbfL&md5=bcdd2945231ac73a751f0771b46b6201</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.142464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.142464%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DBhatia%26aufirst%3DH.%26aulast%3DGrewal%26aufirst%3DN.%26aulast%3DNatt%26aufirst%3DN.%26atitle%3DSofosbuvir%253A%2520A%2520novel%2520treatment%2520option%2520for%2520chronic%2520hepatitis%2520C%2520infection%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2014%26volume%3D5%26spage%3D278%26epage%3D282%26doi%3D10.4103%2F0976-500X.142464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espiritu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a β-d-2-Deoxy-2-α-fluoro-2-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7202</span>– <span class="NLM_lpage">7218</span>, <span class="refDoi"> DOI: 10.1021/jm100863x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100863x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7202-7218&author=M.+J.+Sofiaauthor=D.+Baoauthor=W.+Changauthor=J.+Duauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=P.+G.+Reddyauthor=B.+S.+Rossauthor=P.+Wangauthor=H.+R.+Zhangauthor=S.+Bansalauthor=C.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=H.+M.+Steuerauthor=C.+Niuauthor=M.+J.+Ottoauthor=P.+A.+Furman&title=Discovery+of+a+%CE%B2-d-2-Deoxy-2-%CE%B1-fluoro-2-%CE%B2-C-methyluridine+nucleotide+prodrug+%28PSI-7977%29+for+the+treatment+of+hepatitis+C+virus&doi=10.1021%2Fjm100863x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus</span></div><div class="casAuthors">Sofia, Michael J.; Bao, Donghui; Chang, Wonsuk; Du, Jinfa; Nagarathnam, Dhanapalan; Rachakonda, Suguna; Reddy, P. Ganapati; Ross, Bruce S.; Wang, Peiyuan; Zhang, Hai-Ren; Bansal, Shalini; Espiritu, Christine; Keilman, Meg; Lam, Angela M.; Steuer, Holly M. Micolochick; Niu, Congrong; Otto, Michael J.; Furman, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7202-7218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a global health problem requiring novel approaches for effective treatment of this disease.  The HCV NS5B polymerase has been demonstrated to be a viable target for the development of HCV therapies.  β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-Me nucleosides are selective inhibitors of the HCV NS5B polymerase and have demonstrated potent activity in the clinic.  Phosphoramidate prodrugs of the 5'-phosphate deriv. of the β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleoside were prepd. and showed significant potency in the HCV subgenomic replicon assay (<1 μM) and produced high levels of triphosphate 6 in primary hepatocytes and in the livers of rats, dogs, and monkeys when administered in vivo.  The single diastereomer 51 of diastereomeric mixt. 14 was crystd., and an X-ray structure was detd. establishing the phosphoramidate stereochem. as Sp, thus correlating for the first time the stereochem. of a phosphoramidate prodrug with biol. activity.  51 (PSI-7977) was selected as a clin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWAkLi9-odWbVg90H21EOLACvtfcHk0linDD9O3wwFXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO&md5=33d371e557e9d70562a326f97798f45c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm100863x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100863x%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%2BR.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520%25CE%25B2-d-2-Deoxy-2-%25CE%25B1-fluoro-2-%25CE%25B2-C-methyluridine%2520nucleotide%2520prodrug%2520%2528PSI-7977%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7202%26epage%3D7218%26doi%3D10.1021%2Fjm100863x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fordyce, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, M. J. M.</span></span> <span> </span><span class="NLM_article-title">Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2015.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1016%2Fj.antiviral.2015.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=26640223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVSktLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2016&pages=63-70&author=A.+S.+Rayauthor=M.+W.+Fordyceauthor=M.+J.+M.+Hitchcock&title=Tenofovir+alafenamide%3A+a+novel+prodrug+of+tenofovir+for+the+treatment+of+human+immunodeficiency+virus&doi=10.1016%2Fj.antiviral.2015.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus</span></div><div class="casAuthors">Ray, Adrian S.; Fordyce, Marshall W.; Hitchcock, Michael J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Despite substantial progress in the development of antiretroviral regimens that durably suppress Human Immunodeficiency Virus (HIV) infection, new agents that maintain high efficacy while further optimizing the safety of lifelong, chronic therapy are needed.  Tenofovir alafenamide (TAF; formerly known as GS-7340) is a novel prodrug of the antiviral acyclic nucleoside phosphonate tenofovir (TFV) with improved properties relative to tenofovir disoproxil fumarate (TDF).  Although potent and generally well tolerated, TDF therapy has been assocd. with changes in markers of renal function, decreases in bone mineral d. and a rare occurrence of serious renal adverse events, including Fanconi's Syndrome.  The renal and bone toxicity obsd. with TDF is assocd. with high circulating plasma levels of TFV.  TAF was discovered to be a more efficient prodrug able to further refine HIV therapy and better address life-long therapy in an older and increasingly comorbid HIV infected population.  By enhancing stability in biol. matrixes while being rapidly activated in cells, TAF produces higher levels of intracellular TFV diphosphate, the pharmacol. active metabolite, in HIV-target cells at substantially reduced oral doses of TFV equiv.  All TFV released in the body is eventually eliminated renally; therefore, lowering the TFV equiv. administered reduces off-target kidney exposure.  Effective therapy is thus achieved at approx. 90% lower systemic exposure to TFV, translating to statistically and clin. significant improvement in safety parameters assocd. with bone mineral d. and markers of renal function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxOKefbojWgLVg90H21EOLACvtfcHk0linDD9O3wwFXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVSktLjN&md5=ac4a87d3e80f6f46b454ebac70809842</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DFordyce%26aufirst%3DM.%2BW.%26aulast%3DHitchcock%26aufirst%3DM.%2BJ.%2BM.%26atitle%3DTenofovir%2520alafenamide%253A%2520a%2520novel%2520prodrug%2520of%2520tenofovir%2520for%2520the%2520treatment%2520of%2520human%2520immunodeficiency%2520virus%26jtitle%3DAntiviral%2520Res.%26date%3D2016%26volume%3D125%26spage%3D63%26epage%3D70%26doi%3D10.1016%2Fj.antiviral.2015.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cundy, K. C.</span></span> <span> </span><span class="NLM_article-title">Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1898</span>– <span class="NLM_lpage">1906</span>, <span class="refDoi"> DOI: 10.1128/AAC.49.5.1898-1906.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1128%2FAAC.49.5.1898-1906.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=15855512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFSntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=1898-1906&author=W.+A.+Leeauthor=G.+X.+Heauthor=E.+Eisenbergauthor=T.+Cihlarauthor=S.+Swaminathanauthor=A.+Mulatoauthor=K.+C.+Cundy&title=Selective+intracellular+activation+of+a+novel+prodrug+of+the+human+immunodeficiency+virus+reverse+transcriptase+inhibitor+tenofovir+leads+to+preferential+distribution+and+accumulation+in+lymphatic+tissue&doi=10.1128%2FAAC.49.5.1898-1906.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue</span></div><div class="casAuthors">Lee, William A.; He, Gong-Xin; Eisenberg, Eugene; Cihlar, Tomas; Swaminathan, Swami; Mulato, Andrew; Cundy, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1898-1906</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">An isopropylalaninyl monoamidate Ph monoester prodrug of tenofovir (GS 7340) was prepd., and its in vitro antiviral activity, metab., and pharmacokinetics in dogs were detd.  The 50% effective concn. (EC50) of GS 7340 against human immunodeficiency virus type 1 in MT-2 cells was 0.005 μM compared to an EC50 of 5 μM for the parent drug, tenofovir.  The (L)-alaninyl analog (GS 7340) was >1000-fold more active than the (D)-alaninyl analog.  GS 7340 has a half-life of 90 min in human plasma at 37° and a half-life of 28.3 min in an MT-2 cell ext. at 37°.  The antiviral activity (>10× the EC50) and the metabolic stability in MT-2 cell exts. (>35×) and plasma (>2.5×) were also sensitive to the stereochem. at the phosphorus.  After a single oral dose of GS 7340 (10 mg-eq/kg tenofovir) to male beagle dogs, the plasma bioavailability of tenofovir compared to an i.v. dose of tenofovir was 17%.  The total intracellular concn. of all tenofovir species in isolated peripheral blood mononuclear cells at 24 h was 63 μg-eq/mL compared to 0.2 μg-eq/mL in plasma.  A radiolabeled distribution study with dogs resulted in an increased distribution of tenofovir to tissues of lymphatic origin compared to the com. available prodrug tenofovir DF (Viread).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbOoU4rGP0xrVg90H21EOLACvtfcHk0linDD9O3wwFXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFSntL0%253D&md5=b5e724620a1cafa4b473a84aea841282</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.5.1898-1906.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.5.1898-1906.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DW.%2BA.%26aulast%3DHe%26aufirst%3DG.%2BX.%26aulast%3DEisenberg%26aufirst%3DE.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DMulato%26aufirst%3DA.%26aulast%3DCundy%26aufirst%3DK.%2BC.%26atitle%3DSelective%2520intracellular%2520activation%2520of%2520a%2520novel%2520prodrug%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520reverse%2520transcriptase%2520inhibitor%2520tenofovir%2520leads%2520to%2520preferential%2520distribution%2520and%2520accumulation%2520in%2520lymphatic%2520tissue%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D1898%26epage%3D1906%26doi%3D10.1128%2FAAC.49.5.1898-1906.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham-Huy, C.</span></span> <span> </span><span class="NLM_article-title">Chiral drugs: an overview</span>. <i>Int. J. Biomed. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=23674971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlSltrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=85-100&author=L.+A.+Nguyenauthor=H.+Heauthor=C.+Pham-Huy&title=Chiral+drugs%3A+an+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Chiral drugs. An overview</span></div><div class="casAuthors">Nguyen, Lien Ai; He, Hua; Chuong, Pham-Huy</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biomedical Science (Monterey Park, CA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-100</span>CODEN:
                <span class="NLM_cas:coden">IJBSDB</span>;
        ISSN:<span class="NLM_cas:issn">1550-9702</span>.
    
            (<span class="NLM_cas:orgname">Master Publishing Group</span>)
        </div><div class="casAbstract">A review.  About more than half of the drugs currently in use are chiral compds. and near 90% of the last ones are marketed as racemates consisting of an equimolar mixt. of two enantiomers.  Although they have the same chem. structure, most isomers of chiral drugs exhibit marked differences in biol. activities such as pharmacol., toxicol., pharmacokinetics, metab. etc.  Some mechanisms of these properties are also explained.  Therefore, it is important to promote the chiral sepn. and anal. of racemic drugs in pharmaceutical industry as well as in clinic in order to eliminate the unwanted isomer from the prepn. and to find an optimal treatment and a right therapeutic control for the patient.  In this article, we review the nomenclature, pharmacol., toxicol., pharmacokinetics, metab. etc of some usual chiral drugs as well as their mechanisms.  Different techniques used for the chiral sepn. in pharmaceutical industry as well as in clin. analyses are also examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovoqsLM_3bxLVg90H21EOLACvtfcHk0lhUcGLcTA2pew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlSltrnJ&md5=254cbca060bb4cfd04eac365488f5b62</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%2BA.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DPham-Huy%26aufirst%3DC.%26atitle%3DChiral%2520drugs%253A%2520an%2520overview%26jtitle%3DInt.%2520J.%2520Biomed.%2520Sci.%26date%3D2006%26volume%3D2%26spage%3D85%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-new-stereoisomeric-drugs" class="extLink">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-new-stereoisomeric-drugs</a> (accessed 20121-02-23).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fregulatory-information%2Fsearch-fda-guidance-documents%2Fdevelopment-new-stereoisomeric-drugs+%28accessed+20121-02-23%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, C.</span></span> <span> </span><span class="NLM_article-title">Diastereoselective synthesis of aryloxy phosphoramidate prodrugs of 3′-deoxy-2’,3′-didehydrothymidine monophosphate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7675</span>– <span class="NLM_lpage">7681</span>, <span class="refDoi"> DOI: 10.1021/jm100817f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100817f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yktLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7675-7681&author=C.+A.+Romanauthor=J.+Balzariniauthor=C.+Meier&title=Diastereoselective+synthesis+of+aryloxy+phosphoramidate+prodrugs+of+3%E2%80%B2-deoxy-2%E2%80%99%2C3%E2%80%B2-didehydrothymidine+monophosphate&doi=10.1021%2Fjm100817f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Diastereoselective Synthesis of Aryloxy Phosphoramidate Prodrugs of 3'-Deoxy-2',3'-didehydrothymidine Monophosphate</span></div><div class="casAuthors">Roman, Cristina Arbelo; Balzarini, Jan; Meier, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7675-7681</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first diastereoselective synthesis of aryloxy phosphoramidate prodrugs of 3'-deoxy-2',3'-didehydrothymidine monophosphate (d4TMP) is reported.  In our approach, (S)-4-isopropylthiazolidine-2-thione 1 was used as a chiral auxiliary to introduce the stereochem. at the phosphorus atom.  In the last step of the developed reaction sequence, the nucleoside analog d4T was introduced to a stereochem. pure phosphordiamidate which led to the formation of the almost diastereomerically pure phosphoramidate prodrugs, e.g. I, (≥95% de).  As expected, the individually prepd. diastereomers of the phosphoramidate prodrugs showed significant differences in the antiviral activity.  Moreover, the difference was strongly dependent on the aryl substituent attached to the phosphoramidate moiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Wwym4_S97bVg90H21EOLACvtfcHk0lhUcGLcTA2pew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yktLzE&md5=2fdc109dadda8cf6fa9f75be1f43f196</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm100817f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100817f%26sid%3Dliteratum%253Aachs%26aulast%3DRoman%26aufirst%3DC.%2BA.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DMeier%26aufirst%3DC.%26atitle%3DDiastereoselective%2520synthesis%2520of%2520aryloxy%2520phosphoramidate%2520prodrugs%2520of%25203%25E2%2580%25B2-deoxy-2%25E2%2580%2599%252C3%25E2%2580%25B2-didehydrothymidine%2520monophosphate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7675%26epage%3D7681%26doi%3D10.1021%2Fjm100817f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapati Reddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of diastereomerically pure nucleotide phosphoramidates</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">8311</span>– <span class="NLM_lpage">8319</span>, <span class="refDoi"> DOI: 10.1021/jo201492m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo201492m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ags77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=8311-8319&author=B.+S.+Rossauthor=P.+Ganapati+Reddyauthor=H.-R.+Zhangauthor=S.+Rachakondaauthor=M.+J.+Sofia&title=Synthesis+of+diastereomerically+pure+nucleotide+phosphoramidates&doi=10.1021%2Fjo201492m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Diastereomerically Pure Nucleotide Phosphoramidates</span></div><div class="casAuthors">Ross, Bruce S.; Ganapati Reddy, P.; Zhang, Hai-Ren; Rachakonda, Suguna; Sofia, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8311-8319</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prodrugs of therapeutic nucleoside monophosphates masked as phosphoramidate derivs. have become an increasingly important class of antiviral drugs in pharmaceutical research for delivering nucleotides in vitro and in vivo.  Conventionally, phosphoramidate derivs. are prepd. as a mixt. of two diastereomers.  We report a class of stable phosphoramidate reagents contg. an amino acid ester and two phenolic groups, one unsubstituted and the other with electron-withdrawing substituents.  The reagents can be isolated as single diastereomers and reacted with the 5'-hydroxyl group of nucleosides through selective nucleophilic displacement of the substituted phenol to prep. single diastereomer phosphoramidate products.  This method has been used to prep. the HCV clin. candidate PSI-7977 I in high yield and high diastereomeric purity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgDGdlH3gLa7Vg90H21EOLACvtfcHk0lhUcGLcTA2pew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ags77F&md5=747a893daa7d9c4784cc29619d05ab81</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjo201492m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo201492m%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DGanapati%2BReddy%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520of%2520diastereomerically%2520pure%2520nucleotide%2520phosphoramidates%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26spage%3D8311%26epage%3D8319%26doi%3D10.1021%2Fjo201492m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span> <i>Synthesis of substantially diastereomerically pure
phosphate protides</i>. WO Patent <span class="NLM_patent">2018/229493</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Synthesis+of+substantially+diastereomerically+pure%0Aphosphate+protides.+WO+Patent+2018%2F229493%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthesis%2520of%2520substantially%2520diastereomerically%2520pure%250Aphosphate%2520protides%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span> <i>Diastereoselective synthesis of phosphate derivatives and
of the
gemcitabine prodrug NUC-1031</i>. WO Patent <span class="NLM_patent">2017/098252 A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Diastereoselective+synthesis+of+phosphate+derivatives+and%0Aof+the%0Agemcitabine+prodrug+NUC-1031.+WO+Patent+2017%2F098252+A1%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26jtitle%3DDiastereoselective%2520synthesis%2520of%2520phosphate%2520derivatives%2520and%250Aof%2520the%250Agemcitabine%2520prodrug%2520NUC-1031%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pertusati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">Diastereoselective synthesis of P-chirogenic phosphoramidate prodrugs of nucleoside analogues (protides) via copper catalysed reaction</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">8070</span>– <span class="NLM_lpage">8073</span>, <span class="refDoi"> DOI: 10.1039/C5CC00448A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1039%2FC5CC00448A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=25867944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvFWhu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=8070-8073&author=F.+Pertusatiauthor=C.+McGuigan&title=Diastereoselective+synthesis+of+P-chirogenic+phosphoramidate+prodrugs+of+nucleoside+analogues+%28protides%29+via+copper+catalysed+reaction&doi=10.1039%2FC5CC00448A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Diastereoselective synthesis of P-chirogenic phosphoramidate prodrugs of nucleoside analogues (ProTides) via copper catalysed reaction</span></div><div class="casAuthors">Pertusati, F.; McGuigan, C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">8070-8073</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The first copper-catalyzed diastereoselective synthesis of P-chiral phosphoramidate prodrugs (ProTides) is reported.  This procedure allows the synthesis of diastereomeric-enriched mixts. of ProTides.  Application of this methodol. to the asym. phosphorylation of purine and pyrimidine nucleoside analogs is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxTx1v1huKfLVg90H21EOLACvtfcHk0lgN4KGwmAIVhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvFWhu7g%253D&md5=8dbcffb9d06e2037912b427928c95e61</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1039%2FC5CC00448A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC00448A%26sid%3Dliteratum%253Aachs%26aulast%3DPertusati%26aufirst%3DF.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DDiastereoselective%2520synthesis%2520of%2520P-chirogenic%2520phosphoramidate%2520prodrugs%2520of%2520nucleoside%2520analogues%2520%2528protides%2529%2520via%2520copper%2520catalysed%2520reaction%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D8070%26epage%3D8073%26doi%3D10.1039%2FC5CC00448A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A. I.</span></span> <span> </span><span class="NLM_article-title">Facile and highly selective 5′-desilylation of multisilylated nucleosides</span>. <i>Chem. Soc. Perkin. Trans 1</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_fpage">2305</span>– <span class="NLM_lpage">2306</span>, <span class="refDoi"> DOI: 10.1039/b003562i</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1039%2Fb003562i" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=2305-2306&author=X.-F.+Zhuauthor=H.+J.+Williamsauthor=A.+I.+Scott&title=Facile+and+highly+selective+5%E2%80%B2-desilylation+of+multisilylated+nucleosides&doi=10.1039%2Fb003562i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1039%2Fb003562i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb003562i%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DX.-F.%26aulast%3DWilliams%26aufirst%3DH.%2BJ.%26aulast%3DScott%26aufirst%3DA.%2BI.%26atitle%3DFacile%2520and%2520highly%2520selective%25205%25E2%2580%25B2-desilylation%2520of%2520multisilylated%2520nucleosides%26jtitle%3DChem.%2520Soc.%2520Perkin.%2520Trans%25201%26date%3D2000%26spage%3D2305%26epage%3D2306%26doi%3D10.1039%2Fb003562i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srihari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagesh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiranmai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagesh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idris, M. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of readily accessible triazole-linked dimer deoxynucleoside phosphoramidite for solid-phase oligonucleotide synthesis</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2010</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">3710</span>– <span class="NLM_lpage">3714</span>, <span class="refDoi"> DOI: 10.1055/s-0030-1258243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1055%2Fs-0030-1258243" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=3710-3714&issue=21&author=S.+Chandrasekharauthor=P.+Srihariauthor=C.+Nageshauthor=N.+Kiranmaiauthor=N.+Nageshauthor=M.+M.+Idris&title=Synthesis+of+readily+accessible+triazole-linked+dimer+deoxynucleoside+phosphoramidite+for+solid-phase+oligonucleotide+synthesis&doi=10.1055%2Fs-0030-1258243"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1055%2Fs-0030-1258243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0030-1258243%26sid%3Dliteratum%253Aachs%26aulast%3DChandrasekhar%26aufirst%3DS.%26aulast%3DSrihari%26aufirst%3DP.%26aulast%3DNagesh%26aufirst%3DC.%26aulast%3DKiranmai%26aufirst%3DN.%26aulast%3DNagesh%26aufirst%3DN.%26aulast%3DIdris%26aufirst%3DM.%2BM.%26atitle%3DSynthesis%2520of%2520readily%2520accessible%2520triazole-linked%2520dimer%2520deoxynucleoside%2520phosphoramidite%2520for%2520solid-phase%2520oligonucleotide%2520synthesis%26jtitle%3DSynthesis%26date%3D2010%26volume%3D2010%26issue%3D21%26spage%3D3710%26epage%3D3714%26doi%3D10.1055%2Fs-0030-1258243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambabu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, A. S.</span></span> <span> </span><span class="NLM_article-title">Spirastrellolide B: the synthesis of southern (C<sub>9</sub>–C<sub>25</sub>) region</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4355</span>– <span class="NLM_lpage">4357</span>, <span class="refDoi"> DOI: 10.1021/ol801771s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol801771s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVymtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=4355-4357&author=S.+Chandrasekharauthor=C.+Rambabuauthor=A.+S.+Reddy&title=Spirastrellolide+B%3A+the+synthesis+of+southern+%28C9%E2%80%93C25%29+region&doi=10.1021%2Fol801771s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Spirastrellolide B: The Synthesis of Southern (C9-C25) Region</span></div><div class="casAuthors">Chandrasekhar, Srivari; Rambabu, Chegondi; Reddy, Annareddy Syamprasad</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4355-4357</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A combination of "chiron" and "asym." approaches is utilized to construct the southern (C9-C25) region I of marine natural product spirastrellolide B.  The key functionalities are derived from D-glucose and Sharpless asym. epoxidn. and dihydroxylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPmmKafeZqqbVg90H21EOLACvtfcHk0lgN4KGwmAIVhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVymtb3J&md5=12debd71b48a856168402d9a6c4192f6</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fol801771s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol801771s%26sid%3Dliteratum%253Aachs%26aulast%3DChandrasekhar%26aufirst%3DS.%26aulast%3DRambabu%26aufirst%3DC.%26aulast%3DReddy%26aufirst%3DA.%2BS.%26atitle%3DSpirastrellolide%2520B%253A%2520the%2520synthesis%2520of%2520southern%2520%2528C9%25E2%2580%2593C25%2529%2520region%26jtitle%3DOrg.%2520Lett.%26date%3D2008%26volume%3D10%26spage%3D4355%26epage%3D4357%26doi%3D10.1021%2Fol801771s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span> <span> </span><span class="NLM_article-title">Human carboxylesterases: a comprehensive review</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2018.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1016%2Fj.apsb.2018.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=30245959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A280%3ADC%252BB3czhvVOjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=699-712&author=D.+Wangauthor=L.+Zouauthor=Q.+Jinauthor=J.+Houauthor=G.+Geauthor=L.+Yang&title=Human+carboxylesterases%3A+a+comprehensive+review&doi=10.1016%2Fj.apsb.2018.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Human carboxylesterases: a comprehensive review</span></div><div class="casAuthors">Wang Dandan; Zou Liwei; Jin Qiang; Ge Guangbo; Yang Ling; Hou Jie</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">699-712</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Mammalian carboxylesterases (CEs) are key enzymes from the serine hydrolase superfamily.  In the human body, two predominant carboxylesterases (CES1 and CES2) have been identified and extensively studied over the past decade.  These two enzymes play crucial roles in the metabolism of a wide variety of endogenous esters, ester-containing drugs and environmental toxicants.  The key roles of CES in both human health and xenobiotic metabolism arouse great interest in the discovery of potent CES modulators to regulate endobiotic metabolism or to improve the efficacy of ester drugs.  This review covers the structural and catalytic features of CES, tissue distributions, biological functions, genetic polymorphisms, substrate specificities and inhibitor properties of CES1 and CES2, as well as the significance and recent progress on the discovery of CES modulators.  The information presented here will help pharmacologists explore the relevance of CES to human diseases or to assign the contribution of certain CES in xenobiotic metabolism.  It will also facilitate medicinal chemistry efforts to design prodrugs activated by a given CES isoform, or to develop potent and selective modulators of CES for potential biomedical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHzNUaecqdULHHuJhbyicZfW6udTcc2ea-sehBzDNq57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czhvVOjug%253D%253D&md5=4c0b70b0208577496c8e0270af5eda8e</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2018.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2018.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DL.%26atitle%3DHuman%2520carboxylesterases%253A%2520a%2520comprehensive%2520review%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2018%26volume%3D8%26spage%3D699%26epage%3D712%26doi%3D10.1016%2Fj.apsb.2018.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit39b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taketani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosokawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, K.</span></span> <span> </span><span class="NLM_article-title">Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1734</span>– <span class="NLM_lpage">1741</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.009381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1124%2Fdmd.106.009381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=16837570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVCltbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=1734-1741&author=T.+Imaiauthor=M.+Taketaniauthor=M.+Shiiauthor=M.+Hosokawaauthor=K.+Chiba&title=Substrate+specificity+of+carboxylesterase+isozymes+and+their+contribution+to+hydrolase+activity+in+human+liver+and+small+intestine&doi=10.1124%2Fdmd.106.009381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine</span></div><div class="casAuthors">Imai, Teruko; Taketani, Megumi; Shii, Mayumi; Hosokawa, Masakiyo; Chiba, Kan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1734-1741</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Hydrolase activity from human liver and small intestine microsomes was compared with that of recombinant human carboxylesterases, hCE-1 and hCE-2.  Although both hCE-1 and hCE-2 are present in human liver, the dominant component was found to be hCE-1, whereas the hydrolase activity of the human small intestine was found to be predominantly hCE-2.  HCE-2 has a limited ability to hydrolyze large acyl compd. substrates.  Interestingly, propranolol derivs., good substrates for hCE-2, were easily hydrolyzed by substitution of the Me group on the 2-position of the acyl moiety, but were barely hydrolyzed when the Me group was substituted on the 3-position.  These findings suggest that hCE-2 does not easily form acylated intermediates because of conformational interference in its active site.  In contrast, hCE-1 could hydrolyze a variety of substrates.  The hydrolytic activity of hCE-2 increased with increasing alc. chain length in benzoic acid deriv. substrates, whereas hCE-1 preferentially catalyzed the hydrolysis of substrates with short alc. chains.  Kinetic data showed that the detg. factor for the rate of hydrolysis of p-aminobenzoic acid esters was Vmax for hCE-1 and Km for hCE-2.  Furthermore, the addn. of hydrophobic alcs. to the reaction mixt. with p-aminobenzoic acid Pr ester induced high and low levels of transesterification by hCE-1 and hCE-2, resp.  When considering the substrate specificities of hCE-1, it is necessary to consider the transesterification ability of hCE-1, in addn. to the binding structure of the substrate in the active site of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_5Qby7_S88LVg90H21EOLACvtfcHk0liviwH7iODARw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVCltbvI&md5=b2d3c1d2aee89b647e1c8030daee8c3a</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.009381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.009381%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DT.%26aulast%3DTaketani%26aufirst%3DM.%26aulast%3DShii%26aufirst%3DM.%26aulast%3DHosokawa%26aufirst%3DM.%26aulast%3DChiba%26aufirst%3DK.%26atitle%3DSubstrate%2520specificity%2520of%2520carboxylesterase%2520isozymes%2520and%2520their%2520contribution%2520to%2520hydrolase%2520activity%2520in%2520human%2520liver%2520and%2520small%2520intestine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D1734%26epage%3D1741%26doi%3D10.1124%2Fdmd.106.009381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutty, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacArthur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, M.</span></span> <span> </span><span class="NLM_article-title">Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1128/AAC.00968-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1128%2FAAC.00968-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=17145787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=543-550&author=G.+Birkusauthor=R.+Wangauthor=X.+Liuauthor=N.+Kuttyauthor=H.+MacArthurauthor=T.+Cihlarauthor=C.+Gibbsauthor=S.+Swaminathanauthor=W.+Leeauthor=M.+McDermott&title=Cathepsin+A+is+the+major+hydrolase+catalyzing+the+intracellular+hydrolysis+of+the+antiretroviral+nucleotide+phosphonoamidate+prodrugs+GS-7340+and+GS-9131&doi=10.1128%2FAAC.00968-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131</span></div><div class="casAuthors">Birkus, Gabriel; Wang, Ruth; Liu, Xiaohong; Kutty, Nilima; MacArthur, Holly; Cihlar, Tomas; Gibbs, Craig; Swaminathan, Swami; Lee, William; McDermott, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">543-550</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">GS-7340 and GS-9131 {9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine and 9-(R)-4'-(R)-[[[(S)-1-[(ethoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]-2'-fluoro-1'-furanyladenine, resp.} are novel alkylalaninyl Ph ester prodrugs of tenofovir {9-R-[(2-phosphonomethoxy)propyl]adenine} (TFV) and a cyclic nucleotide analog, GS-9148 (phosphonomethoxy-2'-fluoro-2',3'-dideoxydidehydroadenosine), resp.  Both prodrugs exhibit potent antiretroviral activity against both wild-type and drug-resistant human immunodeficiency virus type 1 strains and excellent in vivo pharmacokinetic properties.  In this study, the main enzymic activity responsible for the initial step in the intracellular activation of GS-7340 and GS-9131 was isolated from human peripheral blood mononuclear cells and identified as lysosomal carboxypeptidase A (cathepsin A [CatA]; EC 3.4.16.5).  Biochem. properties of the purified hydrolase (native complex and catalytic subunit mol. masses of 100 and 29 kDa, resp.; isoelec. point [pI] of 5.5) matched those of CatA.  Recombinant CatA and the isolated prodrug hydrolase displayed identical susceptibilities to inhibitors and identical substrate preferences toward a panel of tenofovir phosphonoamidate prodrugs.  Incubation of both enzymes with 14C-labeled GS-7340 or [3H]difluorophosphonate resulted in the covalent labeling of identical 29-kDa catalytic subunits.  Finally, following a 4-h incubation with GS-7340 and GS-9131, the intracellular concns. of prodrug metabolites detected in CatA-neg. fibroblasts were approx. 7.5- and 3-fold lower, resp., than those detected in normal control fibroblasts.  Collectively, these data demonstrate the key role of CatA in the intracellular activation of nucleotide phosphonoamidate prodrugs and open new possibilities for further improvement of this important class of antiviral prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr00GVCN10SLVg90H21EOLACvtfcHk0liviwH7iODARw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOqu70%253D&md5=3c9bbdfaf343f9a0fed9e4d584c3565b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1128%2FAAC.00968-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00968-06%26sid%3Dliteratum%253Aachs%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKutty%26aufirst%3DN.%26aulast%3DMacArthur%26aufirst%3DH.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DGibbs%26aufirst%3DC.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DM.%26atitle%3DCathepsin%2520A%2520is%2520the%2520major%2520hydrolase%2520catalyzing%2520the%2520intracellular%2520hydrolysis%2520of%2520the%2520antiretroviral%2520nucleotide%2520phosphonoamidate%2520prodrugs%2520GS-7340%2520and%2520GS-9131%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D543%26epage%3D550%26doi%3D10.1128%2FAAC.00968-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lapidot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vormoor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murdoch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caceres-Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, J. E.</span></span> <span> </span><span class="NLM_article-title">A cell initiating human acute myeloid leukaemia after transplantation into SCID mice</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1038/367645a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1038%2F367645a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=7509044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A280%3ADyaK2c7ltVKrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=1994&pages=645-648&author=T.+Lapidotauthor=C.+Sirardauthor=J.+Vormoorauthor=B.+Murdochauthor=T.+Hoangauthor=J.+Caceres-Cortesauthor=M.+Mindenauthor=B.+Patersonauthor=M.+A.+Caligiuriauthor=J.+E.+Dick&title=A+cell+initiating+human+acute+myeloid+leukaemia+after+transplantation+into+SCID+mice&doi=10.1038%2F367645a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A cell initiating human acute myeloid leukaemia after transplantation into SCID mice</span></div><div class="casAuthors">Lapidot T; Sirard C; Vormoor J; Murdoch B; Hoang T; Caceres-Cortes J; Minden M; Paterson B; Caligiuri M A; Dick J E</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">6464</span>),
    <span class="NLM_cas:pages">645-8</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Most human acute myeloid leukaemia (AML) cells have limited proliferative capacity, suggesting that the leukaemic clone may be maintained by a rare population of stem cells.  This putative leukaemic stem cell has not been characterized because the available in vitro assays can only detect progenitors with limited proliferative and replating potential.  We have now identified an AML-initiating cell by transplantation into severe combined immune-deficient (SCID) mice.  These cells homed to the bone marrow and proliferated extensively in response to in vivo cytokine treatment, resulting in a pattern of dissemination and leukaemic cell morphology similar to that seen in the original patients.  Limiting dilution analysis showed that the frequency of these leukaemia-initiating cells in the peripheral blood of AML patients was one engraftment unit in 250,000 cells.  We fractionated AML cells on the basis of cell-surface-marker expression and found that the leukaemia-initiating cells that could engraft SCID mice to produce large numbers of colony-forming progenitors were CD34+ CD38-; however, the CD34+ CD38+ and CD34- fractions contained no cells with these properties.  This in vivo model replicates many aspects of human AML and defines a new leukaemia-initiating cell which is less mature than colony-forming cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvfHJZ5BZZYP3jf77P2BG3fW6udTcc2eZY4H8oYTsGxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c7ltVKrsg%253D%253D&md5=692809a03a33f917ae2815cedadb7973</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2F367645a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F367645a0%26sid%3Dliteratum%253Aachs%26aulast%3DLapidot%26aufirst%3DT.%26aulast%3DSirard%26aufirst%3DC.%26aulast%3DVormoor%26aufirst%3DJ.%26aulast%3DMurdoch%26aufirst%3DB.%26aulast%3DHoang%26aufirst%3DT.%26aulast%3DCaceres-Cortes%26aufirst%3DJ.%26aulast%3DMinden%26aufirst%3DM.%26aulast%3DPaterson%26aufirst%3DB.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DDick%26aufirst%3DJ.%2BE.%26atitle%3DA%2520cell%2520initiating%2520human%2520acute%2520myeloid%2520leukaemia%2520after%2520transplantation%2520into%2520SCID%2520mice%26jtitle%3DNature%26date%3D1994%26volume%3D367%26spage%3D645%26epage%3D648%26doi%3D10.1038%2F367645a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phi, L. T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sari, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H. Y.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment</span>. <i>Stem Cells Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2018</i></span>,  <span class="NLM_fpage">5416923</span>, <span class="refDoi"> DOI: 10.1155/2018/5416923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1155%2F2018%2F5416923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=29681949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A280%3ADC%252BC1MjltlGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2018&publication_year=2018&pages=5416923&author=L.+T.+H.+Phiauthor=I.+N.+Sariauthor=Y.-G.+Yangauthor=S.-H.+Leeauthor=N.+Junauthor=K.+S.+Kimauthor=Y.+K.+Leeauthor=H.+Y.+Kwon&title=Cancer+stem+cells+%28CSCs%29+in+drug+resistance+and+their+therapeutic+implications+in+cancer+treatment&doi=10.1155%2F2018%2F5416923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment</span></div><div class="casAuthors">Phi Lan Thi Hanh; Sari Ita Novita; Yang Ying-Gui; Lee Sang-Hyun; Jun Nayoung; Kim Kwang Seock; Lee Yun Kyung; Kwon Hyog Young</div><div class="citationInfo"><span class="NLM_cas:title">Stem cells international</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2018</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5416923</span>
        ISSN:<span class="NLM_cas:issn">1687-966X</span>.
    </div><div class="casAbstract">Cancer stem cells (CSCs), also known as tumor-initiating cells (TICs), are suggested to be responsible for drug resistance and cancer relapse due in part to their ability to self-renew themselves and differentiate into heterogeneous lineages of cancer cells.  Thus, it is important to understand the characteristics and mechanisms by which CSCs display resistance to therapeutic agents.  In this review, we highlight the key features and mechanisms that regulate CSC function in drug resistance as well as recent breakthroughs of therapeutic approaches for targeting CSCs.  This promises new insights of CSCs in drug resistance and provides better therapeutic rationales to accompany novel anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ832gT2olHIa91pGlMMoT5fW6udTcc2eZY4H8oYTsGxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjltlGgsQ%253D%253D&md5=e90fa5e53fbb5ccf47d267ce645daf2a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1155%2F2018%2F5416923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2018%252F5416923%26sid%3Dliteratum%253Aachs%26aulast%3DPhi%26aufirst%3DL.%2BT.%2BH.%26aulast%3DSari%26aufirst%3DI.%2BN.%26aulast%3DYang%26aufirst%3DY.-G.%26aulast%3DLee%26aufirst%3DS.-H.%26aulast%3DJun%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLee%26aufirst%3DY.%2BK.%26aulast%3DKwon%26aufirst%3DH.%2BY.%26atitle%3DCancer%2520stem%2520cells%2520%2528CSCs%2529%2520in%2520drug%2520resistance%2520and%2520their%2520therapeutic%2520implications%2520in%2520cancer%2520treatment%26jtitle%3DStem%2520Cells%2520Int.%26date%3D2018%26volume%3D2018%26spage%3D5416923%26doi%3D10.1155%2F2018%2F5416923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paschall, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redd, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak-Kapoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span> <span> </span><span class="NLM_article-title">CD133<sup>+</sup>CD24<sup>lo</sup> defines a 5-fluorouracil-resistant colon cancer stem cell-like phenotype</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">78698</span>– <span class="NLM_lpage">78712</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.12168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.18632%2Foncotarget.12168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=27659530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A280%3ADC%252BC2svjtFKmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=78698-78712&author=A.+V.+Paschallauthor=D.+Yangauthor=C.+Luauthor=P.+S.+Reddauthor=J.-H.+Choiauthor=C.+M.+Heatonauthor=J.+R.+Leeauthor=A.+Nayak-Kapoorauthor=K.+Liu&title=CD133%2BCD24lo+defines+a+5-fluorouracil-resistant+colon+cancer+stem+cell-like+phenotype&doi=10.18632%2Foncotarget.12168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">CD133+CD24lo defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype</span></div><div class="casAuthors">Paschall Amy V; Yang Dafeng; Lu Chunwan; Redd Priscilla S; Liu Kebin; Paschall Amy V; Redd Priscilla S; Choi Jeong-Hyeon; Nayak-Kapoor Asha; Liu Kebin; Paschall Amy V; Yang Dafeng; Lu Chunwan; Redd Priscilla S; Heaton Christopher M; Lee Jeffrey R; Nayak-Kapoor Asha; Liu Kebin</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">78698-78712</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The chemotherapeutic agent 5-Fluorouracil (5-FU) is the most commonly used drug for patients with advanced colon cancer.  However, development of resistance to 5-FU is inevitable in almost all patients.  The mechanism by which colon cancer develops 5-FU resistance is still unclear.  One recently proposed theory is that cancer stem-like cells underlie colon cancer 5-FU resistance, but the phenotypes of 5-FU-resistant colon cancer stem cells are still controversial.  We report here that 5-FU treatment selectively enriches a subset of CD133+ colon cancer cells in vitro. 5-FU chemotherapy also increases CD133+ tumor cells in human colon cancer patients.  However, sorted CD133+ colon cancer cells exhibit no increased resistance to 5-FU, and CD133 levels exhibit no correlation with colon cancer patient survival or cancer recurrence.  Genome-wide analysis of gene expression between sorted CD133+ colon cancer cells and 5-FU-selected colon cancer cells identifies 207 differentially expressed genes.  CD24 is one of the genes whose expression level is lower in the CD133+ and 5-FU-resistant colon cancer cells as compared to CD133+ and 5-FU-sensitive colon cancer cells.  Consequently, CD133+CD24lo cells exhibit decreased sensitivity to 5-FU.  Therefore, we determine that CD133+CD24lo phenotype defines 5-FU-resistant human colon cancer stem cell-like cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSLzFZSPREW4mZyxfu64m4ffW6udTcc2eZY4H8oYTsGxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svjtFKmtw%253D%253D&md5=3f185f29fce66d62364a40e57c0a3312</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12168%26sid%3Dliteratum%253Aachs%26aulast%3DPaschall%26aufirst%3DA.%2BV.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DRedd%26aufirst%3DP.%2BS.%26aulast%3DChoi%26aufirst%3DJ.-H.%26aulast%3DHeaton%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BR.%26aulast%3DNayak-Kapoor%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DK.%26atitle%3DCD133%252BCD24lo%2520defines%2520a%25205-fluorouracil-resistant%2520colon%2520cancer%2520stem%2520cell-like%2520phenotype%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D78698%26epage%3D78712%26doi%3D10.18632%2Foncotarget.12168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
den broeck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gremeaux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vankelecom, H.</span></span> <span> </span><span class="NLM_article-title">Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">354</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-12-354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1186%2F1471-2407-12-354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=22894607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVWksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=354&author=A.+Van%0Aden+broeckauthor=L.+Gremeauxauthor=B.+Topalauthor=H.+Vankelecom&title=Human+pancreatic+adenocarcinoma+contains+a+side+population+resistant+to+gemcitabine&doi=10.1186%2F1471-2407-12-354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine</span></div><div class="casAuthors">Van den Broeck, Anke; Gremeaux, Lies; Topal, Baki; Vankelecom, Hugo</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">354</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Therapy resistance remains one of the major challenges to improve the prognosis of patients with pancreatic cancer.  Chemoresistant cells, which potentially also display cancer stem cell (CSC) characteristics, can be isolated using the side population (SP) technique.  Our aim was to search for a SP in human pancreatic ductal adenocarcinoma (PDAC) and to examine its chemoresistance and CSC(-like) phenotype.  Human PDAC samples were expanded in immunodeficient mice and first-generation xenografts analyzed for the presence of a Hoechst dye-effluxing SP using flow cytometry (FACS).  To investigate chemoresistance of the SP, mice bearing PDAC xenografts were treated with gemcitabine and SP proportion detd.  In addn., the SP and the main tumor cell population (MP) were sorted by FACS for RNA extn. to profile gene expression, and for culturing under sphere-forming conditions.  A SP was identified in all PDAC samples, analyzed.  This SP was more resistant to gemcitabine than the other tumor cells as examd. in vivo.  Whole-genome expression profiling of the SP revealed upregulation of genes related to therapy resistance, apoptotic regulation and epithelial-mesenchymal transition.  In addn., the SP displayed higher tumorigenic (CSC) activity than the MP as analyzed in vitro by sphere-forming capacity.  We identified a SP in human PDAC and uncovered a chemoresistant and CSC-assocd. phenotype.  This SP may represent a new therapeutic target in pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8IT1GV23OBLVg90H21EOLACvtfcHk0lh30rfkPn0iGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVWksg%253D%253D&md5=6c07bca506dca82bb29b89f235b0ecdf</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-12-354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-12-354%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2Bbroeck%26aufirst%3DA.%26aulast%3DGremeaux%26aufirst%3DL.%26aulast%3DTopal%26aufirst%3DB.%26aulast%3DVankelecom%26aufirst%3DH.%26atitle%3DHuman%2520pancreatic%2520adenocarcinoma%2520contains%2520a%2520side%2520population%2520resistant%2520to%2520gemcitabine%26jtitle%3DBMC%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D354%26doi%3D10.1186%2F1471-2407-12-354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeijlemaker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanekamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbaat-Ham, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oussoren-Brockhoff, Y. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snel, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veldhuizen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholten, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maertens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breems, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manz, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Velden, V. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slomp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preijers, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Loosdrecht, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löwenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valk, P. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jongen-Lavrencic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ossenkoppele, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuurhuis, G. J.</span></span> <span> </span><span class="NLM_article-title">CD34<sup>+</sup> CD38<sup>–</sup> leukemic stem cell frequency to predict outcome in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1102</span>– <span class="NLM_lpage">1112</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0326-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1038%2Fs41375-018-0326-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=30542144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSmsb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=1102-1112&author=W.+Zeijlemakerauthor=T.+Grobauthor=R.+Meijerauthor=D.+Hanekampauthor=A.+Kelderauthor=J.+C.+Carbaat-Hamauthor=Y.+J.+M.+Oussoren-Brockhoffauthor=A.+N.+Snelauthor=D.+Veldhuizenauthor=W.+J.+Scholtenauthor=J.+Maertensauthor=D.+A.+Breemsauthor=T.+Pabstauthor=M.+G.+Manzauthor=V.+H.+J.+van+der+Veldenauthor=J.+Slompauthor=F.+Preijersauthor=J.+Cloosauthor=A.+A.+van+de+Loosdrechtauthor=B.+L%C3%B6wenbergauthor=P.+J.+M.+Valkauthor=M.+Jongen-Lavrencicauthor=G.+J.+Ossenkoppeleauthor=G.+J.+Schuurhuis&title=CD34%2B+CD38%E2%80%93+leukemic+stem+cell+frequency+to+predict+outcome+in+acute+myeloid+leukemia&doi=10.1038%2Fs41375-018-0326-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia</span></div><div class="casAuthors">Zeijlemaker, Wendelien; Grob, Tim; Meijer, Rosa; Hanekamp, Diana; Kelder, Angele; Carbaat-Ham, Jannemieke C.; Oussoren-Brockhoff, Yvonne J. M.; Snel, Alexander N.; Veldhuizen, Dennis; Scholten, Willemijn J.; Maertens, Johan; Breems, Dimitri A.; Pabst, Thomas; Manz, Markus G.; van der Velden, Vincent H. J.; Slomp, Jennichjen; Preijers, Frank; Cloos, Jacqueline; van de Loosdrecht, Arjan A.; Loewenberg, Bob; Valk, Peter J. M.; Jongen-Lavrencic, Mojca; Ossenkoppele, Gert J.; Schuurhuis, Gerrit J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1102-1112</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Current risk algorithms are primarily based on pre-treatment factors and imperfectly predict outcome in acute myeloid leukemia (AML).  We introduce and validate a post-treatment approach of leukemic stem cell (LSC) assessment for prediction of outcome.  LSC contg. CD34+CD38- fractions were measured using flow cytometry in an add-on study of the HOVON102/SAKK trial.  Predefined cut-off levels were prospectively evaluated to assess CD34+CD38-LSC levels at diagnosis (n = 594), and, to identify LSClow/LSChigh (n = 302) and MRDlow/MRDhigh patients (n = 305) in bone marrow in morphol. complete remission (CR).  In 242 CR patients combined MRD and LSC results were available.  At diagnosis the CD34+CD38- LSC frequency independently predicts overall survival (OS).  After achieving CR, combining LSC and MRD showed reduced survival in MRDhigh/LSChigh patients (hazard ratio [HR] 3.62 for OS and 5.89 for cumulative incidence of relapse [CIR]) compared to MRDlow/LSChigh, MRDhigh/LSClow, and esp. MRDlow/LSClow patients.  Moreover, in the NPM1mutant pos. sub-group, prognostic value of golden std. NPM1-MRD by qPCR can be improved by addn. of flow cytometric approaches.  This is the first prospective study demonstrating that LSC strongly improves prognostic impact of MRD detection, identifying a patient subgroup with an almost 100% treatment failure probability, warranting consideration of LSC measurement incorporation in future AML risk schemes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqo_rnaNXF9LVg90H21EOLACvtfcHk0lh30rfkPn0iGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSmsb%252FF&md5=4cab3f5320b2ae12655cf9c3896cc4f1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0326-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0326-3%26sid%3Dliteratum%253Aachs%26aulast%3DZeijlemaker%26aufirst%3DW.%26aulast%3DGrob%26aufirst%3DT.%26aulast%3DMeijer%26aufirst%3DR.%26aulast%3DHanekamp%26aufirst%3DD.%26aulast%3DKelder%26aufirst%3DA.%26aulast%3DCarbaat-Ham%26aufirst%3DJ.%2BC.%26aulast%3DOussoren-Brockhoff%26aufirst%3DY.%2BJ.%2BM.%26aulast%3DSnel%26aufirst%3DA.%2BN.%26aulast%3DVeldhuizen%26aufirst%3DD.%26aulast%3DScholten%26aufirst%3DW.%2BJ.%26aulast%3DMaertens%26aufirst%3DJ.%26aulast%3DBreems%26aufirst%3DD.%2BA.%26aulast%3DPabst%26aufirst%3DT.%26aulast%3DManz%26aufirst%3DM.%2BG.%26aulast%3Dvan%2Bder%2BVelden%26aufirst%3DV.%2BH.%2BJ.%26aulast%3DSlomp%26aufirst%3DJ.%26aulast%3DPreijers%26aufirst%3DF.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3Dvan%2Bde%2BLoosdrecht%26aufirst%3DA.%2BA.%26aulast%3DL%25C3%25B6wenberg%26aufirst%3DB.%26aulast%3DValk%26aufirst%3DP.%2BJ.%2BM.%26aulast%3DJongen-Lavrencic%26aufirst%3DM.%26aulast%3DOssenkoppele%26aufirst%3DG.%2BJ.%26aulast%3DSchuurhuis%26aufirst%3DG.%2BJ.%26atitle%3DCD34%252B%2520CD38%25E2%2580%2593%2520leukemic%2520stem%2520cell%2520frequency%2520to%2520predict%2520outcome%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2019%26volume%3D33%26spage%3D1102%26epage%3D1112%26doi%3D10.1038%2Fs41375-018-0326-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesnowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löhr, J. M.</span></span> <span> </span><span class="NLM_article-title">Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1593/neo.10576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1593%2Fneo.10576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=20824050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGmtrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=740-747&author=W.+Hagmannauthor=R.+Jesnowskiauthor=J.+M.+L%C3%B6hr&title=Interdependence+of+gemcitabine+treatment%2C+transporter+expression%2C+and+resistance+in+human+pancreatic+carcinoma+cells&doi=10.1593%2Fneo.10576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Interdependence of gemcitabine treatment, transporter expression and resistance in human pancreatic carcinoma cells</span></div><div class="casAuthors">Hagmann, Wolfgang; Jesnowski, Ralf; Loehr, Johannes Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">740-747</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">Gemcitabine is widely used as first-line chemotherapeutic drug in the treatment of pancreatic cancer.  Our previous exptl. chemotherapy studies have shown that treatment of human pancreatic carcinoma cells with 5-fluorouracil (5-FU) alters the cellular transporter expression profile and that modulation of the expression of multidrug resistance protein 5 (MRP5; ABCC5) influences the chemoresistance of these tumor cells.  Here, we studied the influence of acute and chronic gemcitabine treatment on the expression of relevant uptake and export transporters in pancreatic carcinoma cells by reverse transcription-polymerase chain reaction (RT-PCR), quant. RT-PCR, and immunoblot analyses.  The specific role of MRP5 in cellular gemcitabine sensitivity was studied by cytotoxicity assays using MRP5-overexpressing and MRP5-silenced cells.  Exposure to gemcitabine (12 nMfor 3 days) did not alter themessenger RNA (mRNA) expression of MRP1, MRP3, MRP5, and equilibrative nucleoside transporter 1 (ENT1), whereas high dosages of the drug (20 μMfor 1 h) elicited up-regulation of these transporters in most cell lines studied.  In cells with acquired gemcitabine resistance (up to 160 nM gemcitabine), the mRNA or protein expression of the gemcitabine transporters MRP5 and ENT1 was upregulated in several cell lines.  Combined treatment with 5-FU and gemcitabine caused a 5- to 40-fold increase in MRP5and ENT1 expressions.  Cytotoxicity assays using either MRP5-overexpressing (HEK and PANC-1) or MRP5-silenced (PANC1/shMRP5) cells indicated that MRP5 contributes to gemcitabine resistance.  Thus, our novel data not only on drug-induced alterations of transporter expression relevant for gemcitabine uptake and export but also on the link between gemcitabine sensitivity and MRP5 expression may lead to improved strategies of future chemotherapy regimens using gemcitabine in pancreatic carcinoma patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI6qrw-xP49LVg90H21EOLACvtfcHk0lh30rfkPn0iGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGmtrfL&md5=4e38efcac8f7073a285749fe7b2bb395</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1593%2Fneo.10576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.10576%26sid%3Dliteratum%253Aachs%26aulast%3DHagmann%26aufirst%3DW.%26aulast%3DJesnowski%26aufirst%3DR.%26aulast%3DL%25C3%25B6hr%26aufirst%3DJ.%2BM.%26atitle%3DInterdependence%2520of%2520gemcitabine%2520treatment%252C%2520transporter%2520expression%252C%2520and%2520resistance%2520in%2520human%2520pancreatic%2520carcinoma%2520cells%26jtitle%3DNeoplasia%26date%3D2010%26volume%3D12%26spage%3D740%26epage%3D747%26doi%3D10.1593%2Fneo.10576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Dynamic quantitative detection of ABC transporter family promoter methylation by MS-HRM for predicting MDR in pancreatic cancer</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5602</span>– <span class="NLM_lpage">5610</span>, <span class="refDoi"> DOI: 10.3892/ol.2018.8041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.3892%2Fol.2018.8041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=29552197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A280%3ADC%252BC1MnisVagtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=5602-5610&author=L.+Yaoauthor=J.+Guauthor=Y.+Maoauthor=X.+Zhangauthor=X.+Wangauthor=C.+Jinauthor=D.+Fuauthor=J.+Li&title=Dynamic+quantitative+detection+of+ABC+transporter+family+promoter+methylation+by+MS-HRM+for+predicting+MDR+in+pancreatic+cancer&doi=10.3892%2Fol.2018.8041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic quantitative detection of ABC transporter family promoter methylation by MS-HRM for predicting MDR in pancreatic cancer</span></div><div class="casAuthors">Yao Lie; Gu Jichun; Wang Xiaoyi; Jin Chen; Fu Deliang; Li Ji; Mao Yishen; Zhang Xinju</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">5602-5610</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">The main focus of the present study was to evaluate whether ABC transporter family promoter methylation predicted multidrug resistance in gemcitabine-resistant cancer cell lines (BxPC-3/Gem and PANC-1/Gem).  Using low concentrations of gemcitabine, the cell lines acquired drug resistance with different initial gemcitabine concentrations.  A novel technology, methylation-sensitive high-resolution melting, was used to monitor the dynamic changes of ABC transporter family promoter methylation, including ATP binding cassette subfamily B member 1 (ABCB1), ATP binding cassette subfamily C (ABCC) and ATP binding cassette subfamily G member 2 (ABCG2) mRNA expression.  It was revealed that, with elevation of initial gemcitabine concentration, expression of ABCB1, ABCC and ABCG2 mRNA and corresponding downstream proteins was increased while promoter methylation was decreased.  These discoveries indicate that promoter methylation of ABCB1, ABCC and ABCG2 may be a valuable indicator of drug-resistance characteristics in BxPC-3/Gem and PANC-1/Gem cells via quantitative and simultaneous detection.  These results also implied that MDR in pancreatic cancer not only arises from gene mutation, but also originates from promoter methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrppWwtIoRB_xQvRxYU81tfW6udTcc2eaEu92I7YNP5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnisVagtQ%253D%253D&md5=ac4fa79d89fbf5e53d661d4b550b3b48</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3892%2Fol.2018.8041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2018.8041%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DC.%26aulast%3DFu%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DDynamic%2520quantitative%2520detection%2520of%2520ABC%2520transporter%2520family%2520promoter%2520methylation%2520by%2520MS-HRM%2520for%2520predicting%2520MDR%2520in%2520pancreatic%2520cancer%26jtitle%3DOncol.%2520Lett.%26date%3D2018%26volume%3D15%26spage%3D5602%26epage%3D5610%26doi%3D10.3892%2Fol.2018.8041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahar, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamshidi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M.</span></span> <span> </span><span class="NLM_article-title">Effects of systematic shortening of noncovalent C8 side chain on the cytotoxicity and NF-κB inhibitory capacity of pyrrolobenzodiazepines (PBDs)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2139</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01849</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01849" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFGqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2127-2139&author=D.+B.+Corcoranauthor=T.+Lewisauthor=K.+S.+Naharauthor=S.+Jamshidiauthor=C.+Feganauthor=C.+Pepperauthor=D.+E.+Thurstonauthor=K.+M.+Rahman&title=Effects+of+systematic+shortening+of+noncovalent+C8+side+chain+on+the+cytotoxicity+and+NF-%CE%BAB+inhibitory+capacity+of+pyrrolobenzodiazepines+%28PBDs%29&doi=10.1021%2Facs.jmedchem.8b01849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of systematic shortening of noncovalent C8 side chain on the cytotoxicity and NF-κB inhibitory capacity of pyrrolobenzodiazepines (PBDs)</span></div><div class="casAuthors">Corcoran, David B.; Lewis, Thomas; Nahar, Kazi S.; Jamshidi, Shirin; Fegan, Christopher; Pepper, Chris; Thurston, David E.; Rahman, Khondaker Miraz.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2127-2139</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The systematic shortening of the noncovalent element of a C8-linked pyrrolobenzodiazepine (PBD) conjugate (13 (I)) led to the synthesis of a 19-member library of C8-PBD monomers.  The crit. elements of I, which were required to render the mol. cytotoxic, were elucidated by an annexin V assay.  The effects of shortening the noncovalent element of the mol. on transcription factor inhibitory capacity were also explored through an ELISA-based measurement of nuclear NF-κB upon exposure of JJN-3 cells to the synthesized mols.  Although shortening the noncovalent interactive element of I had a less than expected effect upon compd. cytotoxicity due to reduced DNA interaction, the transcription factor inhibitory capacity of the mol. was notably altered.  This study suggests that a relatively short noncovalent side chain at the C8 position of PBD is sufficient to confer cytotoxicity.  The shortened PBD monomers provide a new ADC payload scaffold because of their potent cytotoxicity and drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1QpMyNWLdrLVg90H21EOLACvtfcHk0liz_QCFOTpw5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFGqtbw%253D&md5=d3ca1bce21120b93b211fd905e471886</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01849%26sid%3Dliteratum%253Aachs%26aulast%3DCorcoran%26aufirst%3DD.%2BB.%26aulast%3DLewis%26aufirst%3DT.%26aulast%3DNahar%26aufirst%3DK.%2BS.%26aulast%3DJamshidi%26aufirst%3DS.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26atitle%3DEffects%2520of%2520systematic%2520shortening%2520of%2520noncovalent%2520C8%2520side%2520chain%2520on%2520the%2520cytotoxicity%2520and%2520NF-%25CE%25BAB%2520inhibitory%2520capacity%2520of%2520pyrrolobenzodiazepines%2520%2528PBDs%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2127%26epage%3D2139%26doi%3D10.1021%2Facs.jmedchem.8b01849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, G. M.</span></span> <span> </span><span class="NLM_article-title">A short history of <i>SHELX</i></span>. <i>Acta Crystallogr., Sect. A: Found. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1107/S0108767307043930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1107%2FS0108767307043930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=18156677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=112-122&author=G.+M.+Sheldrick&title=A+short+history+of+SHELX&doi=10.1107%2FS0108767307043930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A short history of SHELX</span></div><div class="casAuthors">Sheldrick, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section A: Foundations of Crystallography</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-122</span>CODEN:
                <span class="NLM_cas:coden">ACACEQ</span>;
        ISSN:<span class="NLM_cas:issn">0108-7673</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">An account is given of the development of the SHELX system of computer programs from SHELX-76 to the present day.  In addn. to identifying useful innovations that have come into general use through their implementation in SHELX, a crit. anal. is presented of the less-successful features, missed opportunities and desirable improvements for future releases of the software.  An attempt is made to understand how a program originally designed for photog. intensity data, punched cards and computers over 10000 times slower than an av. modern personal computer has managed to survive for so long.  SHELXL is the most widely used program for small-mol. refinement and SHELXS and SHELXD are often employed for structure soln. despite the availability of objectively superior programs.  SHELXL also finds a niche for the refinement of macromols. against high-resoln. or twinned data; SHELXPRO acts as an interface for macromol. applications.  SHELXC, SHELXD and SHELXE are proving useful for the exptl. phasing of macromols., esp. because they are fast and robust and so are often employed in pipelines for high-throughput phasing.  This paper could serve as a general literature citation when one or more of the open-source SHELX programs (and the Bruker AXS version SHELXTL) are employed in the course of a crystal-structure detn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfLPYyJyJ2RbVg90H21EOLACvtfcHk0liz_QCFOTpw5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhurzO&md5=8f91f10be4a9df74b2a9dad522c71e6e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1107%2FS0108767307043930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0108767307043930%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26atitle%3DA%2520short%2520history%2520of%2520SHELX%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520A%253A%2520Found.%2520Crystallogr.%26date%3D2008%26volume%3D64%26spage%3D112%26epage%3D122%26doi%3D10.1107%2FS0108767307043930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, G. M.</span></span> <span> </span><span class="NLM_article-title"><i>SHELXT</i> – Integrated space-group and crystal-structure determination</span>. <i>Acta Crystallogr., Sect. C: Struct. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1107/S2053229614024218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1107%2FS2053229614024218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=25643710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFaqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=3-8&author=G.+M.+Sheldrick&title=SHELXT+%E2%80%93+Integrated+space-group+and+crystal-structure+determination&doi=10.1107%2FS2053229614024218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure refinement with SHELXL</span></div><div class="casAuthors">Sheldrick, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section C: Structural Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-8</span>CODEN:
                <span class="NLM_cas:coden">ACSCGG</span>;
        ISSN:<span class="NLM_cas:issn">2053-2296</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The improvements in the crystal structure refinement program SHELXL have been closely coupled with the development and increasing importance of the CIF (Crystallog. Information Framework) format for validating and archiving crystal structures.  An important simplification is that now only one file in CIF format (for convenience, referred to simply as 'a CIF') contg. embedded reflection data and SHELXL instructions is needed for a complete structure archive; the program SHREDCIF can be used to ext. the and files required for further refinement with SHELXL.  Recent developments in SHELXL facilitate refinement against neutron diffraction data, the treatment of H atoms, the detn. of abs. structure, the input of partial structure factors and the refinement of twinned and disordered structures.  SHELXL is available free to academics for the Windows, Linux and Mac OS X operating systems, and is particularly suitable for multiple-core processors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk1_pNHwXR7Vg90H21EOLACvtfcHk0liz_QCFOTpw5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFaqug%253D%253D&md5=4a860804b50fc183e8a701098b98ef59</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1107%2FS2053229614024218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053229614024218%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26atitle%3DSHELXT%2520%25E2%2580%2593%2520Integrated%2520space-group%2520and%2520crystal-structure%2520determination%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520C%253A%2520Struct.%2520Chem.%26date%3D2015%26volume%3D71%26spage%3D3%26epage%3D8%26doi%3D10.1107%2FS2053229614024218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12a','cit12b','cit12c'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23a','cit23b'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39a','cit39b'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Phosphoramidate transformations of anticancer and FDA-approved antiviral nucleoside monophosph(on)ate analogues in the clinic and ongoing clinical studies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Strategy Toward 3′-TBDMS-Protected Nucleosides <b>5</b> and <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) imidazole (5.0 equiv), TBDMSCl (2.2 equiv), DMAP (0.3 equiv), DMF, 0 °C to rt, 1 h; (b) CSA (1.0 equiv), MeOH, rt, 10 min or TCA (28.0 equiv), THF, H<sub>2</sub>O, rt, 2 h.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Strategy Toward Separated Diastereomers of <b>NUC-3373</b> and <b>NUC-1031</b> (<b>9a</b>,<b>9b</b> and <b>10a</b>,<b>10b</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (ArO)(XOC(O)CHCH<sub>3</sub>NH)P(O)Cl (2.0 equiv), <i>tert-</i>BuMgCl, THF, rt, 16 h; (b) separation of diastereomers; and (c) THF/TFA/DCM (4:1:1), 0 °C for 2 h, then rt for 12 h.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structures of <b>10a</b> (NUC-1031_<i>S</i><sub>P</sub>) and <b>10b</b> (NUC-1031_<i>R</i><sub>P</sub>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Overlaid sigmoidal dose–response curves. (A) Comparison of gemcitabine and NUC-1031_mix (diasteromeric mixture) and (B) the separated diastereomers, NUC-1031_<i>S</i><sub>P</sub> (<b>10a</b>) and NUC-1031_<i>R</i><sub>P</sub> (<b>10b</b>). (C) Comparison of the LD<sub>50</sub> values for gemcitabine, NUC-1031_mix, NUC-1031_<i>S</i><sub>P</sub> (<b>10a</b>), NUC-1031_<i>R</i><sub>P</sub> (<b>10b</b>). (D) Comparison of FUDR and NUC-3373_mix (diasteromeric mixture) and (E) the separated diastereomers NUC-3373_isoA (<b>9a</b> or <b>9b</b>) and NUC-3373_isoB (<b>9a</b> or <b>9b</b>). (F) Comparison of the LD<sub>50</sub> values for 5-FU, FUDR, NUC-3373_mix, NUC-3373_isoA (<b>9a</b> or <b>9b</b>), and NUC-3373_isoB (<b>9a</b> or <b>9b</b>). All assays carried out using KG1a cells are presented as mean (±SEM) of five independent experiments. (G,H) Relative sensitivity of primary AML blasts to gemcitabine and NUC-1031_mix (<i>n</i> = 4).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0009.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. General Metabolic Activation Pathway for NUC-3373 and NUC-1031 ProTides</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0004.jpeg" id="rightTab-GRAPHIC-d7e2050-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) <sup>31</sup>P NMR spectra of NUC-3373_isoA (<b>9a</b> or <b>9b</b>) over time after enzymatic incubation with carboxypeptidase Y. (B) Chart representation of percentage of NUC-3373_isoA (<b>9a</b> or <b>9b</b>) and metabolites <b>A</b> and <b>C</b> over time after enzymatic incubation with carboxypeptidase Y. Conditions 202 MHz, 25 °C, <i>d</i><sub>6</sub>-acetone, 0.05 M Trizma buffer, pH 7.6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Differential cytotoxic effects of nucleosides and ProTides on cancer stem cells. (A) Comparison of the viable fraction of KG1a cells exposed to gemcitabine and NUC-1031_mix for 48 h. (B) Both diastereomers of NUC-1031 caused a dose-dependent, statistically significant, reduction in the LSC (CD34<sup>+</sup>/CD38<sup>–</sup>) fraction of KG1a cells. In contrast, gemcitabine had no significant effect on the LSC compartment at concentrations ≤2.5 × 10<sup>–6</sup> M. (C) The diastereomeric mixture of NUC-1031 induced a dose-dependent decrease in the LSC fraction of primary AML blasts. (D) Both diastereomers of NUC-3373 caused a dose-dependent, statistically significant reduction in the LSC (CD34<sup>+</sup>/CD38<sup>–</sup>) fraction of KG1a cells. In contrast, 5-FU and FUDR had no significant effect on the LSC compartment at concentrations ≤5 × 10<sup>–6</sup> M. *<i>P</i> < 0.05, **<i>P</i> < 0.01. (E) A similar effect was observed in the prostate cancer cell line, LNCaP. NUC-1031 preferentially depleted the cancer stem cells (CD44<sup>+</sup>/CD133<sup>+</sup>) at concentrations ≥2.5 × 10<sup>–6</sup> M when compared with gemcitabine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/medium/jm0c02194_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Measurement of intracellular triphosphate ABC transporters in LSC and bulk tumor cell fractions from KG1a cells. (A) Defined concentrations of nucleoside were run through the mass spectrometer in order to construct a standard curve (B) Purified LSCs and bulk tumor cells were treated with 1 μM of gemcitabine or NUC-1031_mix for 1 h prior to cell lysis and mass spectrometry. Both LSC and bulk tumor fractions showed increased intracellular triphosphate following treatment with NUC-1031_mix. (C) Protein expression of ABCB1 and ABCG2 on purified bulk tumor (CD34<sup>+</sup>/CD38<sup>+</sup>) and LSCs (CD34<sup>+</sup>/CD38<sup>–</sup>). Cell sorted LSCs showed significantly higher levels of ABCG2 when compared with bulk tumor cells. (D) Relative gene transcription of ABC transporter genes in purified bulk tumor cells (solid bars) and LSCs (hatched bars). LSCs showed significantly increased relative transcription of ABCB1, ABCG2, and ABCC5 when compared with bulk tumor cells. All data are the mean (±SEM) of five independent experiments, performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02194/20210616/images/large/jm0c02194_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02194&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i44">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34060" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34060" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 50 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cahard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Aryloxy phosphoramidate triesters as pro-tides</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.2174/1389557043403936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.2174%2F1389557043403936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=15134540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1yju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=371-381&author=D.+Cahardauthor=C.+McGuiganauthor=J.+Balzarini&title=Aryloxy+phosphoramidate+triesters+as+pro-tides&doi=10.2174%2F1389557043403936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Aryloxy phosphoramidate triesters as protides</span></div><div class="casAuthors">Cahard, Dominique; McGuigan, Christopher; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-381</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  We herein describe the development of aryloxy phosphoramidate triesters as an effective pro-tide motif for the intracellular delivery of charged bio-active antiviral nucleoside monophosphates.  The review covers the discovery of such aryl phosphoramidates, their mechanism of action and structure-activity relationships.  The application of this strategy to a range of antiviral nucleosides is highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPXB7nTgdhDLVg90H21EOLACvtfcHk0livrFqjA4Yvng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1yju7Y%253D&md5=ed98f170152c0406185126200a28a40e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.2174%2F1389557043403936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043403936%26sid%3Dliteratum%253Aachs%26aulast%3DCahard%26aufirst%3DD.%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DAryloxy%2520phosphoramidate%2520triesters%2520as%2520pro-tides%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D371%26epage%3D381%26doi%3D10.2174%2F1389557043403936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serpi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibbo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caterson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibert, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verson, C. R. A.</span></span> <span> </span><span class="NLM_article-title">Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5807</span>– <span class="NLM_lpage">5812</span>, <span class="refDoi"> DOI: 10.1021/jm800594c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800594c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVeit7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5807-5812&author=C.+McGuiganauthor=M.+Serpiauthor=R.+Bibboauthor=H.+Robertsauthor=C.+Hughesauthor=B.+Catersonauthor=A.+T.+Gibertauthor=C.+R.+A.+Verson&title=Phosphate+prodrugs+derived+from+N-acetylglucosamine+have+enhanced+chondroprotective+activity+in+explant+cultures+and+represent+a+new+lead+in+antiosteoarthritis+drug+discovery&doi=10.1021%2Fjm800594c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphate Prodrugs Derived from N-Acetylglucosamine Have Enhanced Chondroprotective Activity in Explant Cultures and Represent a New Lead in Antiosteoarthritis Drug Discovery</span></div><div class="casAuthors">McGuigan, Christopher; Serpi, Michaela; Bibbo, Rita; Roberts, Helen; Hughes, Clare; Caterson, Bruce; Gibert, Ana Torrent; Verson, Carlos Raul Alez</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5807-5812</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the application of the phosphoramidate ProTide approach, developed by us for antiviral nucleosides, to sugar derivs. with potential chondro-protection against osteoarthritis.  In particular, N-acetylglucosamine was converted to a series of 06 arylaminoacyl phosphoramidates with ester and amino acid variation.  Compds. were prepd. by two routes, with or without sugar protection, and were isolated as phosphate diastereoisomers.  The compds. were assayed for cellular toxicity and for inhibition of IL-1 induced glycosaminoglycan (GAG) release (i.e., proteoglycan degrdn.) from bovine articular cartilage in vitro explant cultures.  By comparison to the N-acetyl glucosamine parent, some of the analogs show a significant enhancement in efficacy in the inhibition of inflammatory cytokine-induced proteoglycan degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpclksqSYf6v7Vg90H21EOLACvtfcHk0livrFqjA4Yvng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVeit7fJ&md5=0a73f4bc96da9eae18b87d16bc3d3267</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm800594c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800594c%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DSerpi%26aufirst%3DM.%26aulast%3DBibbo%26aufirst%3DR.%26aulast%3DRoberts%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DC.%26aulast%3DCaterson%26aufirst%3DB.%26aulast%3DGibert%26aufirst%3DA.%2BT.%26aulast%3DVerson%26aufirst%3DC.%2BR.%2BA.%26atitle%3DPhosphate%2520prodrugs%2520derived%2520from%2520N-acetylglucosamine%2520have%2520enhanced%2520chondroprotective%2520activity%2520in%2520explant%2520cultures%2520and%2520represent%2520a%2520new%2520lead%2520in%2520antiosteoarthritis%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5807%26epage%3D5812%26doi%3D10.1021%2Fjm800594c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serpi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibbo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caterson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibert, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verson, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">Novel phosphoramidate prodrugs of N-acetyl-(D)- glucosamine with antidegenerative activity on bovine and human cartilage explants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4629</span>– <span class="NLM_lpage">4639</span>, <span class="refDoi"> DOI: 10.1021/jm300074y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300074y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFKltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4629-4639&author=M.+Serpiauthor=R.+Bibboauthor=S.+Ratauthor=H.+Robertsauthor=C.+Hughesauthor=B.+Catersonauthor=M.+J.+Alcarazauthor=A.+T.+Gibertauthor=C.+R.+Versonauthor=C.+McGuigan&title=Novel+phosphoramidate+prodrugs+of+N-acetyl-%28D%29-+glucosamine+with+antidegenerative+activity+on+bovine+and+human+cartilage+explants&doi=10.1021%2Fjm300074y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Phosphoramidate Prodrugs of N-Acetyl-(d)-Glucosamine with Antidegenerative Activity on Bovine and Human Cartilage Explants</span></div><div class="casAuthors">Serpi, Michaela; Bibbo, Rita; Rat, Stephanie; Roberts, Helen; Hughes, Claire; Caterson, Bruce; Alcaraz, Maria Jose; Gibert, Anna Torrent; Verson, Carlos Raul Alaez; McGuigan, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4629-4639</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">(d)-Glucosamine and other nutritional supplements have emerged as safe alternative therapies for osteoarthritis (OA), a chronic and degenerative articular joint disease.  In our preceding paper, a series of novel O-6 phosphate N-acetyl (d)-glucosamine prodrugs aimed at improving the oral bioavailability of N-acetyl-(d)-glucosamine as its putative bioactive phosphate form were shown to have greater chondroprotective activity in vitro when compared to the parent agent.  In order to extend the SAR studies, this work focuses on the O-3 and O-4 phosphate prodrugs of N-acetyl-(d)-glucosamine bearing a 4-methoxy Ph group and different amino acid esters on the phosphate moiety.  Among the compds., the (l)-proline amino acid-contg. prodrugs proved to be the most active of the series, more effective than the prior O-6 compds., and well processed in chondrocytes in vitro.  Data on human cartilage support the notion that these novel O-3 and O-4 regioisomers may represent novel promising leads for drug discovery for osteoarthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcKi2AVqV3arVg90H21EOLACvtfcHk0lhqlOV3R1yBoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFKltb0%253D&md5=49363bc5c1b86096d9f79c28ed45584a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm300074y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300074y%26sid%3Dliteratum%253Aachs%26aulast%3DSerpi%26aufirst%3DM.%26aulast%3DBibbo%26aufirst%3DR.%26aulast%3DRat%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DH.%26aulast%3DHughes%26aufirst%3DC.%26aulast%3DCaterson%26aufirst%3DB.%26aulast%3DAlcaraz%26aufirst%3DM.%2BJ.%26aulast%3DGibert%26aufirst%3DA.%2BT.%26aulast%3DVerson%26aufirst%3DC.%2BR.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DNovel%2520phosphoramidate%2520prodrugs%2520of%2520N-acetyl-%2528D%2529-%2520glucosamine%2520with%2520antidegenerative%2520activity%2520on%2520bovine%2520and%2520human%2520cartilage%2520explants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4629%26epage%3D4639%26doi%3D10.1021%2Fjm300074y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintiliani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of prodrugs of 2-fluoro-2-deoxyribose-1-phosphate and 2,2-difluoro-2-deoxyribose-1-phosphate</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2555</span>– <span class="NLM_lpage">2559</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1016%2Fj.bmcl.2013.02.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=23541671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVCis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2555-2559&author=N.+Hamonauthor=M.+Quintilianiauthor=J.+Balzariniauthor=C.+McGuigan&title=Synthesis+and+biological+evaluation+of+prodrugs+of+2-fluoro-2-deoxyribose-1-phosphate+and+2%2C2-difluoro-2-deoxyribose-1-phosphate&doi=10.1016%2Fj.bmcl.2013.02.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of prodrugs of 2-fluoro-2-deoxyribose-1-phosphate and 2,2-difluoro-2-deoxyribose-1-phosphate</span></div><div class="casAuthors">Hamon, Nadege; Quintiliani, Maurizio; Balzarini, Jan; McGuigan, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2555-2559</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report in this Letter the synthesis of prodrugs of 2-fluoro-2-deoxyarabinose-1-phosphates, e.g. I, and 2,2-difluoro-2-deoxyribose-1-phosphates.  We demonstrate the difficulty of realizing a phosphorylation step on the anomeric position of 2-deoxyribose, and we discover that introduction of fluorine atoms on the 2 position of 2-deoxyribose enables the phosphorylation step: in fact, the stability of the prodrugs increases with the degree of 2-fluorination.  Stability studies of prodrugs of 2-fluoro-2-deoxyribose-1-phosphate and 2,2-difluoro-2-deoxyribose-1-phosphate in acidic and neutral conditions were conducted to confirm our observation.  Biol. evaluation of prodrugs of 2,2-difluoro-2-deoxyribose-1-phosphate for antiviral and cytotoxic activity is reported.  Unfortunately, biol. evaluation of the prodrugs of the 2,2-difluoro-2-deoxyribose-1-phosphate showed that they had no inhibitory activity against a variety of virus infections and cancer cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg7v3zBd-uu7Vg90H21EOLACvtfcHk0lhqlOV3R1yBoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVCis7Y%253D&md5=c6410cece574c67b8f1d32bb166c127f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.117%26sid%3Dliteratum%253Aachs%26aulast%3DHamon%26aufirst%3DN.%26aulast%3DQuintiliani%26aufirst%3DM.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520prodrugs%2520of%25202-fluoro-2-deoxyribose-1-phosphate%2520and%25202%252C2-difluoro-2-deoxyribose-1-phosphate%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2555%26epage%3D2559%26doi%3D10.1016%2Fj.bmcl.2013.02.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serpi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of phosphoramidate prodrugs of two analogues of 2-deoxy-D-ribose-1-phosphate directed to the discovery of two carbasugars as new potential anti-HIV leads</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">838</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.12.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1016%2Fj.bmc.2014.12.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=25616343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltVClsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=829-838&author=N.+Hamonauthor=M.+Slusarczykauthor=M.+Serpiauthor=J.+Balzariniauthor=C.+McGuigan&title=Synthesis+and+biological+evaluation+of+phosphoramidate+prodrugs+of+two+analogues+of+2-deoxy-D-ribose-1-phosphate+directed+to+the+discovery+of+two+carbasugars+as+new+potential+anti-HIV+leads&doi=10.1016%2Fj.bmc.2014.12.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of phosphoramidate prodrugs of two analogues of 2-deoxy-D-ribose-1-phosphate directed to the discovery of two carbasugars as new potential anti-HIV leads</span></div><div class="casAuthors">Hamon, Nadege; Slusarczyk, Magdalena; Serpi, Michaela; Balzarini, Jan; McGuigan, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">829-838</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">2-Deoxy-α-D-ribose-1-phosphate is of great interest as it is involved in the biosynthesis and/or catabolic degrdn. of several nucleoside analogs of biol. and therapeutic relevance.  However due to the lack of a stabilizing group at its 2-position, it is difficult to synthesize stable prodrugs of this compd.  In order to overcome this lack of stability, the synthesis of carbasugar analogs of 2-deoxyribose-1-phosphate was envisioned.  Herein the prepn. of a series of prodrugs of two carbocyclic analogs of 2-deoxyribose-1-phosphate using the phosphoramidate ProTide technol., along with their biol. evaluation against HIV and cancer cell proliferation, is reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsBev09xhLN7Vg90H21EOLACvtfcHk0lhqlOV3R1yBoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltVClsA%253D%253D&md5=93ef3df511600da958e43d895ea72237</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.12.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.12.039%26sid%3Dliteratum%253Aachs%26aulast%3DHamon%26aufirst%3DN.%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DSerpi%26aufirst%3DM.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520phosphoramidate%2520prodrugs%2520of%2520two%2520analogues%2520of%25202-deoxy-D-ribose-1-phosphate%2520directed%2520to%2520the%2520discovery%2520of%2520two%2520carbasugars%2520as%2520new%2520potential%2520anti-HIV%2520leads%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D829%26epage%3D838%26doi%3D10.1016%2Fj.bmc.2014.12.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">James, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertusati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brancale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">Kinase-independent phosphoramidate S1P1 receptor agonist benzyl ether derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1371</span>– <span class="NLM_lpage">1378</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1016%2Fj.bmcl.2017.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=28236593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVCksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1371-1378&author=E.+Jamesauthor=F.+Pertusatiauthor=A.+Brancaleauthor=C.+McGuigan&title=Kinase-independent+phosphoramidate+S1P1+receptor+agonist+benzyl+ether+derivatives&doi=10.1016%2Fj.bmcl.2017.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-independent phosphoramidate S1P1 receptor agonist benzyl ether derivs.</span></div><div class="casAuthors">James, Edward; Pertusati, Fabrizio; Brancale, Andrea; McGuigan, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1371-1378</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previously published S1P receptor modulator benzyl ether derivs. have shown potential as being viable therapeutics for the treatment of neurodegenerative diseases, however, two of the most S1P1-selective compds. are reported as being poorly phosphorylated by kinases in vivo.  Phosphoramidates of BED compds. (2a, 2b) were synthesized with the aim of producing kinase-independent S1P receptor modulators.  Carboxypeptidase, human serum and cell lysate processing expts. were conducted.  ProTide BED analogs were found to have an acceptable level of stability in acidic and basic conditions and in vitro metabolic processing expts. showed that they are processed to the desired pharmacol. active monophosphate.  The research describes the development of an entirely novel family of therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGOe6jnvJ69rVg90H21EOLACvtfcHk0lgNu0JEzOUuiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVCksbc%253D&md5=58fbcab904a69659a33ab20298e7c83b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DJames%26aufirst%3DE.%26aulast%3DPertusati%26aufirst%3DF.%26aulast%3DBrancale%26aufirst%3DA.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DKinase-independent%2520phosphoramidate%2520S1P1%2520receptor%2520agonist%2520benzyl%2520ether%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D1371%26epage%3D1378%26doi%3D10.1016%2Fj.bmcl.2017.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osgerby, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amalfitano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Duff, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabeen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miccoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, J. H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muqit, M. M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehellou, Y.</span></span> <span> </span><span class="NLM_article-title">Kinetin riboside and its protides activate the Parkinson’s disease associated PTEN-induced putative kinase 1 (PINK1) independent of mitochondrial depolarization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3518</span>– <span class="NLM_lpage">3524</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01897</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01897" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkslKlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3518-3524&author=L.+Osgerbyauthor=Y.-C.+Laiauthor=P.+J.+Thorntonauthor=J.+Amalfitanoauthor=C.+S.+Le+Duffauthor=I.+Jabeenauthor=H.+Kadriauthor=A.+Miccoliauthor=J.+H.+R.+Tuckerauthor=M.+M.+K.+Muqitauthor=Y.+Mehellou&title=Kinetin+riboside+and+its+protides+activate+the+Parkinson%E2%80%99s+disease+associated+PTEN-induced+putative+kinase+1+%28PINK1%29+independent+of+mitochondrial+depolarization&doi=10.1021%2Facs.jmedchem.6b01897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetin Riboside and Its ProTides Activate the Parkinson's Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial Depolarization</span></div><div class="casAuthors">Osgerby, Laura; Lai, Yu-Chiang; Thornton, Peter J.; Amalfitano, Joseph; Le Duff, Cecile S.; Jabeen, Iqra; Kadri, Hachemi; Miccoli, Ageo; Tucker, James H. R.; Muqit, Miratul M. K.; Mehellou, Youcef</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3518-3524</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since loss of function mutations of PINK1 lead to early onset Parkinson's disease, there has been growing interest in the discovery of small mols. that amplify the kinase activity of PINK1.  We herein report the design, synthesis, serum stability, and hydrolysis of four kinetin riboside ProTides.  These ProTides, along with kinetin riboside, activated PINK1 in cells independent of mitochondrial depolarization.  This highlights the potential of modified nucleosides and their phosphate prodrugs as treatments for neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE0IJ5gXFDs7Vg90H21EOLACvtfcHk0lgNu0JEzOUuiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkslKlt7s%253D&md5=bc90c5fa151f4c8e63d4a96a1297bc3a</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01897%26sid%3Dliteratum%253Aachs%26aulast%3DOsgerby%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DY.-C.%26aulast%3DThornton%26aufirst%3DP.%2BJ.%26aulast%3DAmalfitano%26aufirst%3DJ.%26aulast%3DLe%2BDuff%26aufirst%3DC.%2BS.%26aulast%3DJabeen%26aufirst%3DI.%26aulast%3DKadri%26aufirst%3DH.%26aulast%3DMiccoli%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DJ.%2BH.%2BR.%26aulast%3DMuqit%26aufirst%3DM.%2BM.%2BK.%26aulast%3DMehellou%26aufirst%3DY.%26atitle%3DKinetin%2520riboside%2520and%2520its%2520protides%2520activate%2520the%2520Parkinson%25E2%2580%2599s%2520disease%2520associated%2520PTEN-induced%2520putative%2520kinase%25201%2520%2528PINK1%2529%2520independent%2520of%2520mitochondrial%2520depolarization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3518%26epage%3D3524%26doi%3D10.1021%2Facs.jmedchem.6b01897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davey, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malde, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mykura, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taher, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Duff, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willcox, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehellou, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of (E)-4-hydroxy-3-methylbut-2-enyl phosphate (HMBP) aryloxy triester phosphoramidate prodrugs as activators of Vγ9/Vδ2 T-cell immune responses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2111</span>– <span class="NLM_lpage">2117</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01824</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01824" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCntL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2111-2117&issue=5&author=M.+S.+Daveyauthor=R.+Maldeauthor=R.+C.+Mykuraauthor=A.+T.+Bakerauthor=T.+E.+Taherauthor=C.+S.+Le+Duffauthor=B.+E.+Willcoxauthor=Y.+Mehellou&title=Synthesis+and+biological+evaluation+of+%28E%29-4-hydroxy-3-methylbut-2-enyl+phosphate+%28HMBP%29+aryloxy+triester+phosphoramidate+prodrugs+as+activators+of+V%CE%B39%2FV%CE%B42+T-cell+immune+responses&doi=10.1021%2Facs.jmedchem.7b01824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of (E)-4-Hydroxy-3-methylbut-2-enyl Phosphate (HMBP) Aryloxy Triester Phosphoramidate Prodrugs as Activators of Vγ9/Vδ2 T-Cell Immune Responses</span></div><div class="casAuthors">Davey, Martin S.; Malde, Roshni; Mykura, Rory C.; Baker, Alfie T.; Taher, Taher E.; Le Duff, Cecile S.; Willcox, Benjamin E.; Mehellou, Youcef</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2111-2117</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The aryloxy triester phosphoramidate prodrug approach has been used with success in drug discovery.  Herein, we describe the first application of this prodrug technol. to the monophosphate deriv. of the phosphoantigen HMBPP and one of its analogs.  Some of these prodrugs exhibited specific and potent activation of Vγ9/Vδ2 T-cells, which were then able to lyse bladder cancer cells in vitro.  This work highlights the promise of this prodrug technol. in the discovery of novel immunotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM4h5SljO2ArVg90H21EOLACvtfcHk0lgNu0JEzOUuiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCntL8%253D&md5=a67679dcb0dcd5b81b0fc0b9e70df5ad</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01824%26sid%3Dliteratum%253Aachs%26aulast%3DDavey%26aufirst%3DM.%2BS.%26aulast%3DMalde%26aufirst%3DR.%26aulast%3DMykura%26aufirst%3DR.%2BC.%26aulast%3DBaker%26aufirst%3DA.%2BT.%26aulast%3DTaher%26aufirst%3DT.%2BE.%26aulast%3DLe%2BDuff%26aufirst%3DC.%2BS.%26aulast%3DWillcox%26aufirst%3DB.%2BE.%26aulast%3DMehellou%26aufirst%3DY.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520%2528E%2529-4-hydroxy-3-methylbut-2-enyl%2520phosphate%2520%2528HMBP%2529%2520aryloxy%2520triester%2520phosphoramidate%2520prodrugs%2520as%2520activators%2520of%2520V%25CE%25B39%252FV%25CE%25B42%2520T-cell%2520immune%2520responses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D5%26spage%3D2111%26epage%3D2117%26doi%3D10.1021%2Facs.jmedchem.7b01824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghazaly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">Application of protide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1531</span>– <span class="NLM_lpage">1542</span>, <span class="refDoi"> DOI: 10.1021/jm401853a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401853a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=1531-1542&author=M.+Slusarczykauthor=M.+H.+Lopezauthor=J.+Balzariniauthor=M.+Masonauthor=W.+G.+Jiangauthor=S.+Blagdenauthor=E.+Thompsonauthor=E.+Ghazalyauthor=C.+McGuigan&title=Application+of+protide+technology+to+gemcitabine%3A+a+successful+approach+to+overcome+the+key+cancer+resistance+mechanisms+leads+to+a+new+agent+%28NUC-1031%29+in+clinical+development&doi=10.1021%2Fjm401853a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development</span></div><div class="casAuthors">Slusarczyk, Magdalena; Lopez, Monica Huerta; Balzarini, Jan; Mason, Malcolm; Jiang, Wen G.; Blagden, Sarah; Thompson, Emely; Ghazaly, Essam; McGuigan, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1531-1542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Gemcitabine is a nucleoside analog commonly used in cancer therapy but with limited efficacy due to a high susceptibility to cancer cell resistance.  The addn. of a phosphoramidate motif to the gemcitabine can protect it against many of the key cancer resistance mechanisms.  We have synthesized a series of gemcitabine phosphoramidate prodrugs, e.g. I, and screened for cytostatic activity in a range of different tumor cell lines.  Among the synthesized compds., one in particular (NUC-1031, I) was shown to be potent in vitro.  Importantly, compared with gemcitabine, I activation was significantly less dependent on deoxycytidine kinase and on nucleoside transporters, and it was resistant to cytidine deaminase-mediated degrdn.  Moreover, I showed a significant redn. in tumor vols. in vivo in pancreatic cancer xenografts.  The ProTide I is now in clin. development with encouraging efficacy signals in a Phase I/II study, which strongly supports the ProTide approach to generate promising new anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2UbxkazAxBbVg90H21EOLACvtfcHk0ljboCmwQVQfVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCntbs%253D&md5=981fde9daf27a1e4d9fa59d1d15cfc08</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm401853a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401853a%26sid%3Dliteratum%253Aachs%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DM.%2BH.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DMason%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DW.%2BG.%26aulast%3DBlagden%26aufirst%3DS.%26aulast%3DThompson%26aufirst%3DE.%26aulast%3DGhazaly%26aufirst%3DE.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DApplication%2520of%2520protide%2520technology%2520to%2520gemcitabine%253A%2520a%2520successful%2520approach%2520to%2520overcome%2520the%2520key%2520cancer%2520resistance%2520mechanisms%2520leads%2520to%2520a%2520new%2520agent%2520%2528NUC-1031%2529%2520in%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D1531%26epage%3D1542%26doi%3D10.1021%2Fjm401853a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murziani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonczy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vande Voorde, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liekens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">Phosphoramidate protides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleoside</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">7247</span>– <span class="NLM_lpage">7258</span>, <span class="refDoi"> DOI: 10.1021/jm200815w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200815w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1eru7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7247-7258&author=C.+McGuiganauthor=P.+Murzianiauthor=M.+Slusarczykauthor=B.+Gonczyauthor=J.+Vande+Voordeauthor=S.+Liekensauthor=J.+Balzarini&title=Phosphoramidate+protides+of+the+anticancer+agent+FUDR+successfully+deliver+the+preformed+bioactive+monophosphate+in+cells+and+confer+advantage+over+the+parent+nucleoside&doi=10.1021%2Fjm200815w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoramidate ProTides of the Anticancer Agent FUDR Successfully Deliver the Preformed Bioactive Monophosphate in Cells and Confer Advantage over the Parent Nucleoside</span></div><div class="casAuthors">McGuigan, Christopher; Murziani, Paola; Slusarczyk, Magdalena; Gonczy, Blanka; Vande Voorde, Johan; Liekens, Sandra; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7247-7258</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The fluorinated pyrimidine family of nucleosides continues to represent major current chemotherapeutic agents for treating solid tumors.  We herein report their phosphate prodrugs, ProTides, as promising new derivs., which partially bypass the dependence of the current drugs on active transport and nucleoside kinase-mediated activation.  They are also resistant to metabolic deactivation by phosphorolytic enzymes.  We report 39 ProTides of the fluorinated pyrimidine FUDR with variation in the aryl, ester, and amino acid regions.  Notably, only certain ProTide motifs are successful in delivering the nucleoside monophosphate into intact cells.  We also find that the ProTides retain activity in mycoplasma infected cells, unlike FUDR.  Data suggest these compds. to be worthy of further progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppOiNKgrQqyLVg90H21EOLACvtfcHk0ljboCmwQVQfVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1eru7zP&md5=dbc6dde916700391cbd0b13b5d0c116c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm200815w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200815w%26sid%3Dliteratum%253Aachs%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DMurziani%26aufirst%3DP.%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DGonczy%26aufirst%3DB.%26aulast%3DVande%2BVoorde%26aufirst%3DJ.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DPhosphoramidate%2520protides%2520of%2520the%2520anticancer%2520agent%2520FUDR%2520successfully%2520deliver%2520the%2520preformed%2520bioactive%2520monophosphate%2520in%2520cells%2520and%2520confer%2520advantage%2520over%2520the%2520parent%2520nucleoside%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7247%26epage%3D7258%26doi%3D10.1021%2Fjm200815w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belt, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cass, C. E.</span></span> <span> </span><span class="NLM_article-title">Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4349</span>– <span class="NLM_lpage">4357</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=9766663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADyaK1cXmsVyqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1998&pages=4349-4357&author=J.+R.+Mackeyauthor=R.+S.+Maniauthor=M.+Selnerauthor=D.+Mowlesauthor=J.+D.+Youngauthor=J.+A.+Beltauthor=C.+R.+Crawfordauthor=C.+E.+Cass&title=Functional+nucleoside+transporters+are+required+for+gemcitabine+influx+and+manifestation+of+toxicity+in+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines</span></div><div class="casAuthors">Mackey, John R.; Mani, Rajam S.; Selner, Milada; Mowles, Delores; Young, James D.; Belt, Judith A.; Crawford, Charles R.; Cass, Carol E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4349-4357</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Gemcitabine (2',2'-difluorodeoxycytidine) is a novel pyrimidine nucleoside drug with clin. efficacy in several common epithelial cancers.  We have proposed that gemcitabine requires nucleoside transporter (NT) proteins to permeate the plasma membrane and to exhibit pharmacol. activity.  In humans, there are seven reported distinct NT activities varying in substrate specificity, sodium dependence, and sensitivity to inhibition by nitrobenzylthioinosine (NBMPR) and dipyridamole.  To det. which NTs are required for gemcitabine-dependent growth inhibition, cultures from a panel of 12 cell lines with defined plasma membrane NT activities were incubated with different concns. of gemcitabine.  Cell proliferation was assessed by the sulforhodamine B assay and cell enumeration to identify the concns. of gemcitabine that inhibited cell replication by 50% (IC50s).  NT activity was a prerequisite for growth inhibition in vitro because: (a) the nucleoside transport-deficient cells were highly resistant to gemcitabine; and (b) treatment of cells that exhibited only equilibrative NT activity with NBMPR or dipyridamole increased resistance to gemcitabine by 39- to 1800-fold.  These data suggested that the type of NT activities possessed by a cell may be an important determinant of its sensitivity to gemcitabine and that NT deficiency may confer significant gemcitabine resistance.  We analyzed the uptake kinetics of [3H]gemcitabine by each of five human NT activities in cell lines that exhibited a single NT activity in isolation; transient transfection of the cDNAs encoding the human concentrative NT proteins (hCNT1 and hCNT2) was used to study the cit and cif activities, resp.  The efficiency of gemcitabine uptake varied markedly among the cell lines with single NTs: es ≃ cit > ei > cib >>> cif.  The transportability of [3H]gemcitabine was demonstrated by reconstitution of the human es NT in proteoliposomes, confirming that gemcitabine permeation is a protein-mediated process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEu51WE2MjmrVg90H21EOLACvtfcHk0ljboCmwQVQfVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsVyqsbo%253D&md5=44abf3f52c97ef2a5cbf04f59b97a58f</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMackey%26aufirst%3DJ.%2BR.%26aulast%3DMani%26aufirst%3DR.%2BS.%26aulast%3DSelner%26aufirst%3DM.%26aulast%3DMowles%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DJ.%2BD.%26aulast%3DBelt%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DC.%2BR.%26aulast%3DCass%26aufirst%3DC.%2BE.%26atitle%3DFunctional%2520nucleoside%2520transporters%2520are%2520required%2520for%2520gemcitabine%2520influx%2520and%2520manifestation%2520of%2520toxicity%2520in%2520cancer%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1998%26volume%3D58%26spage%3D4349%26epage%3D4357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gourdeau, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolivet, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafrenière, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cass, C. E.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7217</span>– <span class="NLM_lpage">7224</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=11585758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsVeht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=7217-7224&author=H.+Gourdeauauthor=M.+L.+Clarkeauthor=F.+Ouelletauthor=D.+Mowlesauthor=M.+Selnerauthor=A.+Richardauthor=N.+Leeauthor=J.+R.+Mackeyauthor=J.+D.+Youngauthor=J.+Jolivetauthor=R.+G.+Lafreni%C3%A8reauthor=C.+E.+Cass&title=Mechanisms+of+uptake+and+resistance+to+troxacitabine%2C+a+novel+deoxycytidine+nucleoside+analogue%2C+in+human+leukemic+and+solid+tumor+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines</span></div><div class="casAuthors">Gourdeau, Henriette; Clarke, Marilyn L.; Ouellet, France; Mowles, Delores; Selner, Milada; Richard, Annie; Lee, Nola; Mackey, John R.; Young, James D.; Jolivet, Jacques; Lafreniere, Ronald G.; Cass, Carol E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7217-7224</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Troxacitabine (Troxatyl; BCH-4556; (-)-2'-deoxy-3'-oxacytidine), a deoxycytidine analog with an unusual dioxolane structure and nonnatural L-configuration, has potent antitumor activity in animal models and is in clin. trials against human malignancies.  The current work was undertaken to identify potential biochem. mechanisms of resistance to troxacitabine and to det. whether there are differences in resistance mechanisms between troxacitabine, gemcitabine, and cytarabine in human leukemic and solid tumor cell lines.  The CCRF-CEM leukemia cell line was highly sensitive to the antiproliferative effects of troxacitabine, gemcitabine, and cytarabine with inhibition of proliferation by 50% obsd. at 160, 20, and 10 nM, resp., whereas a deoxycytidine kinase (dCK)-deficient variant (CEM/dCK-) was resistant to all three drugs.  In contrast, a nucleoside transport-deficient variant (CEM/ARAC8C) exhibited high levels of resistance to cytarabine (1150-fold) and gemcitabine (432-fold) but only minimal resistance to troxacitabine (7-fold).  Anal. of troxacitabine transportability by the five molecularly characterized human nucleoside transporters [human equilibrative nucleoside transporters 1 and 2, human concentrative nucleoside transporter (hCNT) 1, hCNT2, and hCNT3] revealed that short- and long-term uptake of 10-30 μM [3H]troxacitabine was low and unaffected by the presence of either nucleoside transport inhibitors or high concns. of nonradioactive troxacitabine.  These results, which suggested that the major route of cellular uptake of troxacitabine was passive diffusion, demonstrated that deficiencies in nucleoside transport were unlikely to impart resistance to troxacitabine.  A troxacitabine-resistant prostate cancer subline (DU145R; 6300-fold) that exhibited reduced uptake of troxacitabine was cross-resistant to both gemcitabine (350-fold) and cytarabine (300-fold).  DCK activity toward deoxycytidine in DU145R cell lysates was <20% of that in DU145 cell lysates, and no activity was detected toward troxacitabine.  Sequence anal. of cDNAs encoding dCK revealed a mutation of a highly conserved amino acid (Trp92→Leu) in DU145R dCK, providing a possible explanation for the reduced phosphorylation of troxacitabine in DU145R lysates.  Reduced deamination of deoxycytidine was also obsd. in DU145R relative to DU145 cells, and this may have contributed to the overall resistance phenotype.  These results, which demonstrated a different resistance profile for troxacitabine, gemcitabine, and cytarabine, suggest that troxacitabine may have an advantage over gemcitabine and cytarabine in human malignancies that lack or have low nucleoside transport activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphoDIwz8UhC7Vg90H21EOLACvtfcHk0lgA6VajuM-GNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsVeht7g%253D&md5=816052844c3dff95c6a7feb4123f4fd1</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGourdeau%26aufirst%3DH.%26aulast%3DClarke%26aufirst%3DM.%2BL.%26aulast%3DOuellet%26aufirst%3DF.%26aulast%3DMowles%26aufirst%3DD.%26aulast%3DSelner%26aufirst%3DM.%26aulast%3DRichard%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DMackey%26aufirst%3DJ.%2BR.%26aulast%3DYoung%26aufirst%3DJ.%2BD.%26aulast%3DJolivet%26aufirst%3DJ.%26aulast%3DLafreni%25C3%25A8re%26aufirst%3DR.%2BG.%26aulast%3DCass%26aufirst%3DC.%2BE.%26atitle%3DMechanisms%2520of%2520uptake%2520and%2520resistance%2520to%2520troxacitabine%252C%2520a%2520novel%2520deoxycytidine%2520nucleoside%2520analogue%252C%2520in%2520human%2520leukemic%2520and%2520solid%2520tumor%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D7217%26epage%3D7224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz van Haperen, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veerman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boven, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegmann, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermorken, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinedo, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span> <span> </span><span class="NLM_article-title">Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4138</span>– <span class="NLM_lpage">4143</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=8033147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADyaK2cXlsVynu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1994&pages=4138-4143&author=V.+W.+Ruiz+van+Haperenauthor=G.+Veermanauthor=S.+Erikssonauthor=E.+Bovenauthor=A.+P.+Stegmannauthor=M.+Hermsenauthor=J.+B.+Vermorkenauthor=H.+M.+Pinedoauthor=G.+J.+Peters&title=Development+and+molecular+characterization+of+a+2%E2%80%B2%2C2%E2%80%B2-difluorodeoxycytidine-resistant+variant+of+the+human+ovarian+carcinoma+cell+line+A2780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780</span></div><div class="casAuthors">Ruiz van Haperen, Veronique W. T.; Veerman, Gijsbert; Eriksson, Staffan; Boven, Epie; Stegmann, Alexander P. A.; Hermsen, Mario; Vermorken, Jan B.; Pinedo, Herbert M.; Peters, Godefridus J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4138-43</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">2',2'-Difluorodeoxycytidine (gemcitabine, dFdCyd) is a deoxycytidine analog with promising antitumor activity.  In order to be active it must be phosphorylated by deoxycytidine kinase (dCK).  The authors induced resistance to dFdCyd in the human ovarian carcinoma cell line A2780 by exposure to increasing concns. of dFdCyd.  The IC50, defined as the concn. of dFdCyd causing 50% growth inhibition, at 72 h exposure increased from 0.6 nM dFdCyd in A2780 to 92 μM in the resistant variant, named AG6000.  Although the resistant cell line is routinely cultured in 6 μM dFdCyd, the resistant phenotype can be maintained for at least 10 passages without dFdCyd.  AG6000 is cross-resistant to other drugs which require activation by dCK, such as 1-β-D-arabinofuranosylcytosine, 5-aza-2'-deoxycytidine, and 2-chlorodeoxyadenosine.  There was no specific dCK activity in exts. from AG6000 cells.  Western blot anal. using a polyclonal anti-dCK antibody did not reveal any dCK protein in AG6000 cell exts.  Reverse-transcribed and PCR-amplified mRNA, using specific dCK primers, demonstrated that AG6000 expressed a normal length amplicon of 701 base pairs, besides an aberrant amplicon of 500 base pairs.  Chromosome spreads from the cell lines showed no major differences between A2780 and AG6000.  The latter cell line was also cross-resistant to 2',2'-difluorodeoxyuridine, the deamination product of dFdCyd.  Addnl., cross-resistance to the multidrug resistance drugs doxorubicin and vincristine was obsd.  This was not assocd. with the induction of P-glycoprotein, as detd. by the RNase protection assay.  Injection of AG6000 cells s.c. into nude mice demonstrated that the cell line had retained its tumorigenicity; AG6000 xenografts were not sensitive to dFdCyd treatment, in contrast to the parental A2780 tumors.  No dFdCyd triphosphate accumulation was found in the resistant tumors, in contrast to the parental A2780 tumors.  These results indicate that the dFdCyd resistance phenotype is stable, and mainly due to dCK deficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7vUGzO626KLVg90H21EOLACvtfcHk0lgA6VajuM-GNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsVynu7w%253D&md5=41070986d07e3bbeef310f568683605f</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRuiz%2Bvan%2BHaperen%26aufirst%3DV.%2BW.%26aulast%3DVeerman%26aufirst%3DG.%26aulast%3DEriksson%26aufirst%3DS.%26aulast%3DBoven%26aufirst%3DE.%26aulast%3DStegmann%26aufirst%3DA.%2BP.%26aulast%3DHermsen%26aufirst%3DM.%26aulast%3DVermorken%26aufirst%3DJ.%2BB.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26atitle%3DDevelopment%2520and%2520molecular%2520characterization%2520of%2520a%25202%25E2%2580%25B2%252C2%25E2%2580%25B2-difluorodeoxycytidine-resistant%2520variant%2520of%2520the%2520human%2520ovarian%2520carcinoma%2520cell%2520line%2520A2780%26jtitle%3DCancer%2520Res.%26date%3D1994%26volume%3D54%26spage%3D4138%26epage%3D4143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kroep, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loves, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Wilt, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talianidis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boven, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braakhuis, B. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Groeningen, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinedo, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, G. J.</span></span> <span> </span><span class="NLM_article-title">Pretreatment deoxycytidine kinase levels predict <i>in vivo</i> gemcitabine sensitivity</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">376</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=12477049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1yqs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=371-376&author=J.+R.+Kroepauthor=W.+J.+Lovesauthor=C.+L.+van+der%0AWiltauthor=E.+Alvarezauthor=I.+Talianidisauthor=E.+Bovenauthor=B.+J.+M.+Braakhuisauthor=C.+J.+van+Groeningenauthor=H.+M.+Pinedoauthor=G.+J.+Peters&title=Pretreatment+deoxycytidine+kinase+levels+predict+in+vivo+gemcitabine+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity</span></div><div class="casAuthors">Kroep, Judith R.; Loves, Willem J. P.; Van der Wilt, Clasina L.; Alvarez, Enrique; Talianidis, Iannis; Boven, Epie; Braakhuis, Boudewijn J. M.; Van Groeningen, Cornelis J.; Pinedo, Herbert M.; Peters, Godefridus J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">371-376</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Deoxycytidine kinase (dCK) is essential for the phosphorylation of gemcitabine (2',2'-difluorodeoxycytidine), a deoxycytidine analog active against various solid tumors.  Cytidine deaminase (CDA) catalyzes the degrdn. of gemcitabine.  We detd. whether dCK and/or CDA levels would predict response to gemcitabine.  Activities of dCK and CDA were measured in a panel of eight gemcitabine-sensitive and -resistant tumors of a different origin (pancreas, lung, colon, ovary, and head and neck) grown as s.c. tumors in mice.  Sensitivity to gemcitabine was expressed as treated vs. control (tumor vol. treated mice/control mice).  Gemcitabine was given on days 0, 3, 6, and 9 (q3dx4) at its max. tolerated dose.  In addn., we measured the mRNA expression and protein levels of dCK in seven human tumor xenografts.  DCK activity (mean ± SE) ranged from 3.3±0.3 to 18.4±1.2 nmol/h/mg protein.  Sensitivity to gemcitabine, expressed as treated vs. control, ranged from 0.98 to 0.02, and the activity of CDA varied from 2±2 to 411±4 nmol/h/mg protein.  In contrast to CDA, dCK activity was clearly related to gemcitabine sensitivity (p = -0.93; P < 0.001).  This indicates that dCK might be an important prognostic marker for gemcitabine sensitivity.  Protein levels were significantly related to both dCK activity (r = 0.96; P < 0.001) and gemcitabine sensitivity (p = -0.96; P < 0.001).  DCK expression as detd. by competitive template reverse transcriptase PCR was significantly related with the dCK activity (r = 0.88; P = 0.025) and protein levels (p = 0.80; P = 0.052) but not with gemcitabine sensitivity, suggesting a post-translational regulation of dCK.  In conclusion, the clear correlation between dCK levels and gemcitabine sensitivity in various murine tumors and human tumor xenografts may be a prognostic parameter when considering gemcitabine therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtmGyuXKsGQbVg90H21EOLACvtfcHk0lgA6VajuM-GNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1yqs78%253D&md5=d624932f2fbcbe7597badefc154dcbcf</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKroep%26aufirst%3DJ.%2BR.%26aulast%3DLoves%26aufirst%3DW.%2BJ.%26aulast%3Dvan%2Bder%2BWilt%26aufirst%3DC.%2BL.%26aulast%3DAlvarez%26aufirst%3DE.%26aulast%3DTalianidis%26aufirst%3DI.%26aulast%3DBoven%26aufirst%3DE.%26aulast%3DBraakhuis%26aufirst%3DB.%2BJ.%2BM.%26aulast%3Dvan%2BGroeningen%26aufirst%3DC.%2BJ.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26atitle%3DPretreatment%2520deoxycytidine%2520kinase%2520levels%2520predict%2520in%2520vivo%2520gemcitabine%2520sensitivity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2002%26volume%3D1%26spage%3D371%26epage%3D376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Galmarini, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordheim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cros, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumontet, C.</span></span> <span> </span><span class="NLM_article-title">Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene</span>. <i>BMC Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.1186/1471-2210-4-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1186%2F1471-2210-4-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=15157282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A280%3ADC%252BD2czgt1Wlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=8&author=C.+M.+Galmariniauthor=M.+L.+Clarkeauthor=L.+Jordheimauthor=C.+L.+Santosauthor=E.+Crosauthor=J.+R.+Mackeyauthor=C.+Dumontet&title=Resistance+to+gemcitabine+in+a+human+follicular+lymphoma+cell+line+is+due+to+partial+deletion+of+the+deoxycytidine+kinase+gene&doi=10.1186%2F1471-2210-4-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene</span></div><div class="casAuthors">Galmarini Carlos Maria; Clarke Marilyn L; Jordheim Lars; Santos Cheryl L; Cros Emeline; Mackey John R; Dumontet Charles</div><div class="citationInfo"><span class="NLM_cas:title">BMC pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Gemcitabine is an analogue of deoxycytidine with activity against several solid tumors.  In order to elucidate the mechanisms by which tumor cells become resistant to gemcitabine, we developed the resistant subline RL-G from the human follicular lymphoma cell line RL-7 by prolonged exposure of parental cells to increasing concentrations of gemcitabine.  RESULTS:  In vitro, the IC50 increased from 0.015 microM in parental RL-7 cells to 25 microM in the resistant variant, RL-G.  Xenografts of both cell lines developed in nude mice were treated with repeated injections of gemcitabine.  Under conditions of gemcitabine treatment which totally inhibited the development of RL-7 tumors, RL-G derived tumors grew similarly to those of untreated animals, demonstrating the in vivo resistance of RL-G cells to gemcitabine.  HPLC experiments showed that RL-G cells accumulated and incorporated less gemcitabine metabolites into DNA and RNA than RL-7 cells.  Gemcitabine induced an S-phase arrest in RL-7 cells but not in RL-G cells.  Exposure to gemcitabine induced a higher degree of apoptosis in RL-7 than in RL-G cells, with poly-(ADP-ribose) polymerase cleavage in RL-7 cells.  No modifications of Bcl-2 nor of Bax expression were observed in RL-7 or RL-G cells exposed to gemcitabine.  These alterations were associated with the absence of the deoxycytidine kinase mRNA expression observed by quantitative RT-PCR in RL-G cells.  PCR amplification of desoxycytidine kinase gene exons showed a partial deletion of the dCK gene in RL-G cells.  CONCLUSIONS:  These results suggest that partial deletion of the dCK gene observed after selection in the presence of gemcitabine is involved with resistance to this agent both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS-7XXrs8c5MevW160gIxP_fW6udTcc2eb2hogJKii8NLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czgt1Wlsw%253D%253D&md5=6f3ab048027d98416786a04a71bcf649</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1186%2F1471-2210-4-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2210-4-8%26sid%3Dliteratum%253Aachs%26aulast%3DGalmarini%26aufirst%3DC.%2BM.%26aulast%3DClarke%26aufirst%3DM.%2BL.%26aulast%3DJordheim%26aufirst%3DL.%26aulast%3DSantos%26aufirst%3DC.%2BL.%26aulast%3DCros%26aufirst%3DE.%26aulast%3DMackey%26aufirst%3DJ.%2BR.%26aulast%3DDumontet%26aufirst%3DC.%26atitle%3DResistance%2520to%2520gemcitabine%2520in%2520a%2520human%2520follicular%2520lymphoma%2520cell%2520line%2520is%2520due%2520to%2520partial%2520deletion%2520of%2520the%2520deoxycytidine%2520kinase%2520gene%26jtitle%3DBMC%2520Pharmacol.%26date%3D2004%26volume%3D4%26spage%3D8%26doi%3D10.1186%2F1471-2210-4-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Beumer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiseman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parise, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egorin, M. J.</span></span> <span> </span><span class="NLM_article-title">Modulation of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3529</span>– <span class="NLM_lpage">3535</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-4885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1158%2F1078-0432.CCR-07-4885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=18519786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslygtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=3529-3535&author=J.+H.+Beumerauthor=J.+L.+Eisemanauthor=R.+A.+Pariseauthor=E.+Josephauthor=J.+M.+Coveyauthor=M.+J.+Egorin&title=Modulation+of+gemcitabine+%282%E2%80%B2%2C2%E2%80%B2-difluoro-2%E2%80%B2-deoxycytidine%29+pharmacokinetics%2C+metabolism%2C+and+bioavailability+in+mice+by+3%2C4%2C5%2C6-tetrahydrouridine&doi=10.1158%2F1078-0432.CCR-07-4885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of Gemcitabine (2',2'-Difluoro-2'-Deoxycytidine) Pharmacokinetics, Metabolism, and Bioavailability in Mice by 3,4,5,6-Tetrahydrouridine</span></div><div class="casAuthors">Beumer, Jan H.; Eiseman, Julie L.; Parise, Robert A.; Joseph, Erin; Covey, Joseph M.; Egorin, Merrill J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3529-3535</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: In vivo, 2',2'-difluoro-2'-deoxycytidine (dFdC) is rapidly inactivated by gut and liver cytidine deaminase (CD) to 2',2'-difluoro-2'-deoxyuridine (dFdU).  Consequently, dFdC has poor oral bioavailability and is administered i.v., with assocd. costs and limitations in administration schedules. 3,4,5,6-Tetrahydrouridine (THU) is a potent CD inhibitor with a 20% oral bioavailability.  We investigated the ability of THU to decrease elimination and first-pass effect by CD, thereby enabling oral dosing of dFdC.  Exptl. Design: A liq. chromatog.-tandem mass spectrometry assay was developed for plasma dFdC and dFdU.  Mice were dosed with 100 mg/kg dFdC i.v. or orally with or without 100 mg/kg THU i.v. or orally.  At specified times between 5 and 1,440 min, mice (n = 3) were euthanized. dFdC, dFdU, and THU concns. were quantitated in plasma and urine.  RESULTS: THU i.v. and orally produced concns. >4 μg/mL for 3 and 2 h, resp., whereas concns. of >1 μg/mL have been assocd. with near-complete inhibition of CD in vitro.  THU i.v. decreased plasma dFdU concns. but had no effect on dFdC plasma area under the plasma concn. vs. time curve after i.v. dFdC dosing.  Both THU i.v. and orally substantially increased oral bioavailability of dFdC.  Absorption of dFdC orally was 59%, but only 10% passed liver and gut CD and eventually reached the systemic circulation.  Coadministration of THU orally increased dFdC oral bioavailability from 10% to 40%.  CONCLUSIONS: Coadministration of THU enables oral dosing of dFdC and warrants clin. testing.  Oral dFdC treatment would be easier and cheaper, potentially prolong dFdC exposure, and enable exploration of administration schedules considered impractical by the i.v. route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc1H9aRg7karVg90H21EOLACvtfcHk0lgu_f8tJYNdRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslygtrY%253D&md5=744bee3dc79923eccdedef29434c098c</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-4885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-4885%26sid%3Dliteratum%253Aachs%26aulast%3DBeumer%26aufirst%3DJ.%2BH.%26aulast%3DEiseman%26aufirst%3DJ.%2BL.%26aulast%3DParise%26aufirst%3DR.%2BA.%26aulast%3DJoseph%26aufirst%3DE.%26aulast%3DCovey%26aufirst%3DJ.%2BM.%26aulast%3DEgorin%26aufirst%3DM.%2BJ.%26atitle%3DModulation%2520of%2520gemcitabine%2520%25282%25E2%2580%25B2%252C2%25E2%2580%25B2-difluoro-2%25E2%2580%25B2-deoxycytidine%2529%2520pharmacokinetics%252C%2520metabolism%252C%2520and%2520bioavailability%2520in%2520mice%2520by%25203%252C4%252C5%252C6-tetrahydrouridine%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D3529%26epage%3D3535%26doi%3D10.1158%2F1078-0432.CCR-07-4885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobili, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caciagli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landini, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzei, T.</span></span> <span> </span><span class="NLM_article-title">Cellular pharmacology of gemcitabine</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">v7</span>– <span class="NLM_lpage">v12</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdj941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1093%2Fannonc%2Fmdj941" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=16807468" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=v7-v12&author=E.+Miniauthor=S.+Nobiliauthor=B.+Caciagliauthor=I.+Landiniauthor=T.+Mazzei&title=Cellular+pharmacology+of+gemcitabine&doi=10.1093%2Fannonc%2Fmdj941"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdj941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdj941%26sid%3Dliteratum%253Aachs%26aulast%3DMini%26aufirst%3DE.%26aulast%3DNobili%26aufirst%3DS.%26aulast%3DCaciagli%26aufirst%3DB.%26aulast%3DLandini%26aufirst%3DI.%26aulast%3DMazzei%26aufirst%3DT.%26atitle%3DCellular%2520pharmacology%2520of%2520gemcitabine%26jtitle%3DAnn.%2520Oncol.%26date%3D2006%26volume%3D17%26spage%3Dv7%26epage%3Dv12%26doi%3D10.1093%2Fannonc%2Fmdj941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzuto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suppiah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiers, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukumaran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharwani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabra, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Bahrawy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habib, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghazaly, E.</span></span> <span> </span><span class="NLM_article-title">Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">815</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1038/s41416-018-0244-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1038%2Fs41416-018-0244-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=30206366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslSrs7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=815-822&author=S.+P.+Blagdenauthor=I.+Rizzutoauthor=P.+Suppiahauthor=D.+O%E2%80%99Sheaauthor=M.+Patelauthor=L.+Spiersauthor=A.+Sukumaranauthor=N.+Bharwaniauthor=A.+Rockallauthor=H.+Gabraauthor=M.+El-Bahrawyauthor=H.+Wasanauthor=R.+Leonardauthor=N.+Habibauthor=E.+Ghazaly&title=Anti-tumour+activity+of+a+first-in-class+agent+NUC-1031+in+patients+with+advanced+cancer%3A+results+of+a+phase+I+study&doi=10.1038%2Fs41416-018-0244-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study</span></div><div class="casAuthors">Blagden, Sarah P.; Rizzuto, Ivana; Suppiah, Puvan; O'Shea, Daniel; Patel, Markand; Spiers, Laura; Sukumaran, Ajithkumar; Bharwani, Nishat; Rockall, Andrea; Gabra, Hani; El-Bahrawy, Mona; Wasan, Harpreet; Leonard, Robert; Habib, Nagy; Ghazaly, Essam</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">815-822</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Gemcitabine is used to treat a wide range of tumors, but its efficacy is limited by cancer cell resistance mechanisms.  NUC-1031, a phosphoramidate modification of gemcitabine, is the first anti-cancer ProTide to enter the clinic and is designed to overcome these key resistance mechanisms.  Sixty-eight patients with advanced solid tumors who had relapsed after treatment with std. therapy were recruited to a dose escalation study to det. the recommended Phase II dose (RP2D) and assess the safety of NUC-1031.  Pharmacokinetics and anti-tumor activity was also assessed.  Sixty-eight patients received treatment, 50% of whom had prior exposure to gemcitabine.  NUC-1031 was well tolerated with the most common Grade 3/4 adverse events of neutropenia, lymphopenia and fatigue occurring in 13 patients each (19%).  In 49 response-evaluable patients, 5 (10%) achieved a partial response and 33 (67%) had stable disease, resulting in a 78% disease control rate.  Cmax levels of the active intracellular metabolite, dFdCTP, were 217-times greater than those reported for equimolar doses of gemcitabine, with minimal toxic metabolite accumulation.  The RP2D was detd. as 825 mg/m2 on days 1, 8 and 15 of a 28-day cycle.  NUC-1031 was well tolerated and demonstrated clin. significant anti-tumor activity, even in patients with prior gemcitabine exposure and in cancers not traditionally perceived as gemcitabine-responsive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzqXWvBd6VLbVg90H21EOLACvtfcHk0li5kXbsV4KLKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslSrs7jM&md5=5cf90783188268b2b884a6e45c8f12f6</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fs41416-018-0244-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-018-0244-1%26sid%3Dliteratum%253Aachs%26aulast%3DBlagden%26aufirst%3DS.%2BP.%26aulast%3DRizzuto%26aufirst%3DI.%26aulast%3DSuppiah%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DSpiers%26aufirst%3DL.%26aulast%3DSukumaran%26aufirst%3DA.%26aulast%3DBharwani%26aufirst%3DN.%26aulast%3DRockall%26aufirst%3DA.%26aulast%3DGabra%26aufirst%3DH.%26aulast%3DEl-Bahrawy%26aufirst%3DM.%26aulast%3DWasan%26aufirst%3DH.%26aulast%3DLeonard%26aufirst%3DR.%26aulast%3DHabib%26aufirst%3DN.%26aulast%3DGhazaly%26aufirst%3DE.%26atitle%3DAnti-tumour%2520activity%2520of%2520a%2520first-in-class%2520agent%2520NUC-1031%2520in%2520patients%2520with%2520advanced%2520cancer%253A%2520results%2520of%2520a%2520phase%2520I%2520study%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D119%26spage%3D815%26epage%3D822%26doi%3D10.1038%2Fs41416-018-0244-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><a href="http://www.nucana.com/downloads/NuCana12June2019.pdf" class="extLink">http://www.nucana.com/downloads/NuCana12June2019.pdf</a> (accessed 2019-07-22).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.nucana.com%2Fdownloads%2FNuCana12June2019.pdf+%28accessed+2019-07-22%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grem, J. L.</span></span> <span> </span><span class="NLM_article-title">5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">299</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1023/A:1006416410198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1023%2FA%3A1006416410198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=11081567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD3cXotFCqurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2000&pages=299-313&author=J.+L.+Grem&title=5-Fluorouracil%3A+forty-plus+and+still+ticking.+A+review+of+its+preclinical+and+clinical+development&doi=10.1023%2FA%3A1006416410198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development</span></div><div class="casAuthors">Grem, Jean L.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">299-313</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review with 128 refs.  5-Fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FdUrd) are pyrimidine analogs that have been part of the therapeutic armamentarium for a variety of solid tumors for over forty years.  5-FU has customarily required i.v. administration due to poor and erratic oral bioavailability, while FdUrd has generally been employed for regional administration to the liver or the peritoneal cavity.  A great deal of knowledge has been gained concerning the cellular pharmacol. and mechanism of action of 5-FU since it was first synthesized in the late 1950's.  A more thorough understanding of the factors influencing the metabolic activation of 5-FU and its cellular effects has generated considerable interest in combining it with both modulatory agents such as leucovorin and methotrexate that enhance its metab. or cytotoxic effects.  In addn., 5-FU has also been employed to enhance the therapeutic activity of other antineoplastic agents or modalities such as cisplatin and ionizing radiation with which it can synergize.  Appreciation of the clin. pharmacol. of 5-FU and FdUrd have led to a variety of schedules that are clin. useful.  The preclin. and clin. pharmacol. of 5-FU is reviewed to provide a basis for exploring the novel approaches to permit oral administration of 5-FU or its prodrugs that will be described in other articles in this issue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjbb7VzAKqwrVg90H21EOLACvtfcHk0li5kXbsV4KLKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXotFCqurc%253D&md5=26b5129a0f45b59de973de3e13b153e6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1023%2FA%3A1006416410198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1006416410198%26sid%3Dliteratum%253Aachs%26aulast%3DGrem%26aufirst%3DJ.%2BL.%26atitle%3D5-Fluorouracil%253A%2520forty-plus%2520and%2520still%2520ticking.%2520A%2520review%2520of%2520its%2520preclinical%2520and%2520clinical%2520development%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2000%26volume%3D18%26spage%3D299%26epage%3D313%26doi%3D10.1023%2FA%3A1006416410198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-S.</span></span> <span> </span><span class="NLM_article-title">5-Fluorouracil: mechanisms of resistance and reversal strategies</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1569</span>, <span class="refDoi"> DOI: 10.3390/molecules13081551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.3390%2Fmolecules13081551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=18794772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVCju7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=1551-1569&author=N.+Zhangauthor=Y.+Yinauthor=S.-J.+Xuauthor=W.-S.+Chen&title=5-Fluorouracil%3A+mechanisms+of+resistance+and+reversal+strategies&doi=10.3390%2Fmolecules13081551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">5-fluorouracil: mechanisms of resistance and reversal strategies</span></div><div class="casAuthors">Zhang, Ning; Yin, Ying; Xu, Sheng-Jie; Chen, Wei-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1551-1569</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  The purpose of this work is to review the published studies on the mechanisms of action and resistance of 5-fluorouracil.  The review is divided into 3 main sections: mechanisms of anti-tumor action, studies of the resistance to the drug, and procedures for the identification of new genes involved in resistance with microarray techniques.  The details of the induction and reversal of the drug resistance are also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIZm3-MGMwO7Vg90H21EOLACvtfcHk0li5kXbsV4KLKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVCju7jK&md5=de07c1be5c5995b8361805b28f237027</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.3390%2Fmolecules13081551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules13081551%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DS.-J.%26aulast%3DChen%26aufirst%3DW.-S.%26atitle%3D5-Fluorouracil%253A%2520mechanisms%2520of%2520resistance%2520and%2520reversal%2520strategies%26jtitle%3DMolecules%26date%3D2008%26volume%3D13%26spage%3D1551%26epage%3D1569%26doi%3D10.3390%2Fmolecules13081551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jetté, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissoon-Haqqani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Francois, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maroun, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnboim, C.</span></span> <span> </span><span class="NLM_article-title">Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by mycoplasma infection</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2175</span>– <span class="NLM_lpage">2180</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=18751392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVaku7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=2175-2180&author=L.+Jett%C3%A9author=S.+Bissoon-Haqqaniauthor=B.+Le+Francoisauthor=J.+A.+Marounauthor=C.+Birnboim&title=Resistance+of+colorectal+cancer+cells+to+5-FUdR+and+5-FU+caused+by+mycoplasma+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by mycoplasma infection</span></div><div class="casAuthors">Jette, Lucie; Bissoon-Haqqani, Seema; Le Francois, Brice; Maroun, Jean A.; Birnboim, H. Chaim</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4B</span>),
    <span class="NLM_cas:pages">2175-2180</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">Background: 5-Fluorouracil (5-FU) is an antineoplastic drug that targets thymidylate synthase (TS).  Tumor cells can develop resistance to anti-TS drugs by a variety of mechanisms including up-regulation of TS protein and alterations in drug uptake and degrdn.  The possible mechanisms of the obsd. rapid development of resistance to the pyrimidine analogs 5-FUdR and 5-FU in cultured HCT116 colon cancer cells were investigated.  Materials and Methods: Cell survival was detd. in resistant and control HCT116 cells treated with 5-FUdR and 5-FU for 7 days.  The ability of the cells to take up and metabolize these drugs was detd. by Western blotting and [3H]thymidine incorporation.  Results and Conclusion: Resistant HCT116 cells were 5- and 100-fold more resistant to killing by 5-FU and 5-FUdR, resp., than the parental cells and exhibited impaired uptake.  Although the HCT116R cells were initially Mycoplasma free, a low level of Mycoplasma contamination was found in these cells after several weeks in culture.  Sensitivity to 5-FUdR was restored by treatment with an anti-Mycoplasma antibiotic.  Our observations emphasize the need for frequent testing for Mycoplasma contamination in any cell line under investigation for resistance to anti-TS drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4LxTWP_ygQrVg90H21EOLACvtfcHk0lhSnscGwVjDcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVaku7%252FN&md5=020dbae6d351ca5244e82d3eb3177533</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJett%25C3%25A9%26aufirst%3DL.%26aulast%3DBissoon-Haqqani%26aufirst%3DS.%26aulast%3DLe%2BFrancois%26aufirst%3DB.%26aulast%3DMaroun%26aufirst%3DJ.%2BA.%26aulast%3DBirnboim%26aufirst%3DC.%26atitle%3DResistance%2520of%2520colorectal%2520cancer%2520cells%2520to%25205-FUdR%2520and%25205-FU%2520caused%2520by%2520mycoplasma%2520infection%26jtitle%3DAnticancer%2520Res.%26date%3D2008%26volume%3D28%26spage%3D2175%26epage%3D2180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diasio, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, B. E.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacology of 5-fluorouracil</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.2165/00003088-198916040-00002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.2165%2F00003088-198916040-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=2656050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADyaL1MXkslSisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1989&pages=215-237&author=R.+B.+Diasioauthor=B.+E.+Harris&title=Clinical+pharmacology+of+5-fluorouracil&doi=10.2165%2F00003088-198916040-00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacology of 5-fluorouracil</span></div><div class="casAuthors">Diasio, Robert B.; Harris, Barry E.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">215-37</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    </div><div class="casAbstract">A review with 150 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon2q3qcBdt77Vg90H21EOLACvtfcHk0lhSnscGwVjDcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkslSisr4%253D&md5=ac71baf8afc1cd77a33d14c4fff5fe9e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2165%2F00003088-198916040-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-198916040-00002%26sid%3Dliteratum%253Aachs%26aulast%3DDiasio%26aufirst%3DR.%2BB.%26aulast%3DHarris%26aufirst%3DB.%2BE.%26atitle%3DClinical%2520pharmacology%2520of%25205-fluorouracil%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1989%26volume%3D16%26spage%3D215%26epage%3D237%26doi%3D10.2165%2F00003088-198916040-00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vande
Voorde, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liekens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murziani, P. G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2’-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2011.05.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1016%2Fj.bcp.2011.05.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=21658373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1ehsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2011&pages=441-452&author=J.+Vande%0AVoordeauthor=S.+Liekensauthor=C.+McGuiganauthor=P.+G.+S.+Murzianiauthor=M.+Slusarczykauthor=J.+Balzarini&title=The+cytostatic+activity+of+NUC-3073%2C+a+phosphoramidate+prodrug+of+5-fluoro-2%E2%80%99-deoxyuridine%2C+is+independent+of+activation+by+thymidine+kinase+and+insensitive+to+degradation+by+phosphorolytic+enzymes&doi=10.1016%2Fj.bcp.2011.05.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2'-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes</span></div><div class="casAuthors">Vande Voorde, Johan; Liekens, Sandra; McGuigan, Christopher; Murziani, Paola G. S.; Slusarczyk, Magdalena; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel phosphoramidate nucleotide prodrug of the anticancer nucleoside analog 5-fluoro-2'-deoxyuridine (5-FdUrd) was synthesized and evaluated for its cytostatic activity.  Whereas 5-FdUrd substantially lost its cytostatic potential in thymidine kinase (TK)-deficient murine leukemia L1210 and human lymphocyte CEM cell cultures, NUC-3073 markedly kept its antiproliferative activity in TK-deficient tumor cells, and thus is largely independent of intracellular TK activity to exert its cytostatic action.  NUC-3073 was found to inhibit thymidylate synthase (TS) in the TK-deficient and wild-type cell lines at drug concns. that correlated well with its cytostatic activity in these cells.  NUC-3073 does not seem to be susceptible to inactivation by catabolic enzymes such as thymidine phosphorylase (TP) and uridine phosphorylase (UP).  These findings are in line with our observations that 5-FdUrd, but not NUC-3073, substantially loses its cytostatic potential in the presence of TP-expressing mycoplasmas in the tumor cell cultures.  Therefore, we propose NUC-3073 as a novel 5-FdUrd phosphoramidate prodrug that (i) may circumvent potential resistance mechanisms of tumor cells (e.g. decreased TK activity) and (ii) is not degraded by catabolic enzymes such as TP which is often upregulated in tumor cells or expressed in mycoplasma-infected tumor tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0BkUUtRLZTrVg90H21EOLACvtfcHk0lhSnscGwVjDcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1ehsrw%253D&md5=50b53ced366a86c9180e178456b902d8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2011.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2011.05.024%26sid%3Dliteratum%253Aachs%26aulast%3DVande%2BVoorde%26aufirst%3DJ.%26aulast%3DLiekens%26aufirst%3DS.%26aulast%3DMcGuigan%26aufirst%3DC.%26aulast%3DMurziani%26aufirst%3DP.%2BG.%2BS.%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DThe%2520cytostatic%2520activity%2520of%2520NUC-3073%252C%2520a%2520phosphoramidate%2520prodrug%2520of%25205-fluoro-2%25E2%2580%2599-deoxyuridine%252C%2520is%2520independent%2520of%2520activation%2520by%2520thymidine%2520kinase%2520and%2520insensitive%2520to%2520degradation%2520by%2520phosphorolytic%2520enzymes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D82%26spage%3D441%26epage%3D452%26doi%3D10.1016%2Fj.bcp.2011.05.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghazaly, E.</span>; <span class="NLM_string-name">Woodcock, V. K.</span>; <span class="NLM_string-name">Spilipoulou, P.</span>; <span class="NLM_string-name">Spiers, L.</span>; <span class="NLM_string-name">Moschandreas, J.</span>; <span class="NLM_string-name">Griffiths, L.</span>; <span class="NLM_string-name">Gnanaranjan, C.</span>; <span class="NLM_string-name">Harrison, D. J.</span>; <span class="NLM_string-name">Evans, T. R. J.</span>; <span class="NLM_string-name">Blagden, S.</span></span> <i>42nd ESMO Congress 2017</i>, Madrid, Spain, September 8–12, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">385-P</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=385-P&author=E.+Ghazaly&author=V.+K.+Woodcock&author=P.+Spilipoulou&author=L.+Spiers&author=J.+Moschandreas&author=L.+Griffiths&author=C.+Gnanaranjan&author=D.+J.+Harrison&author=T.+R.+J.+Evans&author=S.+Blagden&title=42nd+ESMO+Congress+2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGhazaly%26aufirst%3DE.%26jtitle%3D42nd%2520ESMO%2520Congress%25202017%26date%3D2017%26spage%3D385-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03428958" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03428958</a> (accessed 2019-03-28).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03428958+%28accessed+2019-03-28%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><a href="https://clinicaltrials.gov/ct2/show/NCT03829254" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03829254</a> (accessed 2019-08-28).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03829254+%28accessed+2019-08-28%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pradere, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnier-Amblard, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amblard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis of nucleoside phosphate and phosphonate prodrugs</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">9154</span>– <span class="NLM_lpage">9218</span>, <span class="refDoi"> DOI: 10.1021/cr5002035</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr5002035" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=9154-9218&author=U.+Pradereauthor=E.+C.+Garnier-Amblardauthor=S.+J.+Coatsauthor=F.+Amblardauthor=R.+F.+Schinazi&title=Synthesis+of+nucleoside+phosphate+and+phosphonate+prodrugs&doi=10.1021%2Fcr5002035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23aR"><div class="casContent"><span class="casTitleNuber">23a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Nucleoside Phosphate and Phosphonate Prodrugs</span></div><div class="casAuthors">Pradere, Ugo; Garnier-Amblard, Ethel C.; Coats, Steven J.; Amblard, Franck; Schinazi, Raymond F.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">9154-9218</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein, we review the most important mono-, di-, and triphosphate and phosphonate prodrug approaches applied to nucleoside analogs from a chem. point of view, detailing the strengths and limitations of each approach.  We will focus on the various synthetic pathways discussing: (1) the chem. variation of the biolabile phosphonate masking groups; (2) the reliability of using P(III) and/or P(V) chem. for both phosphate and phosphonate prodrug synthesis; (3) the influence of the masking group(s) introduction conditions (solvent, temp., stoichiometry) on the overall outcome for each method; (4) the various protection/deprotection strategies used to impart improved yield and regioselectivity relative to the nature of the nucleobase and the sugar; and (5) the influence of reaction conditions or protective groups on the stereoselectivity (Rp/Sp) obsd. at the phosphorus center as well as the methods employed to sep. both Rp and Sp isomers along with the asym. strategies for the synthesis of predominantly single diastereoisomers at the phosphorus center.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2UgEs4_SnUrVg90H21EOLACvtfcHk0ljYYeYls-U-yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsL7J&md5=115175a0c31890dd5b7b9f4ae9a9191f</span></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=10.1021%2Fcr5002035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr5002035%26sid%3Dliteratum%253Aachs%26aulast%3DPradere%26aufirst%3DU.%26aulast%3DGarnier-Amblard%26aufirst%3DE.%2BC.%26aulast%3DCoats%26aufirst%3DS.%2BJ.%26aulast%3DAmblard%26aufirst%3DF.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26atitle%3DSynthesis%2520of%2520nucleoside%2520phosphate%2520and%2520phosphonate%2520prodrugs%26jtitle%3DChem.%2520Rev.%26date%3D2014%26volume%3D114%26spage%3D9154%26epage%3D9218%26doi%3D10.1021%2Fcr5002035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Slusarczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serpi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertusati, F.</span></span> <span> </span><span class="NLM_article-title">Phosphoramidates and phosphonamidates (protides) with antiviral activity</span>. <i>Antivir. Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>, <span class="refDoi"> DOI: 10.1177/2040206618775243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1177%2F2040206618775243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=29792071" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+Slusarczykauthor=M.+Serpiauthor=F.+Pertusati&title=Phosphoramidates+and+phosphonamidates+%28protides%29+with+antiviral+activity&doi=10.1177%2F2040206618775243"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=10.1177%2F2040206618775243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040206618775243%26sid%3Dliteratum%253Aachs%26aulast%3DSlusarczyk%26aufirst%3DM.%26aulast%3DSerpi%26aufirst%3DM.%26aulast%3DPertusati%26aufirst%3DF.%26atitle%3DPhosphoramidates%2520and%2520phosphonamidates%2520%2528protides%2529%2520with%2520antiviral%2520activity%26jtitle%3DAntivir.%2520Chem.%2520Chemother.%26date%3D2018%26doi%3D10.1177%2F2040206618775243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klapars, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, S. M.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based solution to the protide synthesis problem: selective access to sofosbuvir, acelarin, and INX-08189</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2218</span>– <span class="NLM_lpage">2221</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.7b00469</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.7b00469" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFCmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=2218-2221&author=B.+Simmonsauthor=Z.+Liuauthor=A.+Klaparsauthor=A.+Bellomoauthor=S.+M.+Silverman&title=Mechanism-based+solution+to+the+protide+synthesis+problem%3A+selective+access+to+sofosbuvir%2C+acelarin%2C+and+INX-08189&doi=10.1021%2Facs.orglett.7b00469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-Based Solution to the ProTide Synthesis Problem: Selective Access to Sofosbuvir, Acelarin, and INX-08189</span></div><div class="casAuthors">Simmons, Bryon; Liu, Zhuqing; Klapars, Artis; Bellomo, Ana; Silverman, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2218-2221</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A general and efficient method for the synthesis of pro-nucleotide (ProTide) 5'-phosphoramidate mono-esters is reported.  This method consists of a highly stereoselective 5'-phosphorylation mediated by dimethylaluminum chloride to afford the desired target ProTides in excellent yields without employing 3'-protection strategies.  The application of this methodol. to the synthesis of a no. of pharmaceutically relevant compds. currently marketed or under investigation in clin. research is demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDuwgFmGkb3LVg90H21EOLACvtfcHk0ljYYeYls-U-yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFCmtr4%253D&md5=8cb5b9d994fcd83db7393e376a336bea</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.7b00469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.7b00469%26sid%3Dliteratum%253Aachs%26aulast%3DSimmons%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DKlapars%26aufirst%3DA.%26aulast%3DBellomo%26aufirst%3DA.%26aulast%3DSilverman%26aufirst%3DS.%2BM.%26atitle%3DMechanism-based%2520solution%2520to%2520the%2520protide%2520synthesis%2520problem%253A%2520selective%2520access%2520to%2520sofosbuvir%252C%2520acelarin%252C%2520and%2520INX-08189%26jtitle%3DOrg.%2520Lett.%26date%3D2017%26volume%3D19%26spage%3D2218%26epage%3D2221%26doi%3D10.1021%2Facs.orglett.7b00469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natt, N.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir: A novel treatment option for chronic hepatitis C infection</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.4103/0976-500X.142464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.4103%2F0976-500X.142464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=25422576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFahtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=278-282&author=H.+Singhauthor=H.+Bhatiaauthor=N.+Grewalauthor=N.+Natt&title=Sofosbuvir%3A+A+novel+treatment+option+for+chronic+hepatitis+C+infection&doi=10.4103%2F0976-500X.142464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir: a novel treatment option for chronic hepatitis C infection</span></div><div class="casAuthors">Bhatia, Harmeet Kaur; Singh, Harmanjit; Grewal, Nipunjot; Natt, Navreet Kaur</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">278-284, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPPOGN</span>;
        ISSN:<span class="NLM_cas:issn">0976-500X</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications and Media Pvt. Ltd.</span>)
        </div><div class="casAbstract">Hepatitis C currently infects more than 170 million people around the world, leading to significant morbidity and mortality.  The current std. of care for HCV infection, including one of the two protease inhibitors, telaprevir or boceprevir, for 12-32 wk, along with pegylated interferon alfa-2a (PEG-IFN-α) and ribavirin for up to 48 wk, is unsatisfactory in many cases, either because of lack of efficacy or because of treatment-related adverse effects.  There is an urgent need of new drugs with improved efficacy as well as a safety profile.  Sofosbuvir, a recently approved nucleotide analog, is a highly potent inhibitor of the NS5B polymerase in the Hepatitis C virus (HCV), and has shown high efficacy in combination with several other drugs, with and without PEG-INF, against HCV.  It offers many advantages due to its high potency, low side effects, oral administration, and high barrier to resistance.  The efficacy and safety were demonstrated in many large and well-designed phase 2 and phase 3 clin. trials like NEUTRINO, PROTON, ELECTRON, ATOMIC, COSMOS, FUSION, FISSION, NUCLEAR, POSITRON, and the like.  It is generally well-tolerated.  Adverse events that occurred include: Headache, insomnia, fatigue, nausea, dizziness, pruritis, upper respiratory tract infections, rash, back pain, grade 1 anemia, and grade 4 lymphopenia; however, the exact safety profile can only be judged when this drug is actually used on a large scale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiw8rejud7ubVg90H21EOLACvtfcHk0ljuQsMyGgBFkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFahtbfL&md5=bcdd2945231ac73a751f0771b46b6201</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.142464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.142464%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DBhatia%26aufirst%3DH.%26aulast%3DGrewal%26aufirst%3DN.%26aulast%3DNatt%26aufirst%3DN.%26atitle%3DSofosbuvir%253A%2520A%2520novel%2520treatment%2520option%2520for%2520chronic%2520hepatitis%2520C%2520infection%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2014%26volume%3D5%26spage%3D278%26epage%3D282%26doi%3D10.4103%2F0976-500X.142464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espiritu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a β-d-2-Deoxy-2-α-fluoro-2-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7202</span>– <span class="NLM_lpage">7218</span>, <span class="refDoi"> DOI: 10.1021/jm100863x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100863x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7202-7218&author=M.+J.+Sofiaauthor=D.+Baoauthor=W.+Changauthor=J.+Duauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=P.+G.+Reddyauthor=B.+S.+Rossauthor=P.+Wangauthor=H.+R.+Zhangauthor=S.+Bansalauthor=C.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=H.+M.+Steuerauthor=C.+Niuauthor=M.+J.+Ottoauthor=P.+A.+Furman&title=Discovery+of+a+%CE%B2-d-2-Deoxy-2-%CE%B1-fluoro-2-%CE%B2-C-methyluridine+nucleotide+prodrug+%28PSI-7977%29+for+the+treatment+of+hepatitis+C+virus&doi=10.1021%2Fjm100863x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus</span></div><div class="casAuthors">Sofia, Michael J.; Bao, Donghui; Chang, Wonsuk; Du, Jinfa; Nagarathnam, Dhanapalan; Rachakonda, Suguna; Reddy, P. Ganapati; Ross, Bruce S.; Wang, Peiyuan; Zhang, Hai-Ren; Bansal, Shalini; Espiritu, Christine; Keilman, Meg; Lam, Angela M.; Steuer, Holly M. Micolochick; Niu, Congrong; Otto, Michael J.; Furman, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7202-7218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a global health problem requiring novel approaches for effective treatment of this disease.  The HCV NS5B polymerase has been demonstrated to be a viable target for the development of HCV therapies.  β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-Me nucleosides are selective inhibitors of the HCV NS5B polymerase and have demonstrated potent activity in the clinic.  Phosphoramidate prodrugs of the 5'-phosphate deriv. of the β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleoside were prepd. and showed significant potency in the HCV subgenomic replicon assay (<1 μM) and produced high levels of triphosphate 6 in primary hepatocytes and in the livers of rats, dogs, and monkeys when administered in vivo.  The single diastereomer 51 of diastereomeric mixt. 14 was crystd., and an X-ray structure was detd. establishing the phosphoramidate stereochem. as Sp, thus correlating for the first time the stereochem. of a phosphoramidate prodrug with biol. activity.  51 (PSI-7977) was selected as a clin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWAkLi9-odWbVg90H21EOLACvtfcHk0ljuQsMyGgBFkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO&md5=33d371e557e9d70562a326f97798f45c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm100863x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100863x%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%2BR.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520%25CE%25B2-d-2-Deoxy-2-%25CE%25B1-fluoro-2-%25CE%25B2-C-methyluridine%2520nucleotide%2520prodrug%2520%2528PSI-7977%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7202%26epage%3D7218%26doi%3D10.1021%2Fjm100863x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fordyce, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, M. J. M.</span></span> <span> </span><span class="NLM_article-title">Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2015.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1016%2Fj.antiviral.2015.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=26640223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVSktLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2016&pages=63-70&author=A.+S.+Rayauthor=M.+W.+Fordyceauthor=M.+J.+M.+Hitchcock&title=Tenofovir+alafenamide%3A+a+novel+prodrug+of+tenofovir+for+the+treatment+of+human+immunodeficiency+virus&doi=10.1016%2Fj.antiviral.2015.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus</span></div><div class="casAuthors">Ray, Adrian S.; Fordyce, Marshall W.; Hitchcock, Michael J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Despite substantial progress in the development of antiretroviral regimens that durably suppress Human Immunodeficiency Virus (HIV) infection, new agents that maintain high efficacy while further optimizing the safety of lifelong, chronic therapy are needed.  Tenofovir alafenamide (TAF; formerly known as GS-7340) is a novel prodrug of the antiviral acyclic nucleoside phosphonate tenofovir (TFV) with improved properties relative to tenofovir disoproxil fumarate (TDF).  Although potent and generally well tolerated, TDF therapy has been assocd. with changes in markers of renal function, decreases in bone mineral d. and a rare occurrence of serious renal adverse events, including Fanconi's Syndrome.  The renal and bone toxicity obsd. with TDF is assocd. with high circulating plasma levels of TFV.  TAF was discovered to be a more efficient prodrug able to further refine HIV therapy and better address life-long therapy in an older and increasingly comorbid HIV infected population.  By enhancing stability in biol. matrixes while being rapidly activated in cells, TAF produces higher levels of intracellular TFV diphosphate, the pharmacol. active metabolite, in HIV-target cells at substantially reduced oral doses of TFV equiv.  All TFV released in the body is eventually eliminated renally; therefore, lowering the TFV equiv. administered reduces off-target kidney exposure.  Effective therapy is thus achieved at approx. 90% lower systemic exposure to TFV, translating to statistically and clin. significant improvement in safety parameters assocd. with bone mineral d. and markers of renal function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxOKefbojWgLVg90H21EOLACvtfcHk0ljuQsMyGgBFkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVSktLjN&md5=ac4a87d3e80f6f46b454ebac70809842</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2015.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2015.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DFordyce%26aufirst%3DM.%2BW.%26aulast%3DHitchcock%26aufirst%3DM.%2BJ.%2BM.%26atitle%3DTenofovir%2520alafenamide%253A%2520a%2520novel%2520prodrug%2520of%2520tenofovir%2520for%2520the%2520treatment%2520of%2520human%2520immunodeficiency%2520virus%26jtitle%3DAntiviral%2520Res.%26date%3D2016%26volume%3D125%26spage%3D63%26epage%3D70%26doi%3D10.1016%2Fj.antiviral.2015.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cundy, K. C.</span></span> <span> </span><span class="NLM_article-title">Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1898</span>– <span class="NLM_lpage">1906</span>, <span class="refDoi"> DOI: 10.1128/AAC.49.5.1898-1906.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1128%2FAAC.49.5.1898-1906.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=15855512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFSntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=1898-1906&author=W.+A.+Leeauthor=G.+X.+Heauthor=E.+Eisenbergauthor=T.+Cihlarauthor=S.+Swaminathanauthor=A.+Mulatoauthor=K.+C.+Cundy&title=Selective+intracellular+activation+of+a+novel+prodrug+of+the+human+immunodeficiency+virus+reverse+transcriptase+inhibitor+tenofovir+leads+to+preferential+distribution+and+accumulation+in+lymphatic+tissue&doi=10.1128%2FAAC.49.5.1898-1906.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue</span></div><div class="casAuthors">Lee, William A.; He, Gong-Xin; Eisenberg, Eugene; Cihlar, Tomas; Swaminathan, Swami; Mulato, Andrew; Cundy, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1898-1906</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">An isopropylalaninyl monoamidate Ph monoester prodrug of tenofovir (GS 7340) was prepd., and its in vitro antiviral activity, metab., and pharmacokinetics in dogs were detd.  The 50% effective concn. (EC50) of GS 7340 against human immunodeficiency virus type 1 in MT-2 cells was 0.005 μM compared to an EC50 of 5 μM for the parent drug, tenofovir.  The (L)-alaninyl analog (GS 7340) was >1000-fold more active than the (D)-alaninyl analog.  GS 7340 has a half-life of 90 min in human plasma at 37° and a half-life of 28.3 min in an MT-2 cell ext. at 37°.  The antiviral activity (>10× the EC50) and the metabolic stability in MT-2 cell exts. (>35×) and plasma (>2.5×) were also sensitive to the stereochem. at the phosphorus.  After a single oral dose of GS 7340 (10 mg-eq/kg tenofovir) to male beagle dogs, the plasma bioavailability of tenofovir compared to an i.v. dose of tenofovir was 17%.  The total intracellular concn. of all tenofovir species in isolated peripheral blood mononuclear cells at 24 h was 63 μg-eq/mL compared to 0.2 μg-eq/mL in plasma.  A radiolabeled distribution study with dogs resulted in an increased distribution of tenofovir to tissues of lymphatic origin compared to the com. available prodrug tenofovir DF (Viread).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbOoU4rGP0xrVg90H21EOLACvtfcHk0liHEyodau_tSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFSntL0%253D&md5=b5e724620a1cafa4b473a84aea841282</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.5.1898-1906.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.5.1898-1906.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DW.%2BA.%26aulast%3DHe%26aufirst%3DG.%2BX.%26aulast%3DEisenberg%26aufirst%3DE.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DMulato%26aufirst%3DA.%26aulast%3DCundy%26aufirst%3DK.%2BC.%26atitle%3DSelective%2520intracellular%2520activation%2520of%2520a%2520novel%2520prodrug%2520of%2520the%2520human%2520immunodeficiency%2520virus%2520reverse%2520transcriptase%2520inhibitor%2520tenofovir%2520leads%2520to%2520preferential%2520distribution%2520and%2520accumulation%2520in%2520lymphatic%2520tissue%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D1898%26epage%3D1906%26doi%3D10.1128%2FAAC.49.5.1898-1906.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham-Huy, C.</span></span> <span> </span><span class="NLM_article-title">Chiral drugs: an overview</span>. <i>Int. J. Biomed. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=23674971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlSltrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=85-100&author=L.+A.+Nguyenauthor=H.+Heauthor=C.+Pham-Huy&title=Chiral+drugs%3A+an+overview"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Chiral drugs. An overview</span></div><div class="casAuthors">Nguyen, Lien Ai; He, Hua; Chuong, Pham-Huy</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biomedical Science (Monterey Park, CA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-100</span>CODEN:
                <span class="NLM_cas:coden">IJBSDB</span>;
        ISSN:<span class="NLM_cas:issn">1550-9702</span>.
    
            (<span class="NLM_cas:orgname">Master Publishing Group</span>)
        </div><div class="casAbstract">A review.  About more than half of the drugs currently in use are chiral compds. and near 90% of the last ones are marketed as racemates consisting of an equimolar mixt. of two enantiomers.  Although they have the same chem. structure, most isomers of chiral drugs exhibit marked differences in biol. activities such as pharmacol., toxicol., pharmacokinetics, metab. etc.  Some mechanisms of these properties are also explained.  Therefore, it is important to promote the chiral sepn. and anal. of racemic drugs in pharmaceutical industry as well as in clinic in order to eliminate the unwanted isomer from the prepn. and to find an optimal treatment and a right therapeutic control for the patient.  In this article, we review the nomenclature, pharmacol., toxicol., pharmacokinetics, metab. etc of some usual chiral drugs as well as their mechanisms.  Different techniques used for the chiral sepn. in pharmaceutical industry as well as in clin. analyses are also examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovoqsLM_3bxLVg90H21EOLACvtfcHk0liHEyodau_tSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlSltrnJ&md5=254cbca060bb4cfd04eac365488f5b62</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%2BA.%26aulast%3DHe%26aufirst%3DH.%26aulast%3DPham-Huy%26aufirst%3DC.%26atitle%3DChiral%2520drugs%253A%2520an%2520overview%26jtitle%3DInt.%2520J.%2520Biomed.%2520Sci.%26date%3D2006%26volume%3D2%26spage%3D85%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-new-stereoisomeric-drugs" class="extLink">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-new-stereoisomeric-drugs</a> (accessed 20121-02-23).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fregulatory-information%2Fsearch-fda-guidance-documents%2Fdevelopment-new-stereoisomeric-drugs+%28accessed+20121-02-23%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, C.</span></span> <span> </span><span class="NLM_article-title">Diastereoselective synthesis of aryloxy phosphoramidate prodrugs of 3′-deoxy-2’,3′-didehydrothymidine monophosphate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7675</span>– <span class="NLM_lpage">7681</span>, <span class="refDoi"> DOI: 10.1021/jm100817f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100817f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yktLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7675-7681&author=C.+A.+Romanauthor=J.+Balzariniauthor=C.+Meier&title=Diastereoselective+synthesis+of+aryloxy+phosphoramidate+prodrugs+of+3%E2%80%B2-deoxy-2%E2%80%99%2C3%E2%80%B2-didehydrothymidine+monophosphate&doi=10.1021%2Fjm100817f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Diastereoselective Synthesis of Aryloxy Phosphoramidate Prodrugs of 3'-Deoxy-2',3'-didehydrothymidine Monophosphate</span></div><div class="casAuthors">Roman, Cristina Arbelo; Balzarini, Jan; Meier, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7675-7681</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first diastereoselective synthesis of aryloxy phosphoramidate prodrugs of 3'-deoxy-2',3'-didehydrothymidine monophosphate (d4TMP) is reported.  In our approach, (S)-4-isopropylthiazolidine-2-thione 1 was used as a chiral auxiliary to introduce the stereochem. at the phosphorus atom.  In the last step of the developed reaction sequence, the nucleoside analog d4T was introduced to a stereochem. pure phosphordiamidate which led to the formation of the almost diastereomerically pure phosphoramidate prodrugs, e.g. I, (≥95% de).  As expected, the individually prepd. diastereomers of the phosphoramidate prodrugs showed significant differences in the antiviral activity.  Moreover, the difference was strongly dependent on the aryl substituent attached to the phosphoramidate moiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Wwym4_S97bVg90H21EOLACvtfcHk0liHEyodau_tSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yktLzE&md5=2fdc109dadda8cf6fa9f75be1f43f196</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm100817f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100817f%26sid%3Dliteratum%253Aachs%26aulast%3DRoman%26aufirst%3DC.%2BA.%26aulast%3DBalzarini%26aufirst%3DJ.%26aulast%3DMeier%26aufirst%3DC.%26atitle%3DDiastereoselective%2520synthesis%2520of%2520aryloxy%2520phosphoramidate%2520prodrugs%2520of%25203%25E2%2580%25B2-deoxy-2%25E2%2580%2599%252C3%25E2%2580%25B2-didehydrothymidine%2520monophosphate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7675%26epage%3D7681%26doi%3D10.1021%2Fjm100817f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapati Reddy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis of diastereomerically pure nucleotide phosphoramidates</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">8311</span>– <span class="NLM_lpage">8319</span>, <span class="refDoi"> DOI: 10.1021/jo201492m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo201492m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ags77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=8311-8319&author=B.+S.+Rossauthor=P.+Ganapati+Reddyauthor=H.-R.+Zhangauthor=S.+Rachakondaauthor=M.+J.+Sofia&title=Synthesis+of+diastereomerically+pure+nucleotide+phosphoramidates&doi=10.1021%2Fjo201492m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Diastereomerically Pure Nucleotide Phosphoramidates</span></div><div class="casAuthors">Ross, Bruce S.; Ganapati Reddy, P.; Zhang, Hai-Ren; Rachakonda, Suguna; Sofia, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8311-8319</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prodrugs of therapeutic nucleoside monophosphates masked as phosphoramidate derivs. have become an increasingly important class of antiviral drugs in pharmaceutical research for delivering nucleotides in vitro and in vivo.  Conventionally, phosphoramidate derivs. are prepd. as a mixt. of two diastereomers.  We report a class of stable phosphoramidate reagents contg. an amino acid ester and two phenolic groups, one unsubstituted and the other with electron-withdrawing substituents.  The reagents can be isolated as single diastereomers and reacted with the 5'-hydroxyl group of nucleosides through selective nucleophilic displacement of the substituted phenol to prep. single diastereomer phosphoramidate products.  This method has been used to prep. the HCV clin. candidate PSI-7977 I in high yield and high diastereomeric purity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgDGdlH3gLa7Vg90H21EOLACvtfcHk0liHEyodau_tSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ags77F&md5=747a893daa7d9c4784cc29619d05ab81</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjo201492m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo201492m%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DGanapati%2BReddy%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.-R.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DSynthesis%2520of%2520diastereomerically%2520pure%2520nucleotide%2520phosphoramidates%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26spage%3D8311%26epage%3D8319%26doi%3D10.1021%2Fjo201492m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span> <i>Synthesis of substantially diastereomerically pure
phosphate protides</i>. WO Patent <span class="NLM_patent">2018/229493</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Synthesis+of+substantially+diastereomerically+pure%0Aphosphate+protides.+WO+Patent+2018%2F229493%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthesis%2520of%2520substantially%2520diastereomerically%2520pure%250Aphosphate%2520protides%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span> <i>Diastereoselective synthesis of phosphate derivatives and
of the
gemcitabine prodrug NUC-1031</i>. WO Patent <span class="NLM_patent">2017/098252 A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Diastereoselective+synthesis+of+phosphate+derivatives+and%0Aof+the%0Agemcitabine+prodrug+NUC-1031.+WO+Patent+2017%2F098252+A1%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26jtitle%3DDiastereoselective%2520synthesis%2520of%2520phosphate%2520derivatives%2520and%250Aof%2520the%250Agemcitabine%2520prodrug%2520NUC-1031%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pertusati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuigan, C.</span></span> <span> </span><span class="NLM_article-title">Diastereoselective synthesis of P-chirogenic phosphoramidate prodrugs of nucleoside analogues (protides) via copper catalysed reaction</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">8070</span>– <span class="NLM_lpage">8073</span>, <span class="refDoi"> DOI: 10.1039/C5CC00448A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1039%2FC5CC00448A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=25867944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvFWhu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2015&pages=8070-8073&author=F.+Pertusatiauthor=C.+McGuigan&title=Diastereoselective+synthesis+of+P-chirogenic+phosphoramidate+prodrugs+of+nucleoside+analogues+%28protides%29+via+copper+catalysed+reaction&doi=10.1039%2FC5CC00448A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Diastereoselective synthesis of P-chirogenic phosphoramidate prodrugs of nucleoside analogues (ProTides) via copper catalysed reaction</span></div><div class="casAuthors">Pertusati, F.; McGuigan, C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">8070-8073</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The first copper-catalyzed diastereoselective synthesis of P-chiral phosphoramidate prodrugs (ProTides) is reported.  This procedure allows the synthesis of diastereomeric-enriched mixts. of ProTides.  Application of this methodol. to the asym. phosphorylation of purine and pyrimidine nucleoside analogs is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxTx1v1huKfLVg90H21EOLACvtfcHk0liGnAiUONLlGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvFWhu7g%253D&md5=8dbcffb9d06e2037912b427928c95e61</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1039%2FC5CC00448A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5CC00448A%26sid%3Dliteratum%253Aachs%26aulast%3DPertusati%26aufirst%3DF.%26aulast%3DMcGuigan%26aufirst%3DC.%26atitle%3DDiastereoselective%2520synthesis%2520of%2520P-chirogenic%2520phosphoramidate%2520prodrugs%2520of%2520nucleoside%2520analogues%2520%2528protides%2529%2520via%2520copper%2520catalysed%2520reaction%26jtitle%3DChem.%2520Commun.%26date%3D2015%26volume%3D51%26spage%3D8070%26epage%3D8073%26doi%3D10.1039%2FC5CC00448A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, A. I.</span></span> <span> </span><span class="NLM_article-title">Facile and highly selective 5′-desilylation of multisilylated nucleosides</span>. <i>Chem. Soc. Perkin. Trans 1</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_fpage">2305</span>– <span class="NLM_lpage">2306</span>, <span class="refDoi"> DOI: 10.1039/b003562i</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1039%2Fb003562i" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&pages=2305-2306&author=X.-F.+Zhuauthor=H.+J.+Williamsauthor=A.+I.+Scott&title=Facile+and+highly+selective+5%E2%80%B2-desilylation+of+multisilylated+nucleosides&doi=10.1039%2Fb003562i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1039%2Fb003562i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb003562i%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DX.-F.%26aulast%3DWilliams%26aufirst%3DH.%2BJ.%26aulast%3DScott%26aufirst%3DA.%2BI.%26atitle%3DFacile%2520and%2520highly%2520selective%25205%25E2%2580%25B2-desilylation%2520of%2520multisilylated%2520nucleosides%26jtitle%3DChem.%2520Soc.%2520Perkin.%2520Trans%25201%26date%3D2000%26spage%3D2305%26epage%3D2306%26doi%3D10.1039%2Fb003562i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srihari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagesh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiranmai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagesh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idris, M. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of readily accessible triazole-linked dimer deoxynucleoside phosphoramidite for solid-phase oligonucleotide synthesis</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2010</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">3710</span>– <span class="NLM_lpage">3714</span>, <span class="refDoi"> DOI: 10.1055/s-0030-1258243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1055%2Fs-0030-1258243" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=3710-3714&issue=21&author=S.+Chandrasekharauthor=P.+Srihariauthor=C.+Nageshauthor=N.+Kiranmaiauthor=N.+Nageshauthor=M.+M.+Idris&title=Synthesis+of+readily+accessible+triazole-linked+dimer+deoxynucleoside+phosphoramidite+for+solid-phase+oligonucleotide+synthesis&doi=10.1055%2Fs-0030-1258243"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1055%2Fs-0030-1258243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0030-1258243%26sid%3Dliteratum%253Aachs%26aulast%3DChandrasekhar%26aufirst%3DS.%26aulast%3DSrihari%26aufirst%3DP.%26aulast%3DNagesh%26aufirst%3DC.%26aulast%3DKiranmai%26aufirst%3DN.%26aulast%3DNagesh%26aufirst%3DN.%26aulast%3DIdris%26aufirst%3DM.%2BM.%26atitle%3DSynthesis%2520of%2520readily%2520accessible%2520triazole-linked%2520dimer%2520deoxynucleoside%2520phosphoramidite%2520for%2520solid-phase%2520oligonucleotide%2520synthesis%26jtitle%3DSynthesis%26date%3D2010%26volume%3D2010%26issue%3D21%26spage%3D3710%26epage%3D3714%26doi%3D10.1055%2Fs-0030-1258243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambabu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, A. S.</span></span> <span> </span><span class="NLM_article-title">Spirastrellolide B: the synthesis of southern (C<sub>9</sub>–C<sub>25</sub>) region</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4355</span>– <span class="NLM_lpage">4357</span>, <span class="refDoi"> DOI: 10.1021/ol801771s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol801771s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVymtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2008&pages=4355-4357&author=S.+Chandrasekharauthor=C.+Rambabuauthor=A.+S.+Reddy&title=Spirastrellolide+B%3A+the+synthesis+of+southern+%28C9%E2%80%93C25%29+region&doi=10.1021%2Fol801771s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Spirastrellolide B: The Synthesis of Southern (C9-C25) Region</span></div><div class="casAuthors">Chandrasekhar, Srivari; Rambabu, Chegondi; Reddy, Annareddy Syamprasad</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4355-4357</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A combination of "chiron" and "asym." approaches is utilized to construct the southern (C9-C25) region I of marine natural product spirastrellolide B.  The key functionalities are derived from D-glucose and Sharpless asym. epoxidn. and dihydroxylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPmmKafeZqqbVg90H21EOLACvtfcHk0liGnAiUONLlGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVymtb3J&md5=12debd71b48a856168402d9a6c4192f6</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fol801771s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol801771s%26sid%3Dliteratum%253Aachs%26aulast%3DChandrasekhar%26aufirst%3DS.%26aulast%3DRambabu%26aufirst%3DC.%26aulast%3DReddy%26aufirst%3DA.%2BS.%26atitle%3DSpirastrellolide%2520B%253A%2520the%2520synthesis%2520of%2520southern%2520%2528C9%25E2%2580%2593C25%2529%2520region%26jtitle%3DOrg.%2520Lett.%26date%3D2008%26volume%3D10%26spage%3D4355%26epage%3D4357%26doi%3D10.1021%2Fol801771s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span> <span> </span><span class="NLM_article-title">Human carboxylesterases: a comprehensive review</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2018.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1016%2Fj.apsb.2018.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=30245959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A280%3ADC%252BB3czhvVOjug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=699-712&author=D.+Wangauthor=L.+Zouauthor=Q.+Jinauthor=J.+Houauthor=G.+Geauthor=L.+Yang&title=Human+carboxylesterases%3A+a+comprehensive+review&doi=10.1016%2Fj.apsb.2018.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Human carboxylesterases: a comprehensive review</span></div><div class="casAuthors">Wang Dandan; Zou Liwei; Jin Qiang; Ge Guangbo; Yang Ling; Hou Jie</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">699-712</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Mammalian carboxylesterases (CEs) are key enzymes from the serine hydrolase superfamily.  In the human body, two predominant carboxylesterases (CES1 and CES2) have been identified and extensively studied over the past decade.  These two enzymes play crucial roles in the metabolism of a wide variety of endogenous esters, ester-containing drugs and environmental toxicants.  The key roles of CES in both human health and xenobiotic metabolism arouse great interest in the discovery of potent CES modulators to regulate endobiotic metabolism or to improve the efficacy of ester drugs.  This review covers the structural and catalytic features of CES, tissue distributions, biological functions, genetic polymorphisms, substrate specificities and inhibitor properties of CES1 and CES2, as well as the significance and recent progress on the discovery of CES modulators.  The information presented here will help pharmacologists explore the relevance of CES to human diseases or to assign the contribution of certain CES in xenobiotic metabolism.  It will also facilitate medicinal chemistry efforts to design prodrugs activated by a given CES isoform, or to develop potent and selective modulators of CES for potential biomedical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHzNUaecqdULHHuJhbyicZfW6udTcc2ebyDicL_mIkMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czhvVOjug%253D%253D&md5=4c0b70b0208577496c8e0270af5eda8e</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2018.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2018.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DL.%26atitle%3DHuman%2520carboxylesterases%253A%2520a%2520comprehensive%2520review%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2018%26volume%3D8%26spage%3D699%26epage%3D712%26doi%3D10.1016%2Fj.apsb.2018.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit39b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taketani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosokawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiba, K.</span></span> <span> </span><span class="NLM_article-title">Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1734</span>– <span class="NLM_lpage">1741</span>, <span class="refDoi"> DOI: 10.1124/dmd.106.009381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1124%2Fdmd.106.009381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=16837570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVCltbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=1734-1741&author=T.+Imaiauthor=M.+Taketaniauthor=M.+Shiiauthor=M.+Hosokawaauthor=K.+Chiba&title=Substrate+specificity+of+carboxylesterase+isozymes+and+their+contribution+to+hydrolase+activity+in+human+liver+and+small+intestine&doi=10.1124%2Fdmd.106.009381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine</span></div><div class="casAuthors">Imai, Teruko; Taketani, Megumi; Shii, Mayumi; Hosokawa, Masakiyo; Chiba, Kan</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1734-1741</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Hydrolase activity from human liver and small intestine microsomes was compared with that of recombinant human carboxylesterases, hCE-1 and hCE-2.  Although both hCE-1 and hCE-2 are present in human liver, the dominant component was found to be hCE-1, whereas the hydrolase activity of the human small intestine was found to be predominantly hCE-2.  HCE-2 has a limited ability to hydrolyze large acyl compd. substrates.  Interestingly, propranolol derivs., good substrates for hCE-2, were easily hydrolyzed by substitution of the Me group on the 2-position of the acyl moiety, but were barely hydrolyzed when the Me group was substituted on the 3-position.  These findings suggest that hCE-2 does not easily form acylated intermediates because of conformational interference in its active site.  In contrast, hCE-1 could hydrolyze a variety of substrates.  The hydrolytic activity of hCE-2 increased with increasing alc. chain length in benzoic acid deriv. substrates, whereas hCE-1 preferentially catalyzed the hydrolysis of substrates with short alc. chains.  Kinetic data showed that the detg. factor for the rate of hydrolysis of p-aminobenzoic acid esters was Vmax for hCE-1 and Km for hCE-2.  Furthermore, the addn. of hydrophobic alcs. to the reaction mixt. with p-aminobenzoic acid Pr ester induced high and low levels of transesterification by hCE-1 and hCE-2, resp.  When considering the substrate specificities of hCE-1, it is necessary to consider the transesterification ability of hCE-1, in addn. to the binding structure of the substrate in the active site of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_5Qby7_S88LVg90H21EOLACvtfcHk0lj1PjeWULvk4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVCltbvI&md5=b2d3c1d2aee89b647e1c8030daee8c3a</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.106.009381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.106.009381%26sid%3Dliteratum%253Aachs%26aulast%3DImai%26aufirst%3DT.%26aulast%3DTaketani%26aufirst%3DM.%26aulast%3DShii%26aufirst%3DM.%26aulast%3DHosokawa%26aufirst%3DM.%26aulast%3DChiba%26aufirst%3DK.%26atitle%3DSubstrate%2520specificity%2520of%2520carboxylesterase%2520isozymes%2520and%2520their%2520contribution%2520to%2520hydrolase%2520activity%2520in%2520human%2520liver%2520and%2520small%2520intestine%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D1734%26epage%3D1741%26doi%3D10.1124%2Fdmd.106.009381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Birkus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutty, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacArthur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, M.</span></span> <span> </span><span class="NLM_article-title">Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1128/AAC.00968-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1128%2FAAC.00968-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=17145787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=543-550&author=G.+Birkusauthor=R.+Wangauthor=X.+Liuauthor=N.+Kuttyauthor=H.+MacArthurauthor=T.+Cihlarauthor=C.+Gibbsauthor=S.+Swaminathanauthor=W.+Leeauthor=M.+McDermott&title=Cathepsin+A+is+the+major+hydrolase+catalyzing+the+intracellular+hydrolysis+of+the+antiretroviral+nucleotide+phosphonoamidate+prodrugs+GS-7340+and+GS-9131&doi=10.1128%2FAAC.00968-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131</span></div><div class="casAuthors">Birkus, Gabriel; Wang, Ruth; Liu, Xiaohong; Kutty, Nilima; MacArthur, Holly; Cihlar, Tomas; Gibbs, Craig; Swaminathan, Swami; Lee, William; McDermott, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">543-550</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">GS-7340 and GS-9131 {9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine and 9-(R)-4'-(R)-[[[(S)-1-[(ethoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]-2'-fluoro-1'-furanyladenine, resp.} are novel alkylalaninyl Ph ester prodrugs of tenofovir {9-R-[(2-phosphonomethoxy)propyl]adenine} (TFV) and a cyclic nucleotide analog, GS-9148 (phosphonomethoxy-2'-fluoro-2',3'-dideoxydidehydroadenosine), resp.  Both prodrugs exhibit potent antiretroviral activity against both wild-type and drug-resistant human immunodeficiency virus type 1 strains and excellent in vivo pharmacokinetic properties.  In this study, the main enzymic activity responsible for the initial step in the intracellular activation of GS-7340 and GS-9131 was isolated from human peripheral blood mononuclear cells and identified as lysosomal carboxypeptidase A (cathepsin A [CatA]; EC 3.4.16.5).  Biochem. properties of the purified hydrolase (native complex and catalytic subunit mol. masses of 100 and 29 kDa, resp.; isoelec. point [pI] of 5.5) matched those of CatA.  Recombinant CatA and the isolated prodrug hydrolase displayed identical susceptibilities to inhibitors and identical substrate preferences toward a panel of tenofovir phosphonoamidate prodrugs.  Incubation of both enzymes with 14C-labeled GS-7340 or [3H]difluorophosphonate resulted in the covalent labeling of identical 29-kDa catalytic subunits.  Finally, following a 4-h incubation with GS-7340 and GS-9131, the intracellular concns. of prodrug metabolites detected in CatA-neg. fibroblasts were approx. 7.5- and 3-fold lower, resp., than those detected in normal control fibroblasts.  Collectively, these data demonstrate the key role of CatA in the intracellular activation of nucleotide phosphonoamidate prodrugs and open new possibilities for further improvement of this important class of antiviral prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr00GVCN10SLVg90H21EOLACvtfcHk0lj1PjeWULvk4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOqu70%253D&md5=3c9bbdfaf343f9a0fed9e4d584c3565b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1128%2FAAC.00968-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00968-06%26sid%3Dliteratum%253Aachs%26aulast%3DBirkus%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKutty%26aufirst%3DN.%26aulast%3DMacArthur%26aufirst%3DH.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DGibbs%26aufirst%3DC.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DM.%26atitle%3DCathepsin%2520A%2520is%2520the%2520major%2520hydrolase%2520catalyzing%2520the%2520intracellular%2520hydrolysis%2520of%2520the%2520antiretroviral%2520nucleotide%2520phosphonoamidate%2520prodrugs%2520GS-7340%2520and%2520GS-9131%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2007%26volume%3D51%26spage%3D543%26epage%3D550%26doi%3D10.1128%2FAAC.00968-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lapidot, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vormoor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murdoch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caceres-Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, J. E.</span></span> <span> </span><span class="NLM_article-title">A cell initiating human acute myeloid leukaemia after transplantation into SCID mice</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">645</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1038/367645a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1038%2F367645a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=7509044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A280%3ADyaK2c7ltVKrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=1994&pages=645-648&author=T.+Lapidotauthor=C.+Sirardauthor=J.+Vormoorauthor=B.+Murdochauthor=T.+Hoangauthor=J.+Caceres-Cortesauthor=M.+Mindenauthor=B.+Patersonauthor=M.+A.+Caligiuriauthor=J.+E.+Dick&title=A+cell+initiating+human+acute+myeloid+leukaemia+after+transplantation+into+SCID+mice&doi=10.1038%2F367645a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A cell initiating human acute myeloid leukaemia after transplantation into SCID mice</span></div><div class="casAuthors">Lapidot T; Sirard C; Vormoor J; Murdoch B; Hoang T; Caceres-Cortes J; Minden M; Paterson B; Caligiuri M A; Dick J E</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">6464</span>),
    <span class="NLM_cas:pages">645-8</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">Most human acute myeloid leukaemia (AML) cells have limited proliferative capacity, suggesting that the leukaemic clone may be maintained by a rare population of stem cells.  This putative leukaemic stem cell has not been characterized because the available in vitro assays can only detect progenitors with limited proliferative and replating potential.  We have now identified an AML-initiating cell by transplantation into severe combined immune-deficient (SCID) mice.  These cells homed to the bone marrow and proliferated extensively in response to in vivo cytokine treatment, resulting in a pattern of dissemination and leukaemic cell morphology similar to that seen in the original patients.  Limiting dilution analysis showed that the frequency of these leukaemia-initiating cells in the peripheral blood of AML patients was one engraftment unit in 250,000 cells.  We fractionated AML cells on the basis of cell-surface-marker expression and found that the leukaemia-initiating cells that could engraft SCID mice to produce large numbers of colony-forming progenitors were CD34+ CD38-; however, the CD34+ CD38+ and CD34- fractions contained no cells with these properties.  This in vivo model replicates many aspects of human AML and defines a new leukaemia-initiating cell which is less mature than colony-forming cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvfHJZ5BZZYP3jf77P2BG3fW6udTcc2ebyDicL_mIkMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c7ltVKrsg%253D%253D&md5=692809a03a33f917ae2815cedadb7973</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2F367645a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F367645a0%26sid%3Dliteratum%253Aachs%26aulast%3DLapidot%26aufirst%3DT.%26aulast%3DSirard%26aufirst%3DC.%26aulast%3DVormoor%26aufirst%3DJ.%26aulast%3DMurdoch%26aufirst%3DB.%26aulast%3DHoang%26aufirst%3DT.%26aulast%3DCaceres-Cortes%26aufirst%3DJ.%26aulast%3DMinden%26aufirst%3DM.%26aulast%3DPaterson%26aufirst%3DB.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DDick%26aufirst%3DJ.%2BE.%26atitle%3DA%2520cell%2520initiating%2520human%2520acute%2520myeloid%2520leukaemia%2520after%2520transplantation%2520into%2520SCID%2520mice%26jtitle%3DNature%26date%3D1994%26volume%3D367%26spage%3D645%26epage%3D648%26doi%3D10.1038%2F367645a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Phi, L. T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sari, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, H. Y.</span></span> <span> </span><span class="NLM_article-title">Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment</span>. <i>Stem Cells Int.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2018</i></span>,  <span class="NLM_fpage">5416923</span>, <span class="refDoi"> DOI: 10.1155/2018/5416923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1155%2F2018%2F5416923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=29681949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A280%3ADC%252BC1MjltlGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2018&publication_year=2018&pages=5416923&author=L.+T.+H.+Phiauthor=I.+N.+Sariauthor=Y.-G.+Yangauthor=S.-H.+Leeauthor=N.+Junauthor=K.+S.+Kimauthor=Y.+K.+Leeauthor=H.+Y.+Kwon&title=Cancer+stem+cells+%28CSCs%29+in+drug+resistance+and+their+therapeutic+implications+in+cancer+treatment&doi=10.1155%2F2018%2F5416923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment</span></div><div class="casAuthors">Phi Lan Thi Hanh; Sari Ita Novita; Yang Ying-Gui; Lee Sang-Hyun; Jun Nayoung; Kim Kwang Seock; Lee Yun Kyung; Kwon Hyog Young</div><div class="citationInfo"><span class="NLM_cas:title">Stem cells international</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2018</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5416923</span>
        ISSN:<span class="NLM_cas:issn">1687-966X</span>.
    </div><div class="casAbstract">Cancer stem cells (CSCs), also known as tumor-initiating cells (TICs), are suggested to be responsible for drug resistance and cancer relapse due in part to their ability to self-renew themselves and differentiate into heterogeneous lineages of cancer cells.  Thus, it is important to understand the characteristics and mechanisms by which CSCs display resistance to therapeutic agents.  In this review, we highlight the key features and mechanisms that regulate CSC function in drug resistance as well as recent breakthroughs of therapeutic approaches for targeting CSCs.  This promises new insights of CSCs in drug resistance and provides better therapeutic rationales to accompany novel anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ832gT2olHIa91pGlMMoT5fW6udTcc2eY5VxHQbQA1obntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjltlGgsQ%253D%253D&md5=e90fa5e53fbb5ccf47d267ce645daf2a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1155%2F2018%2F5416923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2018%252F5416923%26sid%3Dliteratum%253Aachs%26aulast%3DPhi%26aufirst%3DL.%2BT.%2BH.%26aulast%3DSari%26aufirst%3DI.%2BN.%26aulast%3DYang%26aufirst%3DY.-G.%26aulast%3DLee%26aufirst%3DS.-H.%26aulast%3DJun%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DLee%26aufirst%3DY.%2BK.%26aulast%3DKwon%26aufirst%3DH.%2BY.%26atitle%3DCancer%2520stem%2520cells%2520%2528CSCs%2529%2520in%2520drug%2520resistance%2520and%2520their%2520therapeutic%2520implications%2520in%2520cancer%2520treatment%26jtitle%3DStem%2520Cells%2520Int.%26date%3D2018%26volume%3D2018%26spage%3D5416923%26doi%3D10.1155%2F2018%2F5416923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paschall, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redd, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak-Kapoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span> <span> </span><span class="NLM_article-title">CD133<sup>+</sup>CD24<sup>lo</sup> defines a 5-fluorouracil-resistant colon cancer stem cell-like phenotype</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">78698</span>– <span class="NLM_lpage">78712</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.12168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.18632%2Foncotarget.12168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=27659530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A280%3ADC%252BC2svjtFKmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=78698-78712&author=A.+V.+Paschallauthor=D.+Yangauthor=C.+Luauthor=P.+S.+Reddauthor=J.-H.+Choiauthor=C.+M.+Heatonauthor=J.+R.+Leeauthor=A.+Nayak-Kapoorauthor=K.+Liu&title=CD133%2BCD24lo+defines+a+5-fluorouracil-resistant+colon+cancer+stem+cell-like+phenotype&doi=10.18632%2Foncotarget.12168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">CD133+CD24lo defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype</span></div><div class="casAuthors">Paschall Amy V; Yang Dafeng; Lu Chunwan; Redd Priscilla S; Liu Kebin; Paschall Amy V; Redd Priscilla S; Choi Jeong-Hyeon; Nayak-Kapoor Asha; Liu Kebin; Paschall Amy V; Yang Dafeng; Lu Chunwan; Redd Priscilla S; Heaton Christopher M; Lee Jeffrey R; Nayak-Kapoor Asha; Liu Kebin</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">78698-78712</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The chemotherapeutic agent 5-Fluorouracil (5-FU) is the most commonly used drug for patients with advanced colon cancer.  However, development of resistance to 5-FU is inevitable in almost all patients.  The mechanism by which colon cancer develops 5-FU resistance is still unclear.  One recently proposed theory is that cancer stem-like cells underlie colon cancer 5-FU resistance, but the phenotypes of 5-FU-resistant colon cancer stem cells are still controversial.  We report here that 5-FU treatment selectively enriches a subset of CD133+ colon cancer cells in vitro. 5-FU chemotherapy also increases CD133+ tumor cells in human colon cancer patients.  However, sorted CD133+ colon cancer cells exhibit no increased resistance to 5-FU, and CD133 levels exhibit no correlation with colon cancer patient survival or cancer recurrence.  Genome-wide analysis of gene expression between sorted CD133+ colon cancer cells and 5-FU-selected colon cancer cells identifies 207 differentially expressed genes.  CD24 is one of the genes whose expression level is lower in the CD133+ and 5-FU-resistant colon cancer cells as compared to CD133+ and 5-FU-sensitive colon cancer cells.  Consequently, CD133+CD24lo cells exhibit decreased sensitivity to 5-FU.  Therefore, we determine that CD133+CD24lo phenotype defines 5-FU-resistant human colon cancer stem cell-like cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSLzFZSPREW4mZyxfu64m4ffW6udTcc2eY5VxHQbQA1obntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svjtFKmtw%253D%253D&md5=3f185f29fce66d62364a40e57c0a3312</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.12168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.12168%26sid%3Dliteratum%253Aachs%26aulast%3DPaschall%26aufirst%3DA.%2BV.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DRedd%26aufirst%3DP.%2BS.%26aulast%3DChoi%26aufirst%3DJ.-H.%26aulast%3DHeaton%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BR.%26aulast%3DNayak-Kapoor%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DK.%26atitle%3DCD133%252BCD24lo%2520defines%2520a%25205-fluorouracil-resistant%2520colon%2520cancer%2520stem%2520cell-like%2520phenotype%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D78698%26epage%3D78712%26doi%3D10.18632%2Foncotarget.12168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
den broeck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gremeaux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vankelecom, H.</span></span> <span> </span><span class="NLM_article-title">Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">354</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-12-354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1186%2F1471-2407-12-354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=22894607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVWksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=354&author=A.+Van%0Aden+broeckauthor=L.+Gremeauxauthor=B.+Topalauthor=H.+Vankelecom&title=Human+pancreatic+adenocarcinoma+contains+a+side+population+resistant+to+gemcitabine&doi=10.1186%2F1471-2407-12-354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine</span></div><div class="casAuthors">Van den Broeck, Anke; Gremeaux, Lies; Topal, Baki; Vankelecom, Hugo</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">354</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Therapy resistance remains one of the major challenges to improve the prognosis of patients with pancreatic cancer.  Chemoresistant cells, which potentially also display cancer stem cell (CSC) characteristics, can be isolated using the side population (SP) technique.  Our aim was to search for a SP in human pancreatic ductal adenocarcinoma (PDAC) and to examine its chemoresistance and CSC(-like) phenotype.  Human PDAC samples were expanded in immunodeficient mice and first-generation xenografts analyzed for the presence of a Hoechst dye-effluxing SP using flow cytometry (FACS).  To investigate chemoresistance of the SP, mice bearing PDAC xenografts were treated with gemcitabine and SP proportion detd.  In addn., the SP and the main tumor cell population (MP) were sorted by FACS for RNA extn. to profile gene expression, and for culturing under sphere-forming conditions.  A SP was identified in all PDAC samples, analyzed.  This SP was more resistant to gemcitabine than the other tumor cells as examd. in vivo.  Whole-genome expression profiling of the SP revealed upregulation of genes related to therapy resistance, apoptotic regulation and epithelial-mesenchymal transition.  In addn., the SP displayed higher tumorigenic (CSC) activity than the MP as analyzed in vitro by sphere-forming capacity.  We identified a SP in human PDAC and uncovered a chemoresistant and CSC-assocd. phenotype.  This SP may represent a new therapeutic target in pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8IT1GV23OBLVg90H21EOLACvtfcHk0lg6rmdARiO_ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVWksg%253D%253D&md5=6c07bca506dca82bb29b89f235b0ecdf</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-12-354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-12-354%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2Bbroeck%26aufirst%3DA.%26aulast%3DGremeaux%26aufirst%3DL.%26aulast%3DTopal%26aufirst%3DB.%26aulast%3DVankelecom%26aufirst%3DH.%26atitle%3DHuman%2520pancreatic%2520adenocarcinoma%2520contains%2520a%2520side%2520population%2520resistant%2520to%2520gemcitabine%26jtitle%3DBMC%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D354%26doi%3D10.1186%2F1471-2407-12-354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeijlemaker, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meijer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanekamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbaat-Ham, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oussoren-Brockhoff, Y. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snel, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veldhuizen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholten, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maertens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breems, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manz, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Velden, V. H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slomp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preijers, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Loosdrecht, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löwenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valk, P. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jongen-Lavrencic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ossenkoppele, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuurhuis, G. J.</span></span> <span> </span><span class="NLM_article-title">CD34<sup>+</sup> CD38<sup>–</sup> leukemic stem cell frequency to predict outcome in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1102</span>– <span class="NLM_lpage">1112</span>, <span class="refDoi"> DOI: 10.1038/s41375-018-0326-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1038%2Fs41375-018-0326-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=30542144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSmsb%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2019&pages=1102-1112&author=W.+Zeijlemakerauthor=T.+Grobauthor=R.+Meijerauthor=D.+Hanekampauthor=A.+Kelderauthor=J.+C.+Carbaat-Hamauthor=Y.+J.+M.+Oussoren-Brockhoffauthor=A.+N.+Snelauthor=D.+Veldhuizenauthor=W.+J.+Scholtenauthor=J.+Maertensauthor=D.+A.+Breemsauthor=T.+Pabstauthor=M.+G.+Manzauthor=V.+H.+J.+van+der+Veldenauthor=J.+Slompauthor=F.+Preijersauthor=J.+Cloosauthor=A.+A.+van+de+Loosdrechtauthor=B.+L%C3%B6wenbergauthor=P.+J.+M.+Valkauthor=M.+Jongen-Lavrencicauthor=G.+J.+Ossenkoppeleauthor=G.+J.+Schuurhuis&title=CD34%2B+CD38%E2%80%93+leukemic+stem+cell+frequency+to+predict+outcome+in+acute+myeloid+leukemia&doi=10.1038%2Fs41375-018-0326-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia</span></div><div class="casAuthors">Zeijlemaker, Wendelien; Grob, Tim; Meijer, Rosa; Hanekamp, Diana; Kelder, Angele; Carbaat-Ham, Jannemieke C.; Oussoren-Brockhoff, Yvonne J. M.; Snel, Alexander N.; Veldhuizen, Dennis; Scholten, Willemijn J.; Maertens, Johan; Breems, Dimitri A.; Pabst, Thomas; Manz, Markus G.; van der Velden, Vincent H. J.; Slomp, Jennichjen; Preijers, Frank; Cloos, Jacqueline; van de Loosdrecht, Arjan A.; Loewenberg, Bob; Valk, Peter J. M.; Jongen-Lavrencic, Mojca; Ossenkoppele, Gert J.; Schuurhuis, Gerrit J.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1102-1112</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Current risk algorithms are primarily based on pre-treatment factors and imperfectly predict outcome in acute myeloid leukemia (AML).  We introduce and validate a post-treatment approach of leukemic stem cell (LSC) assessment for prediction of outcome.  LSC contg. CD34+CD38- fractions were measured using flow cytometry in an add-on study of the HOVON102/SAKK trial.  Predefined cut-off levels were prospectively evaluated to assess CD34+CD38-LSC levels at diagnosis (n = 594), and, to identify LSClow/LSChigh (n = 302) and MRDlow/MRDhigh patients (n = 305) in bone marrow in morphol. complete remission (CR).  In 242 CR patients combined MRD and LSC results were available.  At diagnosis the CD34+CD38- LSC frequency independently predicts overall survival (OS).  After achieving CR, combining LSC and MRD showed reduced survival in MRDhigh/LSChigh patients (hazard ratio [HR] 3.62 for OS and 5.89 for cumulative incidence of relapse [CIR]) compared to MRDlow/LSChigh, MRDhigh/LSClow, and esp. MRDlow/LSClow patients.  Moreover, in the NPM1mutant pos. sub-group, prognostic value of golden std. NPM1-MRD by qPCR can be improved by addn. of flow cytometric approaches.  This is the first prospective study demonstrating that LSC strongly improves prognostic impact of MRD detection, identifying a patient subgroup with an almost 100% treatment failure probability, warranting consideration of LSC measurement incorporation in future AML risk schemes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqo_rnaNXF9LVg90H21EOLACvtfcHk0liVOOsaq6_VXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSmsb%252FF&md5=4cab3f5320b2ae12655cf9c3896cc4f1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fs41375-018-0326-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-018-0326-3%26sid%3Dliteratum%253Aachs%26aulast%3DZeijlemaker%26aufirst%3DW.%26aulast%3DGrob%26aufirst%3DT.%26aulast%3DMeijer%26aufirst%3DR.%26aulast%3DHanekamp%26aufirst%3DD.%26aulast%3DKelder%26aufirst%3DA.%26aulast%3DCarbaat-Ham%26aufirst%3DJ.%2BC.%26aulast%3DOussoren-Brockhoff%26aufirst%3DY.%2BJ.%2BM.%26aulast%3DSnel%26aufirst%3DA.%2BN.%26aulast%3DVeldhuizen%26aufirst%3DD.%26aulast%3DScholten%26aufirst%3DW.%2BJ.%26aulast%3DMaertens%26aufirst%3DJ.%26aulast%3DBreems%26aufirst%3DD.%2BA.%26aulast%3DPabst%26aufirst%3DT.%26aulast%3DManz%26aufirst%3DM.%2BG.%26aulast%3Dvan%2Bder%2BVelden%26aufirst%3DV.%2BH.%2BJ.%26aulast%3DSlomp%26aufirst%3DJ.%26aulast%3DPreijers%26aufirst%3DF.%26aulast%3DCloos%26aufirst%3DJ.%26aulast%3Dvan%2Bde%2BLoosdrecht%26aufirst%3DA.%2BA.%26aulast%3DL%25C3%25B6wenberg%26aufirst%3DB.%26aulast%3DValk%26aufirst%3DP.%2BJ.%2BM.%26aulast%3DJongen-Lavrencic%26aufirst%3DM.%26aulast%3DOssenkoppele%26aufirst%3DG.%2BJ.%26aulast%3DSchuurhuis%26aufirst%3DG.%2BJ.%26atitle%3DCD34%252B%2520CD38%25E2%2580%2593%2520leukemic%2520stem%2520cell%2520frequency%2520to%2520predict%2520outcome%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2019%26volume%3D33%26spage%3D1102%26epage%3D1112%26doi%3D10.1038%2Fs41375-018-0326-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesnowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löhr, J. M.</span></span> <span> </span><span class="NLM_article-title">Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1593/neo.10576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1593%2Fneo.10576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=20824050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGmtrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=740-747&author=W.+Hagmannauthor=R.+Jesnowskiauthor=J.+M.+L%C3%B6hr&title=Interdependence+of+gemcitabine+treatment%2C+transporter+expression%2C+and+resistance+in+human+pancreatic+carcinoma+cells&doi=10.1593%2Fneo.10576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Interdependence of gemcitabine treatment, transporter expression and resistance in human pancreatic carcinoma cells</span></div><div class="casAuthors">Hagmann, Wolfgang; Jesnowski, Ralf; Loehr, Johannes Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">740-747</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">Gemcitabine is widely used as first-line chemotherapeutic drug in the treatment of pancreatic cancer.  Our previous exptl. chemotherapy studies have shown that treatment of human pancreatic carcinoma cells with 5-fluorouracil (5-FU) alters the cellular transporter expression profile and that modulation of the expression of multidrug resistance protein 5 (MRP5; ABCC5) influences the chemoresistance of these tumor cells.  Here, we studied the influence of acute and chronic gemcitabine treatment on the expression of relevant uptake and export transporters in pancreatic carcinoma cells by reverse transcription-polymerase chain reaction (RT-PCR), quant. RT-PCR, and immunoblot analyses.  The specific role of MRP5 in cellular gemcitabine sensitivity was studied by cytotoxicity assays using MRP5-overexpressing and MRP5-silenced cells.  Exposure to gemcitabine (12 nMfor 3 days) did not alter themessenger RNA (mRNA) expression of MRP1, MRP3, MRP5, and equilibrative nucleoside transporter 1 (ENT1), whereas high dosages of the drug (20 μMfor 1 h) elicited up-regulation of these transporters in most cell lines studied.  In cells with acquired gemcitabine resistance (up to 160 nM gemcitabine), the mRNA or protein expression of the gemcitabine transporters MRP5 and ENT1 was upregulated in several cell lines.  Combined treatment with 5-FU and gemcitabine caused a 5- to 40-fold increase in MRP5and ENT1 expressions.  Cytotoxicity assays using either MRP5-overexpressing (HEK and PANC-1) or MRP5-silenced (PANC1/shMRP5) cells indicated that MRP5 contributes to gemcitabine resistance.  Thus, our novel data not only on drug-induced alterations of transporter expression relevant for gemcitabine uptake and export but also on the link between gemcitabine sensitivity and MRP5 expression may lead to improved strategies of future chemotherapy regimens using gemcitabine in pancreatic carcinoma patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI6qrw-xP49LVg90H21EOLACvtfcHk0liVOOsaq6_VXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGmtrfL&md5=4e38efcac8f7073a285749fe7b2bb395</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1593%2Fneo.10576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.10576%26sid%3Dliteratum%253Aachs%26aulast%3DHagmann%26aufirst%3DW.%26aulast%3DJesnowski%26aufirst%3DR.%26aulast%3DL%25C3%25B6hr%26aufirst%3DJ.%2BM.%26atitle%3DInterdependence%2520of%2520gemcitabine%2520treatment%252C%2520transporter%2520expression%252C%2520and%2520resistance%2520in%2520human%2520pancreatic%2520carcinoma%2520cells%26jtitle%3DNeoplasia%26date%3D2010%26volume%3D12%26spage%3D740%26epage%3D747%26doi%3D10.1593%2Fneo.10576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Dynamic quantitative detection of ABC transporter family promoter methylation by MS-HRM for predicting MDR in pancreatic cancer</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5602</span>– <span class="NLM_lpage">5610</span>, <span class="refDoi"> DOI: 10.3892/ol.2018.8041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.3892%2Fol.2018.8041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=29552197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A280%3ADC%252BC1MnisVagtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=5602-5610&author=L.+Yaoauthor=J.+Guauthor=Y.+Maoauthor=X.+Zhangauthor=X.+Wangauthor=C.+Jinauthor=D.+Fuauthor=J.+Li&title=Dynamic+quantitative+detection+of+ABC+transporter+family+promoter+methylation+by+MS-HRM+for+predicting+MDR+in+pancreatic+cancer&doi=10.3892%2Fol.2018.8041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic quantitative detection of ABC transporter family promoter methylation by MS-HRM for predicting MDR in pancreatic cancer</span></div><div class="casAuthors">Yao Lie; Gu Jichun; Wang Xiaoyi; Jin Chen; Fu Deliang; Li Ji; Mao Yishen; Zhang Xinju</div><div class="citationInfo"><span class="NLM_cas:title">Oncology letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">5602-5610</span>
        ISSN:<span class="NLM_cas:issn">1792-1074</span>.
    </div><div class="casAbstract">The main focus of the present study was to evaluate whether ABC transporter family promoter methylation predicted multidrug resistance in gemcitabine-resistant cancer cell lines (BxPC-3/Gem and PANC-1/Gem).  Using low concentrations of gemcitabine, the cell lines acquired drug resistance with different initial gemcitabine concentrations.  A novel technology, methylation-sensitive high-resolution melting, was used to monitor the dynamic changes of ABC transporter family promoter methylation, including ATP binding cassette subfamily B member 1 (ABCB1), ATP binding cassette subfamily C (ABCC) and ATP binding cassette subfamily G member 2 (ABCG2) mRNA expression.  It was revealed that, with elevation of initial gemcitabine concentration, expression of ABCB1, ABCC and ABCG2 mRNA and corresponding downstream proteins was increased while promoter methylation was decreased.  These discoveries indicate that promoter methylation of ABCB1, ABCC and ABCG2 may be a valuable indicator of drug-resistance characteristics in BxPC-3/Gem and PANC-1/Gem cells via quantitative and simultaneous detection.  These results also implied that MDR in pancreatic cancer not only arises from gene mutation, but also originates from promoter methylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrppWwtIoRB_xQvRxYU81tfW6udTcc2ebawK-CtHQ0KLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnisVagtQ%253D%253D&md5=ac4fa79d89fbf5e53d661d4b550b3b48</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3892%2Fol.2018.8041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2018.8041%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DC.%26aulast%3DFu%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DDynamic%2520quantitative%2520detection%2520of%2520ABC%2520transporter%2520family%2520promoter%2520methylation%2520by%2520MS-HRM%2520for%2520predicting%2520MDR%2520in%2520pancreatic%2520cancer%26jtitle%3DOncol.%2520Lett.%26date%3D2018%26volume%3D15%26spage%3D5602%26epage%3D5610%26doi%3D10.3892%2Fol.2018.8041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahar, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamshidi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurston, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, K. M.</span></span> <span> </span><span class="NLM_article-title">Effects of systematic shortening of noncovalent C8 side chain on the cytotoxicity and NF-κB inhibitory capacity of pyrrolobenzodiazepines (PBDs)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2139</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01849</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01849" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFGqtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2127-2139&author=D.+B.+Corcoranauthor=T.+Lewisauthor=K.+S.+Naharauthor=S.+Jamshidiauthor=C.+Feganauthor=C.+Pepperauthor=D.+E.+Thurstonauthor=K.+M.+Rahman&title=Effects+of+systematic+shortening+of+noncovalent+C8+side+chain+on+the+cytotoxicity+and+NF-%CE%BAB+inhibitory+capacity+of+pyrrolobenzodiazepines+%28PBDs%29&doi=10.1021%2Facs.jmedchem.8b01849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of systematic shortening of noncovalent C8 side chain on the cytotoxicity and NF-κB inhibitory capacity of pyrrolobenzodiazepines (PBDs)</span></div><div class="casAuthors">Corcoran, David B.; Lewis, Thomas; Nahar, Kazi S.; Jamshidi, Shirin; Fegan, Christopher; Pepper, Chris; Thurston, David E.; Rahman, Khondaker Miraz.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2127-2139</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The systematic shortening of the noncovalent element of a C8-linked pyrrolobenzodiazepine (PBD) conjugate (13 (I)) led to the synthesis of a 19-member library of C8-PBD monomers.  The crit. elements of I, which were required to render the mol. cytotoxic, were elucidated by an annexin V assay.  The effects of shortening the noncovalent element of the mol. on transcription factor inhibitory capacity were also explored through an ELISA-based measurement of nuclear NF-κB upon exposure of JJN-3 cells to the synthesized mols.  Although shortening the noncovalent interactive element of I had a less than expected effect upon compd. cytotoxicity due to reduced DNA interaction, the transcription factor inhibitory capacity of the mol. was notably altered.  This study suggests that a relatively short noncovalent side chain at the C8 position of PBD is sufficient to confer cytotoxicity.  The shortened PBD monomers provide a new ADC payload scaffold because of their potent cytotoxicity and drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1QpMyNWLdrLVg90H21EOLACvtfcHk0lj4W29aO128vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFGqtbw%253D&md5=d3ca1bce21120b93b211fd905e471886</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01849%26sid%3Dliteratum%253Aachs%26aulast%3DCorcoran%26aufirst%3DD.%2BB.%26aulast%3DLewis%26aufirst%3DT.%26aulast%3DNahar%26aufirst%3DK.%2BS.%26aulast%3DJamshidi%26aufirst%3DS.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26atitle%3DEffects%2520of%2520systematic%2520shortening%2520of%2520noncovalent%2520C8%2520side%2520chain%2520on%2520the%2520cytotoxicity%2520and%2520NF-%25CE%25BAB%2520inhibitory%2520capacity%2520of%2520pyrrolobenzodiazepines%2520%2528PBDs%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2127%26epage%3D2139%26doi%3D10.1021%2Facs.jmedchem.8b01849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, G. M.</span></span> <span> </span><span class="NLM_article-title">A short history of <i>SHELX</i></span>. <i>Acta Crystallogr., Sect. A: Found. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">112</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1107/S0108767307043930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1107%2FS0108767307043930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=18156677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVGhurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=112-122&author=G.+M.+Sheldrick&title=A+short+history+of+SHELX&doi=10.1107%2FS0108767307043930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">A short history of SHELX</span></div><div class="casAuthors">Sheldrick, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section A: Foundations of Crystallography</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">112-122</span>CODEN:
                <span class="NLM_cas:coden">ACACEQ</span>;
        ISSN:<span class="NLM_cas:issn">0108-7673</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">An account is given of the development of the SHELX system of computer programs from SHELX-76 to the present day.  In addn. to identifying useful innovations that have come into general use through their implementation in SHELX, a crit. anal. is presented of the less-successful features, missed opportunities and desirable improvements for future releases of the software.  An attempt is made to understand how a program originally designed for photog. intensity data, punched cards and computers over 10000 times slower than an av. modern personal computer has managed to survive for so long.  SHELXL is the most widely used program for small-mol. refinement and SHELXS and SHELXD are often employed for structure soln. despite the availability of objectively superior programs.  SHELXL also finds a niche for the refinement of macromols. against high-resoln. or twinned data; SHELXPRO acts as an interface for macromol. applications.  SHELXC, SHELXD and SHELXE are proving useful for the exptl. phasing of macromols., esp. because they are fast and robust and so are often employed in pipelines for high-throughput phasing.  This paper could serve as a general literature citation when one or more of the open-source SHELX programs (and the Bruker AXS version SHELXTL) are employed in the course of a crystal-structure detn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfLPYyJyJ2RbVg90H21EOLACvtfcHk0lj4W29aO128vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVGhurzO&md5=8f91f10be4a9df74b2a9dad522c71e6e</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1107%2FS0108767307043930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0108767307043930%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26atitle%3DA%2520short%2520history%2520of%2520SHELX%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520A%253A%2520Found.%2520Crystallogr.%26date%3D2008%26volume%3D64%26spage%3D112%26epage%3D122%26doi%3D10.1107%2FS0108767307043930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheldrick, G. M.</span></span> <span> </span><span class="NLM_article-title"><i>SHELXT</i> – Integrated space-group and crystal-structure determination</span>. <i>Acta Crystallogr., Sect. C: Struct. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1107/S2053229614024218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=10.1107%2FS2053229614024218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=25643710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFaqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=3-8&author=G.+M.+Sheldrick&title=SHELXT+%E2%80%93+Integrated+space-group+and+crystal-structure+determination&doi=10.1107%2FS2053229614024218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure refinement with SHELXL</span></div><div class="casAuthors">Sheldrick, George M.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section C: Structural Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-8</span>CODEN:
                <span class="NLM_cas:coden">ACSCGG</span>;
        ISSN:<span class="NLM_cas:issn">2053-2296</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The improvements in the crystal structure refinement program SHELXL have been closely coupled with the development and increasing importance of the CIF (Crystallog. Information Framework) format for validating and archiving crystal structures.  An important simplification is that now only one file in CIF format (for convenience, referred to simply as 'a CIF') contg. embedded reflection data and SHELXL instructions is needed for a complete structure archive; the program SHREDCIF can be used to ext. the and files required for further refinement with SHELXL.  Recent developments in SHELXL facilitate refinement against neutron diffraction data, the treatment of H atoms, the detn. of abs. structure, the input of partial structure factors and the refinement of twinned and disordered structures.  SHELXL is available free to academics for the Windows, Linux and Mac OS X operating systems, and is particularly suitable for multiple-core processors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk1_pNHwXR7Vg90H21EOLACvtfcHk0lj4W29aO128vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFaqug%253D%253D&md5=4a860804b50fc183e8a701098b98ef59</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1107%2FS2053229614024218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053229614024218%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrick%26aufirst%3DG.%2BM.%26atitle%3DSHELXT%2520%25E2%2580%2593%2520Integrated%2520space-group%2520and%2520crystal-structure%2520determination%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520C%253A%2520Struct.%2520Chem.%26date%3D2015%26volume%3D71%26spage%3D3%26epage%3D8%26doi%3D10.1107%2FS2053229614024218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i40"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02194">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_88446"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02194?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02194</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Compound molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02194/suppl_file/jm0c02194_si_001.csv">CSV</a>)</p></li><li><p class="inline">Carboxypeptidase Y assay for NUC-3373_isoB, <b>10a</b>, and <b>10b</b> (Figures S1a–c); list of primers used for RT-PCR (Table S1); compound purity analyses; and crystal data and structure refinement for the compounds <b>10a</b> and <b>10b</b> (Table S2) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02194/suppl_file/jm0c02194_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02194/suppl_file/jm0c02194_si_001.csv">jm0c02194_si_001.csv (2.14 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02194/suppl_file/jm0c02194_si_002.pdf">jm0c02194_si_002.pdf (9.83 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">CCDC 2049153 and 2049154 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <a href="http://www.ccdc.cam.ac.uk/structures" class="extLink">www.ccdc.cam.ac.uk/structures</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02194&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02194%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-12%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02194" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a4c011935d952","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
